PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 15/31, C07K 14/315, C12N 1/21, C07K 16/12, A61K 39/09, 39/395, G01N 33/569, C12Q 1/68

A1

(11) International Publication Number: WO 96/40928

(43) International Publication Date: 19 December 1996 (19.12.96)

(21) International Application Number: PCT/CA96/00322

(22) International Filing Date: 17 May 1996 (17.05.96)

(30) Priority Data:

08/472,534	7 June 1995 (07.06.95)	US
60/001,805	4 August 1995 (04.08.95)	US

(71) Applicant *(for all designated States except US)*: IAF BIOVAC INC. [CA/CA]; 525 Des Prairies Boulevard, Laval, Quebec H7N 4Z2 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HAMEL, Josée [CA/CA]; (CA). BRODEUR, Bernard [CA/CA]; 2401 Maritain Street, Sillery, Quebec G1T 1N6 (CA). MARTIN, Denis [CA/CA]; 4728-G Gaboury Street, St-Augustin-de-DesMaures, Quebec G3A 2X1 (CA). RIOUX, Clément [CA/CA]; 1012 Jean Charles Cantin, Ville de Cap-Rouge, Quebec G1Y 2X1 (CA).

(74) Agents: DUBUC, Jean, Y. et al.; The Stock Exchange Tower, Suite 3400, 800 Square Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: STREPTOCOCCAL HEAT SHOCK PROTEINS MEMBERS OF THE HSP70 FAMILY

(57) Abstract

Novel heat shock proteins (HSPs) of *Streptococcus pneumoniae, Streptococcus pyogenes* and *Streptococcus agalactiae* having apparent molecular masses of 70-72 kDa, immunologically related polypeptides, the nucleotide and derived amino acid sequences of HSP72 of *S. pneumoniae* (SEQ ID NO:4; SEQ ID NO:5), the nucleotide and derived amino acid sequences of HSP70 of *S. pyogenes* (SEQ ID NO:19; SEQ ID NO:20), the nucleotide and derived amino acid sequences of HSP 70 of *S. agalactiae* (SEQ ID NO:21; SEQ ID NO:22), antibodies that bind to the HSPs, and recombinant DNA methods for the production of the HSPs and immunologically related polypeptides are described. The polypeptides, DNA sequences and antibodies of this invention provide new means for the diagnosis, prevention and/or treatment of Streptococcal disease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

STREPTOCOCCAL HEAT SHOCK PROTEINS MEMBERS OF THE HSP70 FAMILY

TECHNICAL FIELD OF THE INVENTION

This invention relates to novel heat shock proteins of *Streptococcus pneumoniae, Streptococcus pyogenes* and *Streptococcus agalactiae* and immunologically related polypeptides, which provide the basis for new immunotherapeutic, prophylactic and diagnostic agents useful in the treatment, prevention and diagnosis of disease. More particularly, this invention relates to heat shock proteins of *S. pneumoniae, S. pyogenes* and *S. agalactiae*, members of the HSP70 family which have an apparent molecular mass of 70-72 kilodaltons, to the corresponding nucleotide and derived amino acid sequences, to recombinant DNA methods for the production of HSP70/HSP72 and immunologically related polypeptides, to antibodies that bind to these HSP's, and to methods and compositions for the diagnosis, prevention and treatment of diseases caused by *S. pneumoniae* and related bacteria, such as *Streptococcus pyogenes and Streptococcus agalactiae*

BACKGROUND OF THE INVENTION

S. pneumoniae is an important agent of disease in humans, especially among infants, the elderly and immunocompromised persons. It is a bacterium frequently isolated from patients with invasive diseases such as bacteraemia/septicaemia, pneumonia, and meningitis with high morbidity and mortality throughout the world. Although the advent of antimicrobial drugs has reduced the overall mortality from pneumococcal diseases, the presence of resistant pneumococcal organisms has become a major problem in the world today. Effective pneumococcal vaccines could have a major impact on the morbidity and mortality associated with *S. pneumoniae* disease. Such

vaccines would also potentially be useful to prevent otitis media in infants and young children.

It is clear that a number of pneumococcal factors are potentially important in the pathogenesis of disease [G.J. Boulnois, J. Gen. Microbiol., 138, pp. 249-259 (1992); C.J. Lee et al., Crit. Rev. Microbiol., 18, pp. 89-114 (1991)]. The capsule of the pneumococcus, despite its lack of toxicity, is considered to be the *sine qua non* of pneumococcal virulence. More than 80 pneumococcal capsular serotypes are identified on the basis of antigenic differences. Antibodies are the mechanism of protection and the importance of anticapsular antibodies in host defenses against *S. pneumoniae* is well established [R. Austrian, Am. J. Med., 67, pp. 547-549 (1979)]. Nevertheless, the currently available pneumococcal vaccine, comprising 23 capsular polysaccharides that most frequently caused disease, has significant shortcomings such as the poor immunogenicity of capsular polysaccharides, the diversity of the serotypes and the differences in the distribution of serotypes over time, geographic areas and age groups. In particular, the failure of existing vaccines to protect young children against most serotypes has spurred evaluation of other *S. pneumoniae* components. Increasing evidence indicates that certain pneumococcal proteins may play an active role both in terms of protection and pathogenicity [J.C. Paton, Ann. Rev. Microbiol., 47, pp. 89-115 (1993)]. So far, however, only a few *S. pneumoniae* proteins have been studied. This might result from the lack of protein-specific antibodies which renders difficult the study of the role of protein antigens in protection and pathogenicity. It is believed that the pneumococcal protein antigens are not very immunogenic and that most antibody responses are to the phosphocholine and the capsular polysaccharides [L.S. McDaniel et al., J. Exp. Med., 160, pp. 386-397 (1984); R.M. Krause, Adv. Immunol., 12, pp. 1-56 (1970); D.G. Braun et al., J. Exp.

Med., 129, pp. 809-830 (1969)]. In a study using X-linked immunodeficient mice, which respond poorly to carbohydrate antigens and to phosphocholine, but make relatively normal responses to protein antigens, the frequency for obtaining monoclonal antibodies reactive with pneumococcal protein antigens was less than 10%, thus suggesting that *S. pneumoniae* proteins are poor immunogens [McDaniel et al., supra].

Streptococcus agalactiae, also called Group B *Streptococcus* (GBS), is the most common cause of sepsis (blood infection) and meningitis in newborns. GBS is also a frequent cause of newborn pneumonia. Approximately 8,000 babies in the United States get GBS disease each year; 5%-15% of these babies die. Babies that survive, particularly those who have meningitis, may have long-term problems, such as hearing or vision loss or learning disabilities. In pregnant women, GBS can cause urinary tract infections, womb infections (amnionitis, endometritis), and stillbirth. Among women who are not pregnant and men, the most common diseases caused by GBS are blood infections, skin or soft tissue infections, and pneumonia. Approximately 20% of men and nonpregnant women with GBS disease die of the disease. GBS infections in both newborns and adults are usually treated with antibiotics (e.g., penicillin or ampicillin) given intravenously. Most GBS disease in newborns can be prevented by giving certain pregnant women antibiotics intravenously during labor. Vaccines to prevent GBS disease are being developed. In the future, it is expected that women who will be vaccinated will make antibodies that cross the placenta and protect the baby during birth and early infancy.

Since the 1980s, *Streptococcus pyogenes*, also called Group A *Streptococcus* (GAS) is reemerging as a cause of severe diseases which would be due to an increase

in virulence of the organism. GAS causes pharyngitis, commonly called "strep throat", and skin infections (impetigo, erysipelas/cellulitis). "Strep throat" and impetigo can lead to glomerulonephritis (kidney damage). Approximately 3% of "strep throat" infections result into rheumatic fever (migrating arthritis) whose complications include chorea (neurological symptoms) and, in 50% of the cases, rheumatic heart disease (heart valve damage) with endocarditis as a possible long term consequence. It is important to treat impetigo and "strep throat" with antibiotics to prevent the development of complications. Infection with toxin-producing strains can result in scarlet fever (diffuse rash and fever) or in the extremely severe streptococcal toxic shock syndromes (TSS; GAS have been termed 'flesh eating bacteria') which are characterized by the rapid development of shock and multiple organ system failure. TSS have a 30 to 70% fatality rate in spite of aggressive treatment involving the removing of the focus of bacterial infection and antibiotic therapy. The incidence of TSS is 10 to 20 cases per 100,000. No vaccine against GAS is presently available.

Heat shock or stress proteins ("HSPs") are among the most highly conserved and abundant proteins found in nature [F.C. Neidhardt et al., Ann. Rev. Genet., 18, pp. 295-329 (1984); S. Lindquist, Ann. Rev. Biochem., 55, pp. 1151-1191 (1986)]. They are produced by all cells in response to various physiological and nonphysiological stimuli. The heat shock response, in which a sudden increase in temperature induces the synthesis of HSPs, is the best studied of the stress responses. Other environmental conditions such as low pH, iron deficiency and hydrogen peroxyde can also induce HSPs. The HSPs have been defined by their size, and members of hsp90, hsp70, and hsp60 families are among the major HSPs found in all prokaryotes and eukaryotes. These proteins fulfill a

variety of chaperon functions by aiding protein folding and assembly and assisting translocation across membranes [C. Georgopoulos and W.J. Welch, Ann. Rev. Cell. Biol., 9, pp. 601-634 (1993); D. Ang et al., J. Biol. Chem., 266, pp. 24233-24236 (1991)]. As molecular chaperons and possibly via other mechanisms, HSPs are likely involved in protecting cells from the deleterious effects of stress. The fact that several virulence factors are regulated by environmental conditions suggests a role for HSPs in microbial pathogenicity [J.J. Mekalanos, J. Bacteriol., 174, pp. 1-7 (1992); P.J. Murray and R.A. Young, J. Bacteriol., 174, pp. 4193-4196 (1992)]. In that respect, recent studies on *Salmonella* species suggest that the stress response might be critically linked to the ability of intracellular pathogens to initiate and sustain an infection [N.A. Buchmeir and F. Heffron, Science, 248, pp. 730-732 (1990); K.Z. Abshire and F.C. Neidhardt, J. Bacteriol., 175, pp. 3734-3743 (1993); B.B. Finlay et al., Science, 243, pp. 940-943 (1989)]. Others have demonstrated that lysteriolysin, an essential virulence factor in *L. monocytogenes*, is induced under heat shock conditions [Z. Sokolovic and W. Goebel, Infect. Immun., 57, pp. 295-298 (1989)].

Evidence is now accumulating that HSPs are major antigens of many pathogens. Members of the hsp60 family, also called GroEL-related proteins for their similarity to the *E. coli* GroEL protein, are major antigens of a variety of bacterial pathogens including *Mycobacterium leprae* and *Mycobacterium tuberculosis* [D. Young et al., Proc. Natl. Acad. Sci. USA, 85, pp. 4267-4270 (1988)], *Legionella pneumophila* [B.B. Plikaytis et al., J. Clin. Microbiol., 25, pp. 2080-2084 (1987)], *Borrelia burgdorferi* [B.J. Luft et al., J. Immunol., 146, pp. 2776-2782 (1991)], and *Chlamydia trachomatis* [E.A. Wagar et al., J. Infect. Dis., 162, pp. 922-927 (1990)]. This antigen is a homologue of the ubiquitous "common antigen", and is believed to be present in every bacterium [J.E. Thole et al., Microb.

Pathogen., 4, pp. 71-83 (1988). Antibodies to the members of the hsp70 family, or DnaK-related proteins, have also been described for several bacterial and parasitic infections [Young et al., supra; Luft et al., supra; D.M. Engman et al., J. Immunol., 144, pp. 3987-3991 (1990); N.M. Rothstein et al., Molec. Biochem. Parasitol., 33, pp. 229-235 (1989); V. Nussenzweig and R.S. Nussenzweig, Adv. Immunol., 45, pp. 283-334 (1989)]. HSPs can elicit strong B- and T- cell responses and it was shown that 20% of the $CD4^+$ T-lymphocytes from mice inoculated with *M. tuberculosis* were reactive to the hsp60 protein alone [S.H.E. Kaufman et al., Eur. J. Immunol., 17, pp. 351-357 (1987)]. Similarly, 7 out of a collection of 24 monoclonal antibodies to *M. leprae* proteins recognized determinants on hsp60 [H.D. Engers et al., Infect. Immun., 48, pp. 603-605 (1985)]. It seems that the immune response to stress proteins might play an important role in protection against infection. Consistent with that is the demonstration that antibodies and T cells reactive with microbial HSPs can exhibit neutralizing and protective activities [A. Noll et al., Infect. Immun., 62, pp. 2784-2791 (1994); and S.L. Danilition et al., Infect. Immun., 58, pp. 189-196 (1990)]. The immunological properties of stress proteins make them attractive as vaccine components and several HSPs are presently being considered for preventing microbial infection and treating cancer. So far, however, studies have focused on intracellular pathogens such as *Mycobacteria*, *Salmonella*, *Chlamydia* and several parasites. Information concerning the heat shock protein antigens in extracellular gram-positive bacteria is far less documented. In *S. pneumoniae*, *S. pyogenes* and *S. agalactiae*, neither the heat shock proteins nor their gene structures have been identified.

DISCLOSURE OF THE INVENTION

The present invention addresses the problems referred to above by providing novel heat shock proteins

from *S. pneumoniae, S. pyogenes and S. agalactiae*, and immunologically related polypeptides. Also provided are DNA sequences that code for the foregoing polypeptides, vectors containing the polypeptides, unicellular hosts transformed with those vectors, and a process for making substantially pure, recombinant polypeptides. Also provided are antibodies specific to the foregoing polypeptides. The polypeptides, DNA sequences and antibodies of this invention provide the basis for novel methods and pharmaceutical compositions for the detection, prevention and treatment of disease. Particularly, this invention provides a novel vaccine based on fragments of these polypeptides that are specific to streptococcal strains.

The novel heat shock protein is the approximately 72 kDa heat shock protein of *Streptococcus pneumoniae* ("HSP72") (SEQ ID NO:5), the approximately 70 kDa heat shock protein of *Streptococcus pyogenes* ("HSP70") (SEQ ID NO:20)and the approximately 70 kDa heat shock protein of *Streptococcus agalactiae* ("HSP70") (SEQ ID NO:22), including analogues, homologues, and derivatives thereof, and fragments of the foregoing polypeptides containing at least one immunogenic epitope. Preferred fragments of HSP70/72 include the C-terminal portion of the HSP70/72 polypeptides. More particularly,it includes the C_terminal 169-residue fragment ("C-169") (residues 439-607, SEQ ID NO:5), the C-terminal 151-residue fragment ("C-151") (residues 457-607, SEQ ID No:5),and smaller fragments consisting of peptide epitopes within the C-169 region. Particularly preferred fragments within the C-169 region of HSP72 include the peptide sequences GFDAERDAAQAALDD (residues 527-541 of SEQ ID NO:5) and AEGAQATGNAGDDVV (residues 586-600 of SEQ ID NO:5), which are exclusive to HSP72 of *Streptococcus pneumoniae*. Even more preferred are fragments that elicit an immune reaction against *S. pneumoniae, S. pyogenes* and *S.*

agalactiae but do not provoke auto-immune reaction in a human host. Such fragments may be selected from the following peptides: CS870, CS873, CS874, CS875, CS876, CS877, CS878, CS879, CS880, CS882, MAP1, MAP2, MAP3 and MAP4 (see TABLE 5, supra).

Preferred antibodies of this invention are the F1-Pn3.1, F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4 monoclonal antibodies ("MAbs"), which are specific to HSP72.

More preferred antibodies are the F2-Pn3.2 and F2-Pn3.4 monoclonal anibodies that are specific to both HSP 70 and HSP72. Even more preferred are the F1-Pn3.1 antibodies that are specific for *Streptococcus pneumoniae*.

The preferred polypeptides and antibodies of this invention provide the basis for novel methods and pharmaceutical compositions for the detection, prevention and treatment of pneumococcal diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a fluorogram, which shows the effect of heat shock on *S. pneumoniae* protein synthesis. The cell extracts in panel A are *S. pneumoniae* type 6 strain 64. The cell extracts in panel B are *S. pneumoniae* type 4 strain 53. The cell extracts in the odd numbered lanes were incubated at 37°C. The cell extracts in the even numbered lanes were incubated at 45°C for 5 minutes. The cell extracts were then labeled with [^{35}S]methionine for 10 minutes (lanes 1, 2 and 7, 8), 30 minutes (lanes 3, 4 and 9, 10), or 60 minutes (lanes 5, 6). Molecular mass markers in kilodaltons are shown to the left. The positions of HSP80, HSP72 and HSP62 are shown by arrows at the right-hand side of each panel.

FIG. 2 is a graphical depiction of a comparison of the electrophoretic profiles of [^{35}S]methionine-labeled proteins in *S. pneumoniae* in the presence (----) or absence (____) of exposure to heat shock. Densitometric tracings were determined by measuring the relative optical

density (Y axis) vs. the mobility of labeled protein bands (X axis). The densitometric scans of the SDS PAGE of FIG. 1, lanes 1 and 2, is shown.

FIG. 3 depicts a fluorogram, which shows the *S. pneumoniae* protein antigens immunoprecipitated by sera from mice immunized with detergent-soluble *S. pneumoniae* protein extract. [^{35}S]methionine-labeled proteins from *S. pneumoniae* grown at 37°C and incubated at 37°C (lanes 3, 5, 7 and 9) or heat-shocked at 45°C (lanes 4, 6, 8 and 10) were immunoprecipitated with sera from mouse 1 (lanes 3 to 6) or mouse 2 (lanes 7 to 10) and then analyzed by SDS-PAGE and fluorography. The sera were tested after the first (lanes 3,4 and 7,8) and after the second (lanes 5,6 and 9,10) immunization. Cell lysates from [^{35}S]methionine-labeled non heat-shocked and heat-shocked *S. pneumoniae* are shown in lanes 1 and 2, respectively. The position of HSPs is indicated by the arrows at the left of the fluorogram.

FIG. 4 depicts a fluorogram, which shows the *S. pneumoniae* protein antigens immunoprecipitated by sera from mice immunized with heat-killed *S. pneumoniae* bacteria. [^{35}S]methionine-labeled proteins from *S. pneumoniae* grown at 37°C and incubated at 37°C (lanes 3, 5 and 7) or heat-shocked at 45°C (lanes 4, 6 and 8) were immunoprecipitated with sera from mouse 1 (lanes 3,4), mouse 2 (lanes 5,6) or mouse 3 (lanes 7, 8) and then analyzed by SDS-PAGE and fluorography. Sera were tested after the second immunization only. Cell lysates from [^{35}S]methionine-labeled non heat- and heat-shocked *S. pneumoniae* are shown in lanes 1 and 2, respectively. The position of HSPs is indicated by the arrows at the left of the fluorogram.

FIG. 5 depicts a photograph, which shows the *S. pneumoniae* antigens detected by Western blot analysis. Whole cell extracts were probed with sera from 15 mice (lanes 1-15) immunized with heat-killed *S. pneumoniae* bacteria. Lane 16 shows the HSP72 protein detected by MAb

F1-Pn3.1. In panel A, the sera were tested after the second immunization. In panel B, the reactivity of 4 out of 15 sera tested after the first immunization is shown. The positions of 53.5 kDa- and 47 kDa-protein bands are indicated by the bars at the left. The position of HSP72 is shown by the arrows at the right of each panel.

FIG. 6 depicts a fluorogram showing the specificity of MAb F1-Pn3.1 for HSP72. [^{35}S]methionine-labeled proteins of *S. pneumoniae* in the absence (lanes 1, 3 and 5) or presence (lanes 2, 4 and 6) of exposure to heat shock were immunoprecipitated with IgG2a-control MAb (lane 3,4) or F1-Pn3.1 (lane 5,6) and then analyzed by SDS-PAGE and fluorography. Cell lysates from [^{35}S]methionine-labeled non heat-shocked and heat-shocked *S. pneumoniae* are shown in lanes 1 and 2, respectively. The position of HSPs (all three) is shown by the arrows at the left of the fluorogram.

FIG. 7, panel A, depicts an immunoblot, which shows the reaction of heat-shocked and non heat-shocked [^{35}S]methionine-labelled *S. pneumoniae* cell extracts with MAb F1-Pn3.1. Lane 1 contains heat-shocked cell lysates (45°C). Lane 2 contains non heat-shocked cell lysates (37°C). Panel B depicts a fluorogram of the immunoblot shown in panel A.

FIG. 8 depicts a Western Blot, which shows subcellular localization of *S. pneumoniae* HSP72. Sample containing 15 µg protein of membrane fraction (lane 1) and cytoplasmic fraction (lane 2) of *S. pneumoniae* were electrophoresced on SDS-PAGE transferred to nitrocellulose and probed with MAb F1-Pn3.1.

FIG. 9 is a photograph of an immunoblot showing the reactivity of recombinant fusion proteins containing the C-169 region of *S. pneumoniae* HSP72 with MAb F1-Pn3.1. Lane 1 contains whole cell extracts from *S. pneumoniae* strain 64 probed with HSP72-specific MAb F1-Pn3.1. Lanes 2 and 3 contain phage lysates from *E. coli* infected with λJBD17 cultured in the presence (+) or absence (-) of

IPTG and probed with HSP72-specific MAb F1-Pn3.1. Lanes 4 and 5 contain phage lysates from *E. coli* infected with λJBD7 cultured in the presence (+) or absence (-) of IPTG and probed with HSP72-specific MAb F1-Pn3.1. Molecular mass markers are shown to the left. The positions of the 74kDa- and 160 kDa-reactive proteins are shown on the left and on the right, respectively.

FIG. 10 is a schematic representation of the restriction map of the HSP72(DnaK) and *Fuc* loci and inserts of recombinant clones. The relationships between DNA fragments are shown with respect to each other. FIGS. 10A and 10C illustrate the restriction map of the HSP72(DnaK) and *Fuc* loci, respectively. FIG 10B illustrates the inserts of the various phages and plasmids described in Example 3. H(HindIII); E(EcoRI); V(EcoRV); P(PstI); and X(XhoI) indicate positions of restriction endonuclease sites. DNA fragments on the HSP72/DnaK locus (■); the *Fuc* locus (///); and fragments used as probes in the Southern blot analyses (▒) are indicated.

FIG. 11 depicts the SDS-PAGE and Western blot analyses of the recombinant 74 kDa protein. Whole cell extracts from *E. coli* transformed with plasmids pJBD179 (lane 1), pJBDf51 (lanes 2 and 3) and pJBDf62 (lane 4 and 5) and cultured in presence (+) or absence (-) of IPTG were subjected to 10% polyacrylamide gel electrophoresis. The proteins were then visualized by Coomassie Blue staining (A) or Western blotting (B) using HSP-specific MAb F1-Pn3.1. Molecular mass markers in kilodaltons are shown to the left. The arrow at the left-hand side of each panel marks the 74 kDa protein marker.

FIG. 12 depicts the detection of native and recombinant HSP72 antigens by Western blot analysis. Whole cell lysates from *E. coli* transformed with plasmids pJBDk51 (lanes 1 and 3) and pJBD291 (lane 2) and cell lysates from *S. pneumoniae* strain 64 (lane 4) were subjected to 10% polyacrylamide gel electrophoresis and

were electrotransferred to nitrocellulose. The immunoblot was probed with HSP72-specific MAb F1-Pn3.1.

FIGS. 13A-13D depict a comparison of the predicted amino acid sequence of the *S. pneumoniae* HSP72 open reading frame (HSP72 SPNEU) with those previously reported for the following HSP70/DnaK proteins: ECOLI, *Escherichia coli*; BORBU, *Borrelia burgdorferi*; BRUOV, *Brucella ovis*; CHLPN, *Chlamydia pneumonia*; BACME, *Bacillus megatorium*; BACSU, *Bacillus subtilis*; STAAU, *Staphylococcus aureus*; LACLA, *Lactococcus lactis*; and MYCTU, *Mycobacterium tuberculosis*. Only mismatched amino acids are indicated. Identical and conserved amino acids are boxed and shadowed, respectively.

FIG. 14 depicts a photograph of an SDS-PAGE, which shows the recombinant *S. pneumoniae* HSP72 purified by affinity chromatography. Supernatant fractions from *E. coli* (pJBDk51) lysates (lane 2) and 20 µg of immunoaffinity-purified $HSP72_{rec}$ (lane 3) were subjected to 10% polyacrylamide gel electrophoresis. The proteins were then visualized by Coomassie Blue staining. Lane 1 shows the migration of molecular mass markers (106 kDa, 80 kDa, 49.5 kDa, 32.5 kDa, 27.5 kDa and 18.5 kDa).

FIG. 15 depicts a photograph of SDS-PAGE, which shows the recombinant *S. pneumoniae* C-169 fragment purified by solubilization of inclusion bodies. Various amounts of purified C-169 protein (lane 1, 5 µg; lane 2, 2.5 µg; and lane 3, 1 µg) and whole cell lysates from *E. coli* transformed with plasmids pDELTA1 (lane 4) and pJBDΔ1 (lane 5) were subjected to 10% polyacrylamide gel electrophoresis. The proteins were then visualized by Coomassie Blue staining.

FIG. 16 is a graphical depiction of the survival curve of Balb/c mice protected from *S. pneumoniae* infection by immunization with $HSP72_{rec}$. Data are presented as the per cent (%) survival over a period of 14 days for a total of 10 mice per experimental group.

FIG. 17 is a graphical depiction of the survival curve of Balb/c mice protected from *S. pneumoniae* infection by immunization with C-169$_{rec}$. Data are presented as the per cent (%) survival over a period of 14 days for a total of 10 mice per experimental group.

FIG. 18 is a map of plasmid pURV3 containing C-151$_{rec}$, the coding region for the 151 amino acids at the carboxyl end of the HSP72 of *S. pneumoniae*; Ampi^R, ampicillin-resistance coding region; ColE1 *ori*, origin of replication; cI857, bacteriophage λ cI857 temperature-sensitive repressor gene; λ *PL*, bacteriophage λ transcription promoter; T1, T1 transcription terminator. The direction of transcription is indicated by the arrows. *Bgl*II and *Bam*HI are the restriction sites used to insert the coding region for the C-151$_{rec}$ of the HSP72 of *S. pneumoniae*.

FIG. 19 illustrates the distribution of anti-*S. pneumoniae* titers in sera from Balb/c mice immunized with HSP72$_{rec}$. Sera were collected after the first, second and third injection with 1 µg (O) or 5 µg (●) of HSP72$_{rec}$ and evaluated individually for anti-*S. pneumoniae* antibody by ELISA. Titers were defined as the highest dilution at which the A410 values were 0.1 above the background values. Plain lines indicate the median reciprocal of antibody titers for each group of mice while the dashed line indicates the median value for preimmune sera.

FIG. 20 illustrates the distribution of anti-*S. pneumoniae* titers in sera from Balb/c mice immunized with C-169$_{rec}$. Sera were collected after the first, second and third injection with 1 µg (O) or 5 µg (●) of C-169$_{rec}$ and evaluated individually for anti-*S. pneumoniae* antibody by ELISA. Titers were defined as the highest dilution at which the A410 values were 0.1 above the background values. Plain lines indicate the median reciprocal of antibody titers for each group of mice while the dashed line indicates the median value for preimmune sera.

FIG. 21 illustrates the distribution of anti-*S. pneumoniae* titers in sera from Balb/c mice immunized with C-151$_{rec}$. Sera were collected after the first, second and third injection with 0.5 µg of C-151$_{rec}$ and evaluated individually for anti-*S. pneumoniae* antibody by ELISA. Titers were defined as the highest dilution at which the A410 values were 0.1 above the background values. Plain lines indicate the median reciprocal of antibody titers for each group of mice while the dashed line indicates the median value for preimmune sera.

FIG. 22 illustrates the antibody response of cynomolgus monkeys immunized with recombinant HSP72 antigens. Groups of two monkeys were immunized with either HSP72$_{rec}$ or C-169$_{rec}$ protein at day 1, day 22 and day 77. Sera were collected regularly during the course of the immunization and evaluated individually for pneumococcal HSP72 specific antibody by Western blot analysis. Titers were defined as the highest dilution at which the HSP72 band was visualized.

FIG. 23 illustrates the binding of hyperimmune sera to peptides in a solid-phase ELISA. Rabbit, mouse and monkey sera from animals immunized with either HSP72$_{rec}$ or C-169$_{rec}$ protein were tested for their reactivity to peptides. Optical density values were obtained with sera tested at a dilution of 1:100 except for the values corresponding to the reactivity of rabbit sera to peptide MAP2 and murine sera to peptides MAP2 and MAP4 which were obtained with sera diluted 1:1000.

FIG. 24 depicts the consensus sequence established from the DNA sequences of the *hsp70/dnak* open reading frames of *Streptococcus pneumoniae* (spn-orf), *Streptococcus pyogenes* (sga-orf) and *Streptococcus agalactiae* (sgb-orf) and indicates the substitutions and insertions of nucleotides specific to each species.

FIG. 25 depicts the consensus sequence established from the protein sequences of the Hsp70 of *Streptococcus pneumoniae* (spn-prot), *Streptococcus pyogenes* (sga-prot)

and *Streptococcus agalactiae* (sgb-prot) and indicates the substitutions and insertions of amino acids specific to each species.

FIG. 26 depicts a fluorogram, which shows the effect of heat shock on *S. agalactiae* protein synthesis and the *S. agalactiae* protein antigen immunoprecipitated by MAb F2-Pn3.4. Cell lysates from [^{35}S]methionine-labeled proteins from *S. agalactiae* grown at 37°C and incubated at 37°C (odd numbered lanes) or heat-shocked at 43°C (even numbered lanes) were analysed by SDS-PAGE and fluorography. Lanes 3 and 4 show the immunoprecipitates obtained using MAb F2-Pn3.4.

DETAILED DESCRIPTION OF THE INVENTION

According to one aspect of the invention, we provide novel heat shock proteins of *S. pneumoniae*, *S. pyogenes* and *S. agalactiae*, and analogues, homologues, derivatives and fragments thereof, containing at least one immunogenic epitope. As used herein, a "heat shock protein" is a naturally occurring protein that exhibits preferential transcription during heat stress conditions. The heat shock protein according to the invention may be of natural origin, or may be obtained through the application of recombinant DNA techniques, or conventional chemical synthesis techniques.

As used herein, "immunogenic" means having the ability to elicit an immune response. The novel heat shock proteins of this invention are characterized by their ability to elicit a protective immune response against Streptococcal infections, more particularly against lethal *S. pneumoniae*, *S. pyogenes* and *S. agalactiae*.

The invention particularly provides a *Streptoccus pneumoniae* heat shock protein of approximately 72 kDa ("HSP72"), having the deduced amino acid sequence of SEQ ID NO:5, and analogues, homologues, derivatives and

fragments thereof, containing at least one immunogenic epitope.

As used herein, "analogues" of HSP72 are those *S. pneumoniae* proteins wherein one or more amino acid residues in the HSP72 amino acid sequence (SEQ ID NO:5) is replaced by another amino acid residue, providing that the overall functionality and immunogenic properties of the analogue protein are preserved. Such analogues may be naturally occurring, or may be produced synthetically or by recombinant DNA technology, for example, by mutagenesis of the HSP72 sequence. Analogues of HSP72 will possess at least one antigen capable of eliciting antibodies that react with HSP72, e.g. *Streptococcus pyogenes* and *Streptococcus agalactiae*.

As used herein, "homologues" of HSP72 are proteins from Streptococcal species other than *pneumoniae*, *pyogenes* or *agalactiae*, or genera other than Streptococcus wherein one or more amino acid residues in the HSP72 amino acid sequence (SEQ ID NO:5) is replaced by another amino acid residue, providing that the overall functionality and immunogenic properties of the homologue protein are preserved. Such homologues may be naturally occurring, or may be produced synthetically or by recombinant DNA technology. Homologues of HSP72 will possess at least one antigen capable of eliciting antibodies that react with HSP72, e.g. *Enterococcus faecalis*.

As used herein, a "derivative" is a polypeptide in which one or more physical, chemical, or biological properties has been altered. Such alterations include, but are not limited to: amino acid substitutions, modifications, additions or deletions; alterations in the pattern of lipidation, glycosylation or phosphorylation; reactions of free amino, carboxyl, or hydroxyl side groups of the amino acid residues present in the polypeptide with other organic and non-organic molecules; and other alterations, any of which may result in changes in primary, secondary or tertiary structure.

The "fragments" of this invention will have at least one immunogenic epitope. An "immunogenic epitope" is an epitope that is instrumental in eliciting an immune response. The preferred fragments of this invention will elicit an immune response sufficient to prevent or lessen the severity of infection, e.g., *S. pneumoniae* infection. Preferred fragments of HSP72 include the C-terminal region of the polypeptides. More preferred fragment include the C-terminal 169-residue fragment ("C-169") (SEQ ID NO:5, residues 439-607), the C-terminal 151-residue ("C-151") (SEQ ID No:5, residues 457-607) and smaller fragments consisting of peptide epitopes within the C-169 region. Particularly preferred fragments within the C-169 region of HSP72 include the peptide sequences GFDAERDAAQAALDD (residues 527-541 of SEQ ID NO:5) and AEGAQATGNAGDDVV (residues 586-600 of SEQ ID NO:5), which are exclusive to HSP72 of *Streptococcus pneumoniae*, or corresponding degenerate fragments from *S. pyogenes* or *S. agalactiae* (see FIG. 25). Even more preferred are fragments that elicit a specific immune reaction against *Streptococcal strains*. Such fragments may be selected from the following peptides: CS870, CS873, CS874, CS875, CS876, CS877, CS878, CS879, CS880, CS882, MAP1, MAP2, MAP3 and MAP4 (see TABLE 5, supra), or homologues thereof.

In a further aspect of the invention, we provide polypeptides that are immunologically related to HSP70/72. As used herein, "immunologically related" polypeptides are characterized by one or more of the following properties:

(a) they are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with HSP72 (SEQ ID NO:5) and HSP70 (SEQ ID NO:20 and SEQ ID NO:22);

(b) they are capable of eliciting antibodies that are immunologically reactive with HSP72 (SEQ ID NO:5) and HSP70 (SEQ ID NO:20 and SEQ ID NO:22);

(c) they are immunologically reactive with antibodies elicited by immunization of a mammal with HSP72 (SEQ ID NO:5).

By definition, analogues, homologues and derivatives of HSP70/72 are immunologically related polypeptides. Moreover, all immunologically related polypeptides contain at least one HSP70/72 antigen. Accordingly, "HSP70/72 antigens" may be found in HSP70/72 itself, or in immunologically related polypeptides.

In a further aspect of the invention, we provide polypeptides that are immunologically related to HSP72. As used herein, "immunologically related" polypeptides are characterized by one or more of the following properties:

(a) they are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with HSP72 (SEQ ID NO:5);

(b) they are capable of eliciting antibodies that are immunologically reactive with HSP72 (SEQ ID NO:5);

(c) they are immunologically reactive with antibodies elicited by immunization of a mammal with HSP72 (SEQ ID NO:5).

By definition, analogues, homologues and derivatives of HSP72 are immunologically related polypeptides. Moreover, all immunologically related polypeptides contain at least one HSP72 antigen. Accordingly, "HSP72 antigens" may be found in HSP72 itself, or in immunologically related polypeptides.

As used herein, "related bacteria" are bacteria that possess antigens capable of eliciting antibodies that react with HSP72. Examples of related bacteria include Streptococcus pneumoniae, *Streptococcus pyogenes*, *Streptococcus mutans*, *Streptococcus sanguis*, *Streptococcus agalactiae* and *Enterococcus faecalis*.

It will be understood that by following the examples of this invention, one of skill in the art may determine without undue experimentation whether a

particular analogue, homologue, derivative, immunologically related polypeptide, or fragment would be useful in the diagnosis, prevention or treatment of disease. Useful polypeptides and fragments will elicit antibodies that are immunoreactive with HSP72 (Example 4). Preferably, useful polypeptides and fragments will demonstrate the ability to elicit a protective immune response against lethal bacterial infection (Example 5).

Also included are polymeric forms of the polypeptides of this invention. These polymeric forms include, for example, one or more polypeptides that have been crosslinked with crosslinkers such as avidin/biotin, glutaraldehyde or dimethylsuberimidate. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous protein sequences, produced from multicistronic mRNAs generated by recombinant DNA technology.

This invention provides substantially pure HSP72 and immunologically related polypeptides. The term "substantially pure" means that the polypeptides according to the invention, and the DNA sequences encoding them, are substantially free from other proteins of bacterial origin. Substantially pure protein preparations may be obtained by a variety of conventional processes, for example the procedures described in Examples 3 and 5.

In another aspect, this invention provides, for the first time, a DNA sequence coding for a heat shock protein of *S. pneumoniae*, specifically, HSP72 (SEQ ID NO:4, nucleotides 682-2502).

The DNA sequences of this invention also include DNA sequences coding for polypeptide analogues and homologues of HSP72, DNA sequences coding for immunologically related polypeptides, DNA sequences that are degenerate to any of the foregoing DNA sequences, and fragments of any of the foregoing DNA sequences. It will be readily appreciated that a person of ordinary skill in the art will be able to determine the DNA sequence of any

of the polypeptides of this invention, once the polypeptide has been identified and isolated, using conventional DNA sequencing techniques.

Oligonucleotide primers and other nucleic acid probes derived from the genes encoding the polypeptides of this invention may also be used to isolate and clone other related proteins from *S. pneumoniae* and related bacteria which may contain regions of DNA bacteria that are homologous to the DNA sequences of this invention. In addition, the DNA sequences of this invention may be used in PCR reactions to detect the presence of *S. pneumoniae* or related bacteria in a biological sample.

The polypeptides of this invention may be prepared from a variety of processes, for example by protein fractionation from appropriate cell extracts, using conventional separation techniques such as ion exchange and gel chromatography and electrophoresis, or by the use of recombinant DNA techniques. The use of recombinant DNA techniques is particularly suitable for preparing substantially pure polypeptides according to the invention.

Thus according to a further aspect of the invention, we provide a process for the production of HSP72, immunologically related polypeptides, and fragments thereof, comprising the steps of (1) culturing a unicellular host organism transformed with a vector containing a DNA sequence coding for said polypeptide or fragment and one or more expression control sequences operatively linked to the DNA sequence, and (2) recovering a substantially pure polypeptide or fragment.

As is well known in the art, in order to obtain high expression levels of a transfected gene in a host, the gene must be operatively linked to transcriptional and ranslational expression control sequences that are functional in the chosen expression host. Preferably, the expression control sequences, and the gene of interest, will be contained in an expression vector that further

comprises a bacterial selection marker and origin of replication. If the expression host is a eukaryotic cell, the expression vector should further comprise an expression marker useful in the eukaryotic expression host.

The DNA sequences encoding the polypeptides of this invention may or may not encode a signal sequence. If the expression host is eukaryotic, it generally is preferred that a signal sequence be encoded so that the mature protein is secreted from the eukaryotic host.

An amino terminal methionine may or may not be present on the expressed polypeptides of this invention. If the terminal methionine is not cleaved by the expression host, it may, if desired, be chemically removed by standard techniques.

A wide variety of expression host/vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus, and retroviruses. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli,* including pBluescript, pGEX2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g. λgt10 and λgt11, NM989, and other DNA phages, such as M13 and filamentous single stranded DNA phages. Useful expression vectors for yeast cells include the 2μ plasmid and derivatives thereof. Useful vectors for insect cells include pVL 941.

In addition, any of a wide variety of expression control sequences may be used in these vectors to express the DNA sequences of this invention. Useful expression control sequences include the expression control sequences associated with structural genes of the foregoing

expression vectors. Examples of useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the T3 and T7 promoters the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast alpha-mating system and other constitutive and inducible promoter sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. The T7 RNA polymerase promoter Φ10 is particularly useful in the expression of HSP72 in *E. coli* (Example 3).

Host cells transformed with the foregoing vectors form a further aspect of this invention. A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO and mouse cells, African green monkey cells such as COS 1, COS 7, BSC 1, BSC 40, and BMT 10, human cells, and plant cells in tissue culture. Preferred host organisms include bacteria such as *E. coli* and *B. subtilis*, and mammalian cells in tissue culture.

It should of course be understood that not all vectors and expression control sequences will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must replicate

in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered. In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the DNA sequences of this invention, particularly as regards potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the DNA sequences of this invention, their secretion characteristics, their ability to fold the protein correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the DNA sequences of this invention. Within these parameters, one of skill in the art may select various vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

The polypeptides encoded by the DNA sequences of this invention may be isolated from the fermentation or cell culture and purified using any of a variety of conventional methods including: liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like; affinity chromatography (such as with inorganic ligands or monoclonal antibodies); size exclusion chromatography; immobilized metal chelate chromatography; gel electrophoresis; and the like. One of skill in the art may select the most appropriate isolation and purification techniques without departing from the scope of this invention.

In addition, the polypeptides of this invention may be generated by any of several chemical techniques. For example, they may be prepared using the solid-phase synthetic technique originally described by R. B.

Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis Of A Tetrapeptide", J. Am. Chem. Soc., 83, pp. 2149-54 (1963), or they may be prepared by synthesis in solution. A summary of peptide synthesis techniques may be found in E. Gross & H. J. Meinhofer, 4 The Peptides: Analysis, Synthesis, Biology; Modern Techniques Of Peptide And Amino Acid Analysis, John Wiley & Sons, (1981) and M. Bodanszky, Principles Of Peptide Synthesis, Springer-Verlag (1984).

The preferred compositions and methods of this invention comprise polypeptides having enhanced immunogenicity. Such polypeptides may result when the native forms of the polypeptides or fragments thereof are modified or subjected to treatments to enhance their immunogenic character in the intended recipient. Preferred polypeptides are fragments that are specific to Streptococcal species such as fragments selected from the C-terminal portion of thenative polypeptides. Numerous techniques are available and well known to those of skill in the art which may be used, without undue experimentation, to substantially increase the immunogenicity of the polypeptides herein disclosed. For example, the polypeptides may be modified by coupling to dinitrophenol groups or arsanilic acid, or by denaturation with heat and/or SDS. Particularly if the polypeptides are small polypeptides synthesized chemically, it may be desirable to couple them to an immunogenic carrier. The coupling of course, must not interfere with the ability of either the polypeptide or the carrier to function appropriately. For a review of some general considerations in coupling strategies, see Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, ed. E. Harlow and D. Lane (1988). Useful immunogenic carriers are well known in the art. Examples of such carriers are keyhole limpet hemocyanin (KLH); albumins such as bovine serum albumin (BSA) and ovalbumin, PPD (purified protein derivative of tuberculin); red blood cells; tetanus

toxoid; cholera toxoid; agarose beads; activated carbon; or bentonite.

Modification of the amino acid sequence of the polypeptides disclosed herein in order to alter the lipidation state is also a method which may be used to increase their immunogenicity and biochemical properties. For example, the polypeptides or fragments thereof may be expressed with or without the signal sequences that direct addition of lipid moieties.

In accordance with this invention, derivatives of the polypeptides may be prepared by a variety of methods, including by *in vitro* manipulation of the DNA encoding the native polypeptides and subsequent expression of the modified DNA, by chemical synthesis of derivatized DNA sequences, or by chemical or biological manipulation of expressed amino acid sequences.

For example, derivatives may be produced by substitution of one or more amino acids with a different natural amino acid, an amino acid derivative or non-native amino acid, conservative substitution being preferred, e.g., 3-methylhistidine may be substituted for histidine, 4-hydroxyproline may be substituted for proline, 5-hydroxylysine may be substituted for lysine, and the like.

Causing amino acid substitutions which are less conservative may also result in desired derivatives, e.g., by causing changes in charge, conformation and other biological properties. Such substitutions would include for example, substitution of a hydrophilic residue for a hydrophobic residue, substitution of a cysteine or proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge. When the result of a given substitution cannot be predicted with certainty, the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics.

The polypeptides may also be prepared with the objective of increasing stability or rendering the molecules more amenable to purification and preparation. One such technique is to express the polypeptides as fusion proteins comprising other *S. pneumoniae* or non-*S. pneumoniae* sequences. It is preferred that the fusion proteins comprising the polypeptides of this invention be produced at the DNA level, e.g., by constructing a nucleic acid molecule encoding the fusion, transforming host cells with the molecule, inducing the cells to express the fusion protein, and recovering the fusion protein from the cell culture. Alternatively, the fusion proteins may be produced after gene expression according to known methods. An example of a fusion protein according to this invention is the FucI/HSP72 (C-169) protein of Example 3, infra.

The polypeptides of this invention may also be part of larger multimeric molecules which may be produced recombinantly or may be synthesized chemically. Such multimers may also include the polypeptides fused or coupled to moieties other than amino acids, including lipids and carbohydrates.

The polypeptides of this invention are particularly well-suited for the generation of antibodies and for the development of a protective response against disease. Accordingly, in another aspect of this invention, we provide antibodies, or fragments thereof, that are immunologically reactive with HSP72. The antibodies of this invention are either elicited by immunization with HSP72 or an immunologically related polypeptide, or are identified by their reactivity with HSP72 or an immunologically related polypeptide. It should be understood that the antibodies of this invention are not intended to include those antibodies which are normally elicited in an animal upon infection with naturally occurring *S. pneumoniae* and which have not been removed from or altered within the animal in which they were elicited.

The antibodies of this invention may be intact immunoglobulin molecules or fragments thereof that contain an intact antigen binding site, including those fragments known in the art as F(v), Fab, Fab' and F(ab')2. The antibodies may also be genetically engineered or synthetically produced. The antibody or fragment may be of animal origin, specifically of mammalian origin, and more specifically of murine, rat, monkey or human origin. It may be a natural antibody or fragment, or if desired, a recombinant antibody or fragment. The antibody or antibody fragments may be of polyclonal, or preferably, of monoclonal origin. They may be specific for a number of epitopes but are preferably specific for one. Specifically preferred are the monoclonal antibodies F1-Pn3.1, F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4 of Example 2, infra. One of skill in the art may use the polypeptides of this invention to produce other monoclonal antibodies which could be screened for their ability to confer protection against *S. pneumoniae* , *S. pyogenes*, *S. agalactiae* or other Streptococcal related bacterial infection when used to immunize naive animals. Once a given monoclonal antibody is found to confer protection, the particular epitope that is recognized by that antibody may then be identified. Methods to produce polyclonal and monoclonal antibodies are well known to those of skill in the art. For a review of such methods, see *Antibodies, A Laboratory Manual, supra*, and D.E. Yelton, et al., Ann. Rev. of Biochem., 50, pp. 657-80 (1981). Determination of immunoreactivity with a polypeptide of this invention may be made by any of several methods well known in the art, including by immunoblot assay and ELISA.

An antibody of this invention may also be a hybrid molecule formed from immunoglobulin sequences from different species (e.g., mouse and human) or from portions of immunoglobulin light and heavy chain sequences from the same species. It may be a molecule that has multiple binding specificities, such as a bifunctional antibody

prepared by any one of a number of techniques known to those of skill in the art including: the production of hybrid hybridomas; disulfide exchange; chemical cross-linking; addition of peptide linkers between two monoclonal antibodies; the introduction of two sets of immunoglobulin heavy and light chains into a particular cell line; and so forth. The antibodies of this invention may also be human monoclonal antibodies, for example those produced by immortalized human cells, by SCID-hu mice or other non-human animals capable of producing "human" antibodies, or by the expression of cloned human immunoglobulin genes.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

The polypeptides, DNA sequences and antibodies of this invention are useful in prophylactic, therapeutic and diagnostic compositions for preventing, treating and diagnosing disease.

Standard immunological techniques may be employed with the polypeptides and antibodies of this invention in order to use them as immunogens and as vaccines. In particular, any suitable host may be injected with a pharmaceutically effective amount of polypeptide to generate monoclonal or polyvalent antibodies or to induce the development of a protective immunological response against disease. Preferably, the polypeptide is selected from the group consisting of HSP72 (SEQ ID NO:5), HSP70 (SEQ ID NO:20 and SEQ ID NO:22) or fragments thereof.

As used herein, a "pharmaceutically effective amount" of a polypeptide or of an antibody is the amount that, when administered to a patient, elicits an immune response that is effective to prevent or lessen the severity of Streptococcal or related bacterial infections.

The administration of the polypeptides or antibodies of this invention may be accomplished by any of the methods described in Example 10, infra, or by a variety of other standard procedures. For a detailed discussion of such techniques, see *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, ed. E. Harlow and D. Lane (1988). Preferably, if a polypeptide is used, it will be administered with a pharmaceutically acceptable adjuvant, such as complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes). Preferably, the composition will include a water-in-oil emulsion or aluminum hydroxide as adjuvant and will be administered intramuscularly. The vaccine composition may be administered to the patient at one time or over a series of treatments. The most effective mode of administration and dosage regimen will depend upon the level of immunogenicity, the particular composition and/or adjuvant used for treatment, the severity and course of the expected infection, previous therapy, the patient's health status and response to immunization, and the judgment of the treating physician. For example, in an immunocompetent patient, the more highly immunogenic the polypeptide, the lower the dosage and necessary number of immunizations. Similarly, the dosage and necessary treatment time will be lowered if the polypeptide is administered with an adjuvant.

Generally, the dosage will consist of an initial injection, most probably with adjuvant, of about 0.01 to 10 mg, and preferable 0.1 to 1.0 mg, HSP72 antigen per patient, followed most probably by one or maybe more

booster injections. Preferably, boosters will be administered at about 1 and 6 months after the initial injection.

Any of the polypeptides of this invention may be used in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.

To screen the polypeptides and antibodies of this invention for their ability to confer protection against diseases caused by *S. pneumoniae* or related bacteria, or their ability to lessen the severity of such infection, one of skill in the art will recognize that a number of animal models may be used. Any animal that is susceptible to infection with *S. pneumoniae* or related bacteria may be useful. The Balb/c mice of Example 5, infra, are the preferred animal model for active immunoprotection screening, and the severe-combined immunodeficient mice of Example 5 are the preferred animal model for passive screening. Thus, by administering a particular polypeptide or antibody to these animal models, one of skill in the art may determine without undue experimentation whether that polypeptide or antibody would be useful in the methods and compositions claimed herein.

According to another embodiment of this invention, we describe a method which comprises the steps of treating a patient with a vaccine comprising a pharmaceutically effective amount of any of the polypeptides of this invention in a manner sufficient to prevent or lessen the severity, for some period of time, of Streptococcal or related bacterial infection. Again, the preferred polypeptide for use in such methods is HSP70/HSP72, or fragments thereof.

The polypeptides, DNA sequences and antibodies of this invention may also form the basis for diagnostic methods and kits for the detection of pathogenic

organisms. Several diagnostic methods are possible. For example, this invention provides a method for the detection of *Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae* or related bacteria in a biological sample comprising the steps of:

(a) isolating the biological sample from a patient;

(b) incubating an antibody of this invention, or fragment thereof with the biological sample to form a mixture; and

(c) detecting specifically bound antibody or fragment in the mixture which indicates the presence of *Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae* or related bacteria. Preferable antibodies for use in this method include monoclonal antibodies F1-Pn3.1, F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4.

Alternatively, this invention provides a method for the detection of antibodies specific to *Streptococcus pneumoniae* or related bacteria in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating a polypeptide of this invention or fragment thereof, with the biological sample to form a mixture; and

(c) detecting specifically bound polypeptide in the mixture which indicates the presence of antibodies specific to *Streptococcus pneumoniae* or related bacteria. HSP72 (SEQ ID NO:5), the C-169 fragment thereof (residues 439-607 of SEQ ID NO:5), the C-151 fragment thereof (residues 457-607 of SEQ ID NO;5) and peptide fragments GFDAERDAAQAALDD (residues 527-541 of SEQ ID NO:5) and AEGAQATGNAGDDVV (residues 586-600 of SEQ ID NO:5) are the preferred polypeptide and fragments in the above method for the detection of antibodies.

One of skill in the art will recognize that these diagnostic tests may take several forms, including

an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay.

The diagnostic agents may be included in a kit which may also comprise instructions for use and other appropriate reagents, preferably a means for detecting when the polypeptide or antibody is bound. For example, the polypeptide or antibody may be labeled with a detection means that allows for the detection of the polypeptide when it is bound to an antibody, or for the detection of the antibody when it is bound to *S. pneumoniae* or related bacteria. The detection means may be a fluorescent labeling agent such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), and the like, an enzyme, such as horseradish peroxidase (HRP), glucose oxidase or the like, a radioactive element such as ^{125}I or ^{51}Cr that produces gamma ray emissions, or a radioactive element that emits positrons which produce gamma rays upon encounters with electrons present in the test solution, such as ^{11}C, ^{15}O, or ^{13}N. Binding may also be detected by other methods, for example via avidin-biotin complexes. The linking of the detection means is well known in the art. For instance, monoclonal antibody molecules produced by a hybridoma may be metabolically labeled by incorporation of radioisotope-containing amino acids in the culture medium, or polypeptides may be conjugated or coupled to a detection means through activated functional groups.

The DNA sequences of this invention may be used to design DNA probes for use in detecting the presence of *Streptococcus pneumoniae* or related bacteria in a biological sample. The probe-based detection method of this invention comprises the steps of:

(a) isolating the biological sample from a patient;

(b) incubating a DNA probe having a DNA sequence of this invention with the biological sample to form a mixture; and

(c) detecting specifically bound DNA probe in the mixture which indicates the presence of *Streptococcus pneumoniae* or related bacteria.

The DNA probes of this invention may also be used for detecting circulating nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing *Streptococcus pneumoniae* or related bacterial infections. The probes may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labeled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of HSP72 (SEQ ID NO:4, nucleotides 682-2502).

The polypeptides of this invention may also be used to purify antibodies directed against epitopes present on the protein, for example, using immunoaffinity purification of antibodies on an antigen column.

The antibodies or antibody fragments of this invention may be used to prepare substantially pure proteins according to the invention for example, using immunoaffinity purification of antibodies on an antigen column.

EXAMPLES

In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only, and are not to be construed as limiting the scope of the invention in any manner.

Example 1 describes the identification of HSP72, an immunoreactive heat shock protein according to the invention. Example 2 describes the isolation of monoclonal antibodies against epitopes of HSP72. Example 3 describes the preparation of recombinant HSP72 and fragments of HSP72 according to the invention. Example 4 describes the antigenic specificity and immunoreactivity

of monoclonal antibodies directed against HSP72, and the identification of immunologically related proteins according to the invention. Example 5 describes processes for obtaining substantially pure HSP72, and the use of HSP72 or antibodies against it to protect against experimental *S. pneumoniae* infection. Example 6 describes the preparation of recombinant C-151 fragment of HSP72 according to the invention. Example 7 describes the humoral immune response following the immunization with recombinant HSP72 or fragments of HSP72 according to the invention. Example 8 describes the localization of linear B-cell epitopes on the HSP72. Example 9 describes the *hsp70* genes and HSP70 proteins from *S. agalactiae* and *S. pyogenes*. Example 10 describes the use of HSP72 antigen in a human vaccine.

EXAMPLE 1 - Identification of Immunoreactive *S. pneumoniae* Heat Shock Proteins

A. Procedures

Unless otherwise noted, the following procedures were used throughout the Examples herein.

1. Bacteria

S. pneumoniae strains were provided by the Laboratoire de la Santé Publique du Québec, Sainte-Anne de Bellevue. *S. pneumoniae* strains included type 4 strain 53 and type 6 strain 64. If not specified, *S. pneumoniae* type 6 strain 64 was used. Bacterial strains were grown overnight at 37°C in 5% CO_2 on chocolate agar plates.

2. Antigen Preparations

Various *S. pneumoniae* antigens were prepared for immunization and immunoassays. Heat-killed whole cell antigens were obtained by incubating bacterial suspensions

in a water bath prewarmed at 56 C for 20 minutes. Detergent-soluble proteins were extracted from *S. pneumoniae* as follows. Heat-killed bacteria were suspended in 10 mM Hepes buffer (4-(2-Hydroxyethyl)-1-piperazinethan-sulfonsäure) (Boehringer Mannheim GmbH, Germany) at pH 7.4 and sonicated at 20,000 Kz/second, four times for 30 seconds. Intact cells and large debris were removed by centrifugation at 1,700 g for 20 minutes. The supernatant was collected and centrifuged at 100,000 g for 60 minutes. The pellet was resuspended in 1 ml of Hepes buffer, and 1 ml of 2% N-lauroyl sarcosine (Sigma Chemical Co., St. Louis, Mo.) was added. The mixture was incubated for 30 minutes at room temperature and the detergent-soluble fraction was harvested by centrifugation at 100,000 g for 60 minutes.

3. Heat Shock Treatment

S. pneumoniae bacteria (type 4, strain 53 and type 6, strain 64) were resuspended in Eagle's Minimal Essential Medium lacking methionine (ICN Biomedicals Inc., Costa Mesa, CA) and supplemented with 1% BIO-X® (Quelab Laboratories, Montreal, Canada) for 15 minutes at 37°C and then divided into fractions of equal volume. The samples were incubated at either 37°C or 45°C for 5 minutes and then labeled with 100 µCi/ml [^{35}S]methionine (ICN) for 10, 30, or 60 minutes at37°C. The bacteria were harvested and cell extracts were prepared using Tris-HCl lysis buffer as described above, or SDS-PAGE sample buffer.

4. Immunization Of Mice

Female Balb/c mice (Charles River Laboratories, St-Constant, Québec, Canada) were immunized with *S. pneumoniae* antigens. Immune sera to *S. pneumoniae* type 6 strain 64 were obtained from mice immunized, at two-week intervals, by subcutaneous injections of 10^7 heat-killed bacteria or 20 µg of detergent-soluble pneumococcal

proteins absorbed to aluminum hydroxide adjuvant (Alhydrogel®; Cedarlane Laboratories Ltd., Horny, Ontario, Canada). Blood samples were collected prior to immunization and at seven days following the first and second immunization.

5. SDS-PAGE and Immunoassays

Cell extracts were prepared for SDS-PAGE, Western blot analysis and radioimmunoprecipitation assay by incubating bacterial suspensions in Tris-HCl lysis buffer (50mM Tris, 150 mM NaCl, 0.1% Na dodecyl sulfate, 0.5% Na deoxycholate, 2% Triton® X-100, 100 µg/ml phenylmethylsulfonylfluoride, and 2µg/ml aprotinin) at pH 8.0 for 30 minutes on ice. Lysed cells were cleared by centrifugation and the supernatants were aliquoted and kept frozen at -70 C.

SDS-PAGE were performed on a 10% polyacrylamide gel according to the method of Laemmli [Nature, 227, pp. 680-685 (1970)], using the Mini Protean® system (Bio-Rad Laboratories Ltd., Mississauga, Canada). Samples were denatured by boiling for 5 minutes in sample buffer containing 2% 2-mercaptoethanol. Proteins were resolved by staining the polyacrylamide gel with PhastGel Blue® (Pharmacia Biotech Inc., Baie d'Urfé, Canada). The radiolabeled products were visualized by fluorography. Fluorograms were scanned using a laser densitometer.

Immunoblot procedures were performed according to the method of Towbin et al. [Proc. Natl. Acad. Sci. USA, 76, pp. 4350-4354 (1979)]. The detection of antigens reactive with antibodies was performed by an indirect antibody immunoassay using peroxidase-labeled anti-mouse immunoglobulins and the o-dianisidine color substrate.

Radioimmunoprecipitation assays were performed as described by J.A. Wiley et al. [J. Virol., 66, pp. 5744-5751 (1992)]. Briefly, sera or hybridoma culture supernatants were added to radiolabeled samples containing

equal amounts of [^{35}S]methionine. The mixtures were allowed to incubate for 90 minutes at 4 C with constant agitation. The immune complexes were then precipitated with bovine serum albumin-treated protein A Sepharose (Pharmacia) for 1 hour at 4 C. The beads were pelleted and washed three times in Tris buffered saline at pH 8.0, and the antigen complexes were then dissociated by boiling in sample buffer. The antigens were analyzed by electrophoresis on SDS-PAGE. The gels were fixed, enhanced for fluorography using Amplify® (Amersham Canada Limited, Oakville, Ontario, Canada), dried, and then exposed to X-ray film.

B. Characterization of the Heat Shock Response in *S. pneumoniae*

We studied the heat shock response of *S. pneumoniae* by examining the pattern of protein synthesis before and after a shift from 37°C to 45°C. FIG. 1 shows the results when *S. pneumoniae* type 6 strain 64 (panel A) and type 4 strain 53 (panel B) were grown at 37°C, incubated at 37°C (lanes 1,3,5,7 and 9) or at 45°C (lanes 2, 4, 6, 8 and 10) for 5 minutes, and then labeled with [^{35}S]methionine for 10 minutes (lanes 1,2 and 7,8), 30 minutes (lanes 3,4 and 9,10), or 60 minutes (lanes 5,6).

The fluorogram derived from SDS-PAGE indicated that the synthesis of at least three proteins was increased by increasing the temperature (FIG. 1). The most prominent induced protein was about 72 kDa (HSP72), whereas the other two were approximately 80 kDa (HSP80) and 62 kDa (HSP62). Increased protein synthesis was already apparent after 10 minutes of labeling (FIG. 1, lanes 1, 2 and 7, 8) and became more significant when the labeling period was prolonged to 30 minutes (FIG. 1, lanes 3, 4 and 9, 10) and 60 minutes (FIG. 1, lanes 5, 6). The effect of elevated temperature on the protein synthesis profile of two different *S. pneumoniae* strains

was similar, with HSPs of similar molecular mass being synthesized (compare Panel A (type 6 strain 64) to Panel B (type 4 strain 53) in FIG. 1).

Analysis of the densitometric tracings from scanning the protein synthesis profiles allowed the estimation of the relative amounts of proteins. For example, with respect to heat-shocked *S. pneumoniae* type 6 strain 64, after 10 minutes of labeling, HSP80 and HSP62 made up 2.9% and 6.8% of the labeled proteins, respectively, compared to less than 0.1% at 37°C (FIG. 2). Labeled proteins having an apparent molecular mass of 72 kDa were detected at both 37°C and 45°C conditions (FIG. 2). Radioimmunoprecipitation analysis revealed, however, that HSP72 was undetectable at 37°C (supra; and FIGS. 3, 4 and 6) thus indicating that peak 9 from FIG. 2 corresponds to protein component(s) comigrating with HSP72. Assuming no variation in the labeling of this material, these results would suggest that the amount of HSP72 represents 8.7% of the total labeled cell protein after heat shock treatment. A comparison of the densitometric tracings revealed that cellular proteins corresponding to peaks 4, 10, 13, 17, 19, and 21 were synthesized at almost the same rate irrespective of heat shock treatment (FIG. 2). However, the synthesis of several proteins (peaks 1, 2, 3, 15, 20, 22, 24, and 26) declined considerably in response to heat shock (FIG. 2).

C. Immune Responses to *S. pneumoniae* HSPs

In order to assess the antibody response to pneumococcal HSPs, mouse sera were first assayed by radioimmunoprecipitation. The repertoire of labeled proteins recognized by sera from mice immunized with *S. pneumoniae* antigen preparations are shown in FIGS. 3 and 4. FIG. 3 relates to detergent soluble protein preparations. FIG. 4 relates to heat-killed bacterial preparation. Although many bands were detected by most antisera, HSP72 was a major precipitation product. The

specificity of antibodies for HSP72 was demonstrated by the detection of proteins among heat-shocked products only (FIG. 3, lanes 4, 6, 8 and 10; FIG. 4, lanes 4, 6 and 8). Interestingly, all immunized mice consistently recognized HSP72. The antibodies reactive with the HSP72 were not specific to the strain used during the immunization since strong reactivities were observed with heterologous *S. pneumoniae* HSP72. It should be noted that in addition to HSP72, one sera precipitated comigrating product labeled at both 37°C and 45°C (FIG. 4, lane 4). This 72 kDa-product probably corresponds to component from peak 9 in FIG. 2 and was not detected in immunoblots. HSP62 is another immune target which was precipitated by some but not all immune sera (FIG. 3, lane 6 and, FIG. 4, lanes 4 and 6). None of the sera tested reacted with HSP80. No proteins were precipitated when preimmune sera taken from the mice used in this study were tested for the presence of antibodies reactive with the labeled products.

As depicted in FIGS. 3 and 5, antibodies to HSP72 could be detected after one immunization with either detergent-soluble proteins or whole cells extracts of *S. pneumoniae*. In addition, a marked increase in the antibody response to HSP72 was observed after a second immunization (FIG. 3, compare 4 and 6, and lanes 8 and 10).

The immunoblot patterns of 15 mice immunized with heat-killed *S. pneumoniae* bacteria were remarkably consistent with the results of the previously described radioimmunoprecipitation. Although antibody response variation occurred to a variety of proteins, HSP72 was a major immunoreactive antigen with 8 (53%) positive sera after the first immunization (FIG. 5). Antibodies to HSP72 were detected in 13 out of 15 (87%) immune sera tested after the second immunization. Two other prominent antigens having apparent molecular mass of 53.5 and 47 kDa were detected in 5 (33%) and 7 (47%) sera, respectively

(FIG. 5). The 72 kDa-reactive band was confirmed as the pneumococcal HSP72 by using recombinant HSP72 antigens (Example 3, infra) in an immunoblot assay. Preimmune sera failed to detect any pneumococcal proteins.

EXAMPLE 2 - Isolation of Monoclonal Antibodies Against Epitopes of HSP72

A. Procedures

1. Immunization of Mice And Fusion

Female Balb/c mice (Charles River Laboratories) were immunized with *S. pneumoniae* antigens. One set of mice (fusion experiment 1) were immunized by peritoneal injection with 10^7 formalin-killed whole cell antigen from strain MTL suspended in Freund's complete adjuvant, and were boosted at two-week intervals with the same antigen and then with a sonicate from heat-killed bacteria in Freund's incomplete adjuvant. A second group of mice (fusion experiment 2) were immunized three times at three-week intervals with 75 µg of detergent-soluble pneumococcal antigens extracted from strain 64 (type 6) in 25 µg of Quil A adjuvant (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada). Three days before fusion, all mice were injected intraperitoneally with the respective antigen suspended in PBS alone. Hybridomas were produced by fusion of spleen cells with nonsecreting SP2/0 myeloma cells as previously described by J. Hamel et al. [J. Med. Microbiol., 23, pp. 163-170 (1987)]. Specific hybridoma were cloned by sequential limiting dilutions, expanded and frozen in liquid nitrogen. The class, subclass, and light-chain type of MAbs were determined by ELISA as described by D. Martin et al., [Eur. J. Immunol., 18, pp. 601-606 (1988)] using reagents obtained from Southern Biotechnology Associates Inc. (Birmingham, AL).

2. Subcellular Fractionation

Pneumococci were separated into subcellular fractions according to the technique described by Pearce et al. [Mol. Microbiol., 9, pp. 1037-1050 (1993)]. Briefly, *S. pneumoniae* strain 64 (type 6) was grown in Todd Hewitt broth supplemented with 0.5% (w/v) yeast extract for 6 hours at 37°C and isolated by centrifugation. Cell pellets were resuspended in 25 mM Tris-HCl pH 8.0, 1 mM EDTA, 1 mM phenylmethylsulphonylfluoride (PMSF) and sonicated for 4 minutes with 15 second bursts. Cellular debris were removed by centrifugation. The bacterial membranes and cytoplasmic contents were separated by centrifugation at 98,000 g for 4 hours. The cytoplasmic (supernatant) and the membrane (pellet) fractions were adjusted to 1 mg protein per ml and subjected to SDS-PAGE and immunoblot analyses.

B. Identification and Characterization of MAbs to the HSP72 of S. pneumoniae

Culture supernatants of hybridomas were initially screened by dot enzyme immunoassay using whole cells from *S. pneumoniae* strain 65 (type 4) according to the procedures described in D. Martin et al. (supra). Positive hybridomas were then retested by immunoblotting in order to identify the hybridomas secreting MAbs reactive with the HSP72. Of 26 hybridomas with anti-*S. pneumoniae* reactivity in immunoblot, four were found to recognize epitopes present on a protein band with an apparent molecular mass of 72 kDa. The four hybridomas were designated F1-Pn3.1 (from fusion experiment 1) and F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4 (from fusion experiment 2). Isotype analysis revealed that hybridoma F1-Pn3.1 (from fusion experiment 1) secreted IgG_{-2ak} immunoglobulins, whereas hybridomas F2-Pn3.2, F2-Pn3.3, and F2-Pn3.4 (from

fusion experiment 2) all secreted IgG_{1k}. The specificity of the MAbs for HSP72 was clearly demonstrated by the lack of radioimmunoprecipitation activity against [^{35}S]methionine-labeled *S. pneumoniae* proteins obtained from cultures incubated at 37°C and the immunoprecipitation of a 72kDa-protein with heat shock-derived lysates incubated at 45°C. FIG. 6, (lanes 5 and 6) demonstrates the results obtained for MAb F1-Pn3.1. The same results were obtained with MAbs F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4

[^{35}S]methionine-labelled lysates from nonheat-shocked and heat-shocked *S. pneumoniae* cells probed with the MAbs were electrophoresed on SDS-PAGE gels and then subjected to Western blot analysis. The resulting immunoblots revealed the presence of HSP72 antigen in both samples. FIG. 7, panel A, shows the results obtained for MAb F1-Pn3.1. The same results were obtained with MAbs F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4. Accordingly, the heat shock stress did not significantly increase the reactivity of anti-HSP72 monoclonal antibodies. The fluorograph of the immunoblots, however, clearly showed that the heat shock response had occurred (FIG. 7, panel B). These experiments revealed that the rate of synthesis of *S. pneumoniae* HSP72 increases in response to heat shock, but that the absolute amounts of HSP72 do not increase after heat shock.

C. Cellular localization of HSP72

In order to investigate the cellular location of HSP72, *S. pneumoniae* cell lysates were fractionated by differential centrifugation resulting in a soluble fraction and a particulate fraction, enriched in membrane proteins, supra. Sample containing 15 µg protein of membrane fraction (lane 1) and cytoplasmic fraction (lane 2) of *S. pneumoniae* were electrophoresed on SDS-PAGE, transferred to nitrocellulose and probed with MAb F1-

Pn3.1. In the resulting Western blots, HSP72 was found in both fractions, with the majority of the protein associated with the cytoplasmic fraction (FIG. 8).

EXAMPLE 3 - Molecular Cloning, Sequencing and Expression of Genes Coding for HSP72 Antigens

A. Procedures

1. Strains and Plasmids

Strains and plasmids used in this study are listed in Table 1.

TABLE 1: BACTERIAL STRAINS, PHAGES AND PLASMIDS

Strain, Phage Plasmid	Relevant Characteristics	Reference or Source
E. coli Strains		
JM109	Δ(*lac-proAB*)[*F'traD proAB lacI*^{q} ZΔM15]	BRL
Y1090	r_k-m_k- *lon supF* [pMC9]	Amersham
BL21(DE3)	lacUV5-T7 RNA polymerase	Studier et al. (infra)
Phages		
λgt11	*cI857 S100* cloning vector	Amersham
λJBD7	LacZ-HSP72 fusion; 2.3 kb EcoRI fragment in λgt11	This study
λJBD17	FucI-HSP72 chimeric; 2.4 kb EcoRI and 2.3 kb EcoRI fragments in λgt11	This study
Plasmids		
pWSK29	Amp^r; low copy number cloning vector	Wang et al. (infra)
pWKS30	same as pWSK29 but opposite multi cloning site	Wang et al. (infra)
pJBD171	same as λJBD17 but in pWSK29	This study
pJBD177	2.8 kb XhoI-EcoRI fragment in pWKS30 no recombinant HSP72 protein expressed	This study
pJBD179	FucI-HSP72 fusion; 2.4 kb EcoRI and 0.8 kb EcoRI-EcoRV fragments in pWSK29	This study
pT7-5	Amp^r; T7 promoter Φ10	Tabor et al. (infra)
pT7-6	same as pT7-5 but opposite multi cloning site	Tabor et al. (infra)
pJBDf51	same as pJBD179 but in pT7-5	This study
pJBDf62	same as pJBD179 but in pT7-6	This study
pDELTA1	Amp^r; Tn 1000	BRL
pJBDΔ1	same as pJBD179 but in pDELTA1	This study

pJBD291	HSP72; 3.2 kb HindIII fragment in pWSK29	This study
pJBDk51	same as pJBD291 but in pT7-5	This study
pJBDΔ4	same as pJBD291 but in pDELTA1	This study

E. coli strains were grown in L broth or on L agar at 37°C. When necessary, ampicillin was added to the media at the concentration of 50 µg/ml. Plasmids were isolated by using the Magic/Wizard® Mini-Preps kit (Promega, Fisher Scientific, Ottawa, Canada).

2. General Recombinant DNA Techniques

Restriction endonucleases, T4 DNA ligase, and DNA molecular weight standards were purchased from Boehringer Mannheim Canada, Laval, Quebec or Pharmacia Biotech, Uppsala, Sweden. DNA restriction endonuclease digestion and ligation were performed as described by J. Sambrook et al. [Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, N.Y. (1989)]. Agarose gel electrophoresis of DNA fragments was performed following the procedure of J. Sambrook et al. (supra) using the TAE buffer (0.04 M Tris-acetate; 0.002 M EDTA) from Boehringer Mannheim. DNA fragments were purified from agarose gel by using the Prep-A-Gene® DNA purification kit (Bio-Rad Laboratories Ltd., Mississauga, Ontario). Transformation was carried out by electroporation with the Gene Pulser® (Bio-Rad) following the protocol provided by the manufacturer.

3. Construction and Screening of Genomic Library

A genomic *S. pneumoniae* DNA library was generated in the bacteriophage expression vector λgt11 (λgt11 cloning system, Amersham) according to the

procedure provided by the manufacturer. Chromosomal DNA of *S. pneumoniae* type 6 strain 64 was prepared by following the procedure of J.C. Paton et al. [Infect. Immun., 54, pp. 50-55 (1986)]. The *S. pneumoniae* chromosomal DNA was partially digested with EcoRI, and the 4- to 7-kb fragments were fractionated and purified from agarose gel. The fragments were ligated into λgt11 arms, packaged, and the resulting phage mixtures used to infect *E. coli* Y1090. Immunoscreening of plaques expressing recombinant HSP72 antigens was performed using HSP72-specific monoclonal antibody F1-Pn3.1, supra. Plaque clones expressing peptides recognized by MAb F1-Pn3.1 were isolated and purified. Liquid lysates were prepared and DNA was purified from a Promega LambdaSorb phage adsorbent according to the manufacturer's directions followed by conventional DNA purification procedures.

4. Southern Blot Analysis

The nonradioactive DIG DNA Labelling and Detection kit, obtained from Boehringer Mannheim, was used to perform Southern blot analysis in this example. The DNA fragments selected for use as probes (infra) were purified by agarose gel electrophoresis and then labelled with digoxigenin (DIG)-11-dUTP. Pneumococcal chromosomal DNA was digested with HindIII and the digests were separated by electrophoresis on an 0.8% SDS-PAGE gel and transformed onto positive charged nylon membranes (Boehringer Mannheim) as described by J. Sambrook et al. (supra). The membrane was then blotted with the DIG-labelled DNA probes according to the protocol of the manufacturer.

5. DNA Sequencing and Sequence Analysis

The DNA fragments sequenced in this example were first cloned into plasmid pDELTA 1 (GIBCO BRL Life

Technologies, Burlington, Ontario). A series of nested deletions were generated from both strands by *in vivo* deletion mediated by Tn 1000 transposon transposition (Deletion Factory System, GIBCO BRL) following the procedures provided by the supplier. These deletions were sized by agarose gel electrophoresis and appropriate deletion derivatives were selected for sequencing by the dideoxynucleotide chain terminating method of F. Sanger et al. [Proc. Natl. Acad. Sci. USA, 74, pp. 5463-5467 (1977)]. To sequence the gaps between deletion templates, oligonucleotides were synthesized by oligonucleotide synthesizer 392 (ABI, Applied Biosystems Inc., Foster City, CA). The sequencing reaction was carried out by PCR (DNA Thermal Cycler 480®, Perkin Elmer) using the Taq DyeDeoxy Terminator Cycle Sequencing kit (ABI), and DNA electrophoresis was performed on automated DNA sequencer 373A (ABI).

6. Expression of Cloned Gene in E. coli T7 RNA pol/promoter system

High level expression of the cloned gene in this example was achieved by employing the bacteriophage T7 RNA polymerase/promoter system in *E. coli*. The DNA fragment specifying the recombinant protein was ligated into plasmids pT7-5 or pT7-6 [S. Tabor and C.C. Richardson, Proc. Natl. Acad. Sci. USA, 82, PP. 1074-1078 (1985)], in a proper orientation in which the gene to be expressed was placed under the control of phage T7 RNA polymerase specific promoter Φ10. The resulting plasmid was transformed into *E. coli* strain BL21(DE3) [F.W. Studier, and B.A. Moffatt, J. Mol. Biol., 189, pp. 113-130 (1986)] which carries the T7 RNA polymerase structural gene on its chromosome under the control of the inducible lacUV5 promoter. Upon IPTG induction, the T7 RNA polymerase induced in the BL21(DE3) transformants specifically

transcribed the gene under the control of T7 promoter Φ10. The overexpressed recombinant proteins were visualized by either Western blotting or Coomassie Blue staining.

7. N-terminal Amino Acid Sequence Analysis of HSP72

Pneumococcal HSP72 was purified by immunoprecipitation using MAb F1-Pn3.1 (supra) and samples of cell wall extracts of *S. pneumoniae* strain 64 prepared as described by L.S. Daniels et al. [Microb. Pathogen., 1, pp. 519-531 (1986)] as antigen. The immune precipitates were resolved by SDS-PAGE and then transferred to polyvinylidene difluoride (PVDF) membrane by the method of P. Matsudaira [J. Biol. Chem., 262, pp. 10035-10038 (1987)]. PVDF membrane was stained with Coomassie Blue, the HSP72 band excised and then analyzed in an automated protein sequencer (ABI), according to standard procedures.

B. Construction of Plasmids Containing *S. pneumoniae* HSP72 Gene Fragments Corresponding to C-169

The λgt11 *S. pneumoniae* genomic DNA library was screened with the HSP72-specific MAb F1-Pn3.1. Seventeen (17) immunoreactive clones were isolated and purified from a total of 1500 phages tested. To confirm the specificity of the proteins expressed by the recombinant phages, Western blot analysis of the recombinant phage lysates was performed. Two groups of clones were identified among the 17 positive clones recognized by MAb F1-Pn3.1 and their representatives were designated as λJBD7 and λJBD17 for further characterization. As shown in FIG. 9, whole cell extracts from *S. pneumoniae* strain 64 (lane 1) and phage lysates from *E. coli* infected with λJBD17 (lanes 2 and 3) or λJBD7 (lanes 4 and 5) cultured in the presence (+) or absence (-) of IPTG were subjected to 10% polyacrylamide

gel electrophoresis and were electrotransferred to nitrocellulose. The immunoblot was probed with HSP72-specific MAb F1-Pn3.1. Clone λJBD17 had two EcoRI-EcoRI insert fragments of 2.4 kb and 2.3 kb (FIG. 10), and expressed a chimeric recombinant protein having an apparent molecular mass of 74 kDa on SDS-PAGE gel (FIG. 9, lanes 2 and 3). Clone λJBD7 was found to contain a 2.3 kb EcoRI insert fragment and produced an apparent fusion protein consisting of LacZ and the 74 kDa chimeric protein expressed from clone λJBD17. The fusion protein had an apparent molecular mass of 160 kDa as estimated by SDS-PAGE (FIG. 9, lane 5). The expression of the chimeric recombinant protein encoded by phage λJBD17 was independent of IPTG induction (FIG. 9, lanes 2 and 3) while the expression of the recombinant fusion protein encoded by phage λJBD7 was dependent on induction of the lac promoter (FIG. 9, lanes 4 and 5).

In an attempt to subclone the HSP72 gene, the pneumococcal DNA insert from clone λJBD17 was extracted, purified and ligated into a low copy plasmid pWSK29 [R.F. Wang and S.R. Kushner, Gene, 100, pp. 195-199 (1991)] to generate plasmid pJBD171. The insert from pJBD171 was characterized by restriction mapping (Fig. 10B), and a series of subcloning and immunoblotting was carried out to define the boundaries of the gene coding for the antigen reactive with MAb F1-Pn3.1. The region responsible for expression of the 74 kDa chimeric protein was found to localize on the 3.2 kb EcoRI-EcoRV fragment, which consists of the intact 2.4 kb EcoRI-EcoRI fragment and the 0.8 kb EcoRI-EcoRV portion of the 2.3 kb EcoRI-EcoRI fragment. The plasmid carrying the 3.2 kb EcoRI-EcoRV insert was designated pJBD179.

C. Expression and DNA Sequence Analysis of a Chimeric Gene Coding for C-169

To further determine the transcriptional direction of the gene coding for the 74 kDa chimeric protein on the 3.2 kb EcoRI-EcoRV fragment, and to increase the yield of the 74 kDa chimeric protein for immunological study, we decided to express the 74 kDa chimeric protein in the *E. coli* T7 RNA and T7 promoter system. The 3.2 kb EcoRI-EcoRV fragment, derived from pJBD179, was ligated into plasmids pT7-5 and pT7-6 in which the multi-cloning sites were placed in opposite orientation with respect to the T7 RNA polymerase specific T7 promoter Φ10. The ligation mixture was used to transform *E. coli* JM109 and positive transformants reactive with MAb F1-Pn3.1 were identified by the colony lifting method described by J. Sambrook et al. [supra]. The resulting recombinant plasmids, derived from pT7-5 and pT7-6, were designated pJBDf51 and pJBDf62, respectively. The intact 3.2 kb EcoRI-EcoRV insert in these recombinant plasmids and their orientation was determined by restriction mapping. To achieve overexpression of the 74 kDa chimeric protein, pJBDf51 and pJBDf62 were transformed, separately, into *E. coli* BL21(DE3). The transformants were induced with IPTG (1 mM) for 3 hours at 37°C. The cells were harvested, washed, resuspended in 1% SDS and boiled for 10 minutes. The lysates were then used for SDS-PAGE and immunoblot analysis. As expected, both transformants produced the 74 kDa chimeric protein readily detected by Western blotting with MAb F1-Pn3.1 (FIG. 11). However, under the IPTG induction condition, only transformants BL21(DE3)(pJBDf51) overexpressed the 74 kDa chimeric protein (FIG. 11A and B, lane 2) indicating that the transcriptional direction of the gene on the 3.2

kb EcoRI-EcoRV fragment is from the EcoRI end towards the EcoRV end (FIG. 10A).

The 3.2 kb EcoRI-EcoRV fragment was cloned into plasmid pDELTA 1 to yield plasmid pJBDΔ1. A series of overlapping deletions were generated and used as DNA sequencing templates. The DNA sequence of the entire 3.2 kb EcoRI-EcoRV insert is SEQ ID NO:1. Two open reading frames ("ORFs") were found and their orientation is indicated in FIG. 10B ("ORF27" and "FucI-HSP72 (C-169)"). In front of these two ORFs, putative ribosome-binding sites were identified (SEQ ID NO:1, nucleotides 18-21 and 760-763). No obvious -10 and -35 promoter sequences were detected. ORF27 spans nucleotides 30-755 (SEQ ID NO:1) and encodes a protein of 242 amino acids with a calculated molecular weight of 27,066 daltons. The deduced amino acid sequence of this protein is SEQ ID NO:2. We designated this gene *orf27*, and compared it to other known sequences. No homologous gene or protein was found. The large ORF (nucleotides 771-2912, SEQ ID NO:1) specifies a protein of 714 amino acids with a predicted molecular mass of 79,238 daltons. The deduced amino acid sequence of this protein is SEQ ID NO:3. This ORF was compared with other known sequences to determine its relationship to other amino acid sequences. This analysis revealed a high degree of similarity of the encoded protein to the sequence of *E. coli* fucose isomerase (FucI) and to several HSP70 gene family members, also known as *DnaK* genes. Alignment of SEQ ID NO:3 and those of the *E. coli* FucI and HSP70 (Dnak) proteins indicated that the N-terminal portion corresponding to amino acids 1 to 545 (SEQ ID NO:3) of the 74 kDa chimeric protein is highly homologous to *E. coli* FucI, while the C-terminal portion corresponding to amino acids 546-714 (SEQ ID NO:3) is similar to HSP70 (DnaK) proteins. It is noteworthy that there is an EcoRI restriction site lying in the junction of these two portions of the gene coding for the 74 kDa protein (SEQ ID NO:1, between nucleotides 2404 and 2405).

Other restriction sites exist between nucleotides 971 and 972 (Pst I), nucleotides 1916 and 1917 (Pst I), nucleotides 1978 and 1979 (Xho I), and nucleotides 3164 and 3165 (EcoRV). From these data we concluded that the 74 kDa protein was a chimeric protein encoded by two pieces of *S. pneumoniae* chromosomal DNA, a 2.4 kb EcoRI-EcoRI fragment derived from the *FucI* homologous gene and a 2.3 kb EcoRI-EcoRI fragment derived from the HSP72 gene.

D. Southern Blot Analysis

Southern blotting was performed in order to confirm that the 74 kDa protein is a chimeric protein and to attempt to clone the entire pneumococcal HSP72 gene. Chromosomal *S. pneumoniae* DNA was digested with HindIII to completion, separated on a 0.8% agarose gel, and transferred onto two positively charged nylon membranes (Boehringer Mannheim). The membranes were then blotted with either the 0.8 kb EcoRI-EcoRV probe, derived from the 2.3 kb EcoRI-EcoRI fragment, or the 1 kb PstI-PstI probe, obtained from the 2.4 kb EcoRI-EcoRI fragment. Both probes had been previously labelled with digoxigenin-dUTP. These two probes hybridized two individual HindIII fragments of different sizes (FIGS. 10B and 10C). The 0.8 kb EcoRI-EcoRV probe recognized the 3.2 kb HindIII fragment and the 1 kb PstI-PstI probe reacted with the 4 kb HindIII fragment. This result further indicated that the gene responsible for the expression of the 74 kDa chimeric protein was generated by fusion, in frame, of two pieces of EcoRI fragments, one originated from the fragment containing the 5' portion of the *S. pneumoniae FucI* homologue, the other derived from the segment carrying the C-169 fragment of the pneumococcal HSP72 gene. The fact that the 0.8 kb EcoRI-EcoRV probe hybridized a single 3.2 kb fragment suggested that there is only a single HSP72 gene copy in *S. pneumoniae*.

E. Production of Recombinant HSP72

A partial pneumococcal genomic library was generated by ligation of the pool of HindIII digests of chromosomal DNA, with sizes ranging from 2.8 to 3.7 kb, into plasmid pWSK29/HindIII. The ligation mixture was used to transform *E. coli* strain JM 109 and the transformants were screened by hybridization with the 0.8 kb EcoRI-EcoRV probe. One representative plasmid from four positive hybridizing clones was named pJBD291. Restriction analysis of the insert and Western blot of the cell lysate of transformants were employed to verify that the plasmid pJBD291 indeed carries the 3.2 kb HindIII fragment containing the HSP72 gene expressing the recombinant HSP72 protein (FIG. 10B). The HSP72 protein expressed by the transformants (pJBD291) migrated on the SDS-PAGE gel at the same position as the native HSP72 protein (FIG. 12). To sequence the entire HSP72 gene and to overexpress the full-length HSP72 protein, the 3.2 kb HindIII fragment was isolated from plasmid pJBD291, and subcloned into plasmids pDELTA 1 and pT7-5 to generate pJBDΔ4 and pJBDk51, respectively.

The entire 3.2 kb HindIII DNA fragment carried on the plasmid pJBDΔ4 and the 2.3 kb EcoRI-EcoRI DNA fragment contained on the plasmid pJBD177 were sequenced. Altogether, the nucleotide sequence comprised 4320 base pairs and revealed two ORFs (SEQ ID NO:4). The first ORF, starting at nucleotide 682 and ending at nucleotide 2502 (SEQ ID NO:4), was identified as the pneumococcal HSP72 gene, and the second ORF, spanning from nucleotide 3265 to nucleotide 4320 (SEQ ID NO:4), was located 764 base pairs downstream from the HSP72 structural gene and was identified as the 5' portion of the pneumococcal *DnaJ* gene. The putative ribosome binding site ("AGGA") was located 9 base pairs upstream from the start codon of the HSP72 structural gene, while the typical ribosome binding

site ("AGGA") was found 66 base pairs upstream from the start codon of the *DnaJ* structural gene. No typical 5' regulatory region was identified in front of these two genes. Restriction sites are located between nucleotides 1 and 2 (HindIII), nucleotides 1318 and 1319 (EcoRI), nucleotides 1994 and 1995 (EcoRI), nucleotides 3343 and 3344 (HindIII), and nucleotides 4315 and 4316 (EcoRI). The gene organization of HSP72 *(DnaK)* and *DnaJ* in *S. pneumoniae* is similar to that of *E. coli* [Saito, H. and Uchida, Mol. Gen. Genet. 164, 1-8 (1978)] as well as several other Gram positive bacteria [Wetzstein, M. et al., J. Bacteriol. 174, 3300-3310 (1992)]. However, the intragenic region of *S. pneumoniae* is significantly larger and no ORF for the grpE gene was found upstream of the HSP72 *(DnaK)* structural gene.

The predicted HSP72 protein has 607 amino acids and a calculated molecular mass of 64,755 daltons, as compared to the 72 kDa molecular mass estimated by SDS-PAGE. The predicted HSP72 protein is acidic with an isoelectric point (pI) of 4.35. Automated Edman degradation of the purified native HSP72 protein extracted from *S. pneumoniae* strain 64 revealed SKIIGIDLGTTN-AVAVLE as the 19 amino acid N-terminal sequence of the protein. The amino-terminal methionine was not detected, presumably due to *in situ* processing which is known to occur in many proteins. No amino acid residue was identified on position 13. The 19 amino acid N-terminal sequence obtained from the native HSP72 protein is in full agreement with the 19 amino acid N-terminal sequence deduced from the nucleotide sequence of the recombinant *S. pneumoniae* HSP72 gene (SEQ ID NO:5) thus confirming the cloning. This N-terminal sequence showed complete identity with the DnaK protein from *Lactococcus lactis* and 68.4% identity with the DnaK protein from *Escherichia Coli*. Similarly, the alignment of the predicted amino acid sequence of HSP72 (SEQ ID NO:5) with those from other bacterial HSP70 (DnaK) proteins also revealed high

homology (FIGS. 13A-13D). For example, HSP72 showed 54% identity with the *E. coli* DnaK protein. The highest identity value was obtained from comparison with the Gram positive bacterium *Lactococcus lactis*, showing 85% identity with HSP72. Like other HSP70 proteins of Gram positive bacteria, HSP72 misses a stretch of 24 amino acids near the amino terminus when compared with DnaK proteins from Gram negative bacteria (FIGS. 13A-13D).

Although HSP72 shares homology with HSP70 (DnaK) proteins from other organisms, it does possess some unique features. Sequence divergence of the HSP70 (DnaK) proteins is largely localized to two regions (residues 244 to 330 and 510 to 607, SEQ ID NO:5). More specifically, the peptide sequences GFDAERDAAQAALDD (residues 527 to 541, SEQ ID NO:5) and AEGAQATGNAGDDVV (residues 586 to 600, SEQ ID NO:5) are exclusive to HSP72. The fact that the C-terminal portion of HSP72 is highly variable suggests that this portion carries antigenic determinants specific to *S. pneumoniae*. Consistent with this hypothesis, monoclonal antibodies directed against the C-169 fragment of HSP72 (infra), were not reactive with *E. coli* and *S. aureus*, which are known to express DnaK proteins similar to HSP72.

The truncated DnaJ protein of *S. pneumoniae* (SEQ ID NO:6) has 352 amino acids, which show a high degree of similarity with the corresponding portions of the *L. lactis* DnaJ protein (72% identity) and the *E. coli* DnaJ protein (51% identity). The predicted truncated DnaJ protein contains high glycine content (15%). Four Gly-, Cys-rich repeats, each with the Cys-X-X-Cys-X-Gly-X-Gly motif characteristic of DnaJ proteins [P.A. Silver and J.C. Way, Cell, 74, pp. 5-6 (1993)], were identified between amino acids 148 and 212 of the *S. pneumoniae* DnaJ protein (SEQ ID NO:6). Three repeated GGFGG sequences (residues 75-79, 81-85, and 90-94) were found near the N-terminus.

F. Reactivity of MAbs Against Recombinant Antigens

The four HSP72 specific MAbs (F1-Pn3.1, F2-Pn3.2, F2-Pn3.3 and F2-Pn3.4, supra) were tested for their reactivity against proteins expressed by *E. coli* infected or transformed with recombinant phages and plasmids containing HSP72 sequences. The four individual MAbs reacted with the lacZ-HSP72 fusion protein expressed by the clone λJBD7, thus localizing the epitopes recognized by these MAbs to the C-terminal 169 residues. Surprisingly, the proteins encoded by the pneumoccocal inserts in λJBD17 and pJBDΔ1 were recognized by only 3 of 4 Mabs. These results suggest that although the C-169 fragments synthesized in *E. coli* infected with λJBD7 and λJBD17 have the same primary structure, they have distinct conformation. The lack of reactivity of MAb F2-Pn3.2 with some recombinant proteins raised the possibility that this particular MAb recognizes a more complex epitope. Although complex, F2-Pn3.2 epitopes are still recognizable on Western immunoblots. The complete $HSP72_{rec}$ protein expressed by *E. coli* containing the recombinant plasmid pJBDΔ4 was reactive with all four MAbs.

EXAMPLE 4 - Antigenic Specificity and Reactivity of HSP72-Specific Monoclonal Antibodies

The reactivity of MAbs F1-Pn3.1, F2-3.2., F2-Pn3.3 and F2-Pn3.4 to a collection of bacterial strains including 20 *S. pneumoniae* strains representing 16 capsular serotypes (types 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 14, 15, 19, 20, and 22) and the 17 non-pneumococcal bacterial strains listed in Table 2, was tested using a dot enzyme immunoassay as described by D. Martin et al. [supra] and immunoblotting. For dot enzyme immunoassay, the bacteria were grown overnight on chocolate agar plates

and then suspended in PBS, pH 7.4. A volume of 5 µl of a suspension containing approximately 10^9 CFU/ml was applied to a nitrocellulose paper, blocked with PBS containing 3% bovine serum albumin, and then incubated sequentially with MAbs and peroxydase-labeled secondary antibody. Whole cell extracts were prepared for Western blot analysis by boiling bacterial suspensions in sample buffer for 5 minutes.

TABLE 2:LIST OF NON-PNEUMOCOCCAL ISOLATES TESTED BY DOT ENZYME IMMUNOASSAY

Strain Designation	Genus species	group or type
C-2	Streptococcus pyogenes	group A
C-3	Streptococcus agalactiae	group B
C-7	Enterococcus faecalis	group D
C-9	Streptococcus bovis	group D
C-14	Streptococcus mutans	
C-15	Streptococcus salivarius	
C-19	Streptococcus sanguis	I
C-20	Streptococcus sanguis	I
C-21	Streptococcus sanguis	I
C-22	Streptococcus sanguis	II
C-23	Streptococcus sanguis	II
C-24	Streptococcus sanguis	II
C-25	Streptococcus sanguis	II
C-27	Gemella morbillorum	
C-30	Staphylococcus aureus	
C-33	Bacillus	
C-36	Escherichia coli	

When tested by dot enzyme immunoassay, each MAb reacted with each of the *S. pneumoniae* strains and none of the non-pneumococcal isolates. These results were unexpected since comparison studies revealed that HSP72 is

very similar to other known bacterial HSP70 (DnaK) proteins, for example those from *E. coli* and *S. aureus*.

Immunoblots were then performed to further investigate the immunoreactivities of our MAbs. As shown in Table 3, each MAb exhibited some reactivity. Although the percent identity of the *E. coli* amino acid sequence and the HSP72 amino acid sequence (SEQ ID NO:5) is 54%, the four HSP72-specific MAbs did not recognize the *E. coli* HSP70 (DnaK) protein. Similarly, the HSP72-specific MAbs did not react with the *C. trachomatis* HSP70 (DnaK) protein, which has 56% amino acid identity with the amino acid sequence of HSP72. High amino acid sequence homology is observed between HSP72 and the HSP70 (DnaK) proteins from gram positive bacterial species. However, again, none of the HSP72-specific MAbs reacted with *S. aureaus* or *Bacillus* gram positive species, which exhibit 74% and 76% amino acid sequence homology, respectively, with HSP72. From these data it is clear that although HSP70 (DnaK) proteins may be structurally related to HSP72, they are immunologically distinct. Among the non-pneumococcal isolates that reacted with at least one MAb, there is *S. pyogenes*, *Enterococcus faecalis*, *S. mutans* and *S. sanguis*, which all belong to the *Streptococcus* or *Streptococcus*-related *Enterococcus* genus. So far, neither the HSP70 protein, nor the gene structure has been identified in these *Streptococcus* or *Enterococcus* species. Altogether, these observations indicate that hypervariable amino acid sequences or residues within HSP70 (DnaK) proteins are involved in antigenicity. Interestingly, immunoblotting analysis revealed that there was no significant variation in the molecular mass of the HSP70 (DnaK) proteins among both *S. pneumoniae* isolates and immunoreactive non-pneumococcal isolates.

TABLE 3: REACTIVITY OF MABS WITH NON-PNEUMOCOCCAL ISOLATES IN WESTERN IMMUNOBLOTTING

Bacterial Strain			MAbs			
Designation	genus/species	type	F1-PN3.1	F2-Pn3.2	F2-PN3.3	F2-Pn3.4
C-2	*Streptococcus pyogenes*	group A	-	+	-	±[a]
C3	*Streptococcus agalactiae*	group B	-	-	-	-
C-7	*Enterococcus faecalis*	group D	-	+	-	-
C-9	*Streptococcus bovis*	group D	-	-	-	-
C-14	*Streptococcus mutans*		-	+	-	±
C-15	*Streptococcus salivarius*		-	-	-	-
C-19	*Streptococcus sanguis*	I	+	+	-	-
C-20	*Streptococcus sanguis*	I	+	+	-	+
C-21	*Streptococcus sanguis*	I	+	+	+	+
C-22	*Streptococcus sanguis*	II	+	+	+	+
C-23	*Streptococcus sanguis*	II	+	+	-	-
C-24	*Streptococcus sanguis*	II	+	+	+	+
C-25	*Streptococcus sanguis*	II	+	+	+	+
C-27	*Gemella morbillorum*		-	-	-	-
C-30	*Staphylococcus aureus*		-	-	-	-
C-33	*Bacillus*		-	-	-	-
C-36	*Escherichia coli*		-	-	-	-
C-RP	*Chlamydia trachomatis*[b]	L2	-	-	-	-

[a] ± indicates a weak signal compared to the reactivity observed with *S. pneumoniae* antigens

[b] *C. trachomatis* purified elementary bodies were tested.

EXAMPLE 5 - Purification of HSP72 And Its Use As An Immunogen to Protect Against Lethal *S. Pneumoniae* Infection

A. Procedures

1. Preparation of Purified Recombinant HSP72 Protein and Recombinant C-169

High level exclusive expression of the HSP72 gene was achieved by employing the bacteriophage T7 RNA polymerase/T7 promoter system in *E. coli*. The 3.2 kb HindIII fragment was cloned in both orientations in front of the T7 promoter Φ10 in the plasmid pT7-5. The resulting plasmid pJBDk51 was then transformed into *E. coli* strain BL21 (DE3). Overexpression of the recombinant HSP72 protein ($HSP72_{rec}$) was induced by culturing in broth supplemented with antibiotics for a 3-hour period after the addition of IPTG to a final concentration of 1 mM. *E. coli* expressing high levels of $HSP72_{rec}$ were concentrated by centrifugation and lysed by mild sonication in 50 mM Tris-Cl (pH 8.0), 1 mM EDTA and 100 mM NaCl lysis buffer containing 0.2 mg/ml lysozyme. The cell lysates were centrifuged at 12,000 g for 15 minutes and the supernatants were collected. $HSP72_{rec}$ was purified by immunoaffinity using monoclonal antibody F1-Pn3.1 immobilized on sepharose 4B beads (Pharmacia). The purity of eluates was assessed on SDS-PAGE.

The recombinant C-169 protein ($C\text{-}169_{rec}$) was expressed in the form of insoluble inclusion bodies in *E. coli* strain JM109 transformed with the plasmid pJBDΔ1. Protein inclusion bodies were recovered from pelleted bacterial cells disrupted by sonication as described before. The pellets were washed in lysis buffer containing 1 mg/ml of deoxycholate to remove contaminating materials, and the protein inclusion bodies were then solubilized in urea 6 M. The protein solution was

centrifuged at 100,000 g and the cleared supernatant collected and dialysed against phosphate-buffered saline. After purification, the protein content was determined by the Bio-Rad protein assay (Bio-Rad Laboratories, Mississauga, Ontario, Canada).

2. Active Immunoprotection Studies

Two groups of 10 female Balb/c mice (Charles River Laboratories) were immunized subcutaneously three times at two-week intervals with 0.1 ml of purified $HSP72_{rec}$ or $C\text{-}169_{rec}$ antigens absorbed to Alhydrogel adjuvant. Two antigen doses, approximately 1 and 5 µg, were tested. A third group of 10 control mice were immunized identically via the same route with Alhydrogel adjuvant alone. Blood samples were collected from the orbital sinus prior to each immmunization and five to seven days following the third injection. The mice were then challenged with approximately 10^6 CFU of the type 3 *S. pneumoniae* strain WU2. Samples of the *S. pneumoniae* challenge inoculum were plated on chocolate agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded at 6-hour intervals for the first 3-4 days post-infection and then at 24-hour intervals for a period of 14 days. On days 14 or 15, the surviving mice were sacrificed and blood samples tested for the presence of *S. pneumoniae* organisms. Antibody responses to the recombinant HSP72 antigens are described in Example 7.

3. Passive Immunoprotection Studies

One NZW rabbit (Charles River Laboratories) was immunized subcutaneously at multiple sites with approximately 50 µg of the purified $C\text{-}169_{rec}$ protein adsorbed to Alhydrogel adjuvant. The rabbit was boosted three times at two-week intervals with the same antigen and blood samples collected 7 and 14 days following the

last immunization. The serum samples were pooled and antibodies were purified by precipitation using 40% saturated ammonium sulfate.

Severe-combined immunodeficient SCID mice were injected intraperitoneally with 0.25 ml of the purified rabbit antibodies 1 hour before intravenous challenge with 5000 or 880 CFU of the type 3 *S. pneumoniae* strain WU2. Control SCID mice received sterile buffer or antibodies purified from nonimmune rabbit sera. Samples of the *S. pneumoniae* challenge inoculum were plated on chocolate agar plates to determine the CFU and to verify the challenge dose. The SCID mice were chosen because of their high susceptibility to *S. pneumoniae* infection. Blood samples (20 µl each) obtained 24 hours post-challenge were plated on chocolate agar and tested for the presence of *S. pneumoniae* organisms. The level of detection was 50 CFU/ml. Deaths were recorded at 24-hour intervals for a period of 5 days.

B. Results

The availability of cloned *S. pneumoniae* DNA inserts encoding the complete or partial (C-169) HSP72 protein and the expression of recombinant proteins in *E. coli* allowed the obtention of purified proteins useful for the investigation of the vaccinogenic potential of HSP72 protein. Both $HSP72_{rec}$ and $C\text{-}169_{rec}$ proteins were obtained in a relatively pure state with no contaminants detected on Coomassie Blue-stained SDS polyacrylamide gels (FIGS. 14 and 15, respectively).

To evaluate the vaccinogenic potential of HSP72, we first examined the ability of $HSP72_{rec}$ to elicit a protective immune response. Groups of 10 mice were immunized with full-length $HSP72_{rec}$ (1 µg or 5 µg dose) and challenged with 4.2 million CFU of *S. pneumoniae* type 3 strain WU2. Eighty percent (80%) of the mice dosed with 1 µg $HSP72_{rec}$ survived the challenge, as did 50% of the mice

dosed with 5 µg HSP72. None of the naive mice immunized with Alhydrogel adjuvant alone without antigen survived the challenge (FIG. 16). No *S. pneumoniae* organisms were detected in any of the blood samples collected on days 14 or 15 from mice surviving infection. The observation that $HSP72_{rec}$ elicited protection against type 3 strain WU2 pneumococci indicated that HSP72 derived from DNA extracted from a type 6 strain contains epitopes capable of eliciting protection against a heterologous strain having a different capsular type.

We further examined the immune response to the HSP72 protein by using recombinant protein fragments expressed from *E. coli* transformed with a chimeric *fucI-HSP72* gene. Mice immunized with purified $C\text{-}169_{rec}$ were protected from fatal pneumococcal challenge, thus demonstrating that some, if not all, epitopes eliciting protection are present in the C-terminal region of the HSP72 molecule comprising the last 169 residues. Groups of 10 mice were immunized with $C\text{-}169_{rec}$ (1 µg or 5 µg doses) and challenged with 6 million CFU of *S. pneumoniae* type 3 strain WU2. Sixty percent (60%) of the mice dosed with 1 µg $C\text{-}169_{rec}$ survived the challenge, as did 70% of the mice dosed with 5 µg $C\text{-}169_{rec}$ (FIG. 17). In contrast, all of the naive mice were dead by 2 days post-challenge. Therefore, the C-terminal portion of *S. pneumoniae* HSP72, which includes the region of maximum divergence among DnaK proteins, is a target for the protective immune response.

As illustrated in Table 4 below, two independent experiments demonstrated that SCID mice passively transferred with rabbit anti-$C\text{-}169_{rec}$ antibodies were protected from fatal infection with *S. pneumoniae* WU2. In contrast, none of the 15 control mice survived. The control mice received antibodies from nonimmune rabbit sera or received sterile buffer alone. In addition, all mice from the control groups had positive *S. pneumoniae* hemoculture 24 hours post-challenge, while *S. pneumoniae*

organisms were detected in only 2 out of a total of 10 immunized SCID mice.

TABLE 4: PASSIVE IMMUNIZATION STUDIES SHOWING PROTECTION OF SCID MICE FROM EXPERIMENTAL S. PNEUMONIAE INFECTION BY ANTI-C-169$_{rec}$ RABBIT ANTIBODIES

Experiment	Injection	No. of Mice Surviving Challenge after 5 days	No. of Mice Testing Positive for the Presence of S. pneumoniae
1	sterile buffer	0/5	5/5
	anti-C-169$_{rec}$	4/5	2/5
	control antibodies	0/5	5/5
2	sterile buffer	0/5	5/5
	anti-C-169$_{rec}$	5/5	0/5

In experiments 1 and 2 (Table 4), mice were challenged with 5000 and 880 CFU of type 3 *S. pneumoniae* strain WU2, respectively. Results in Table 4 are expressed as the number of mice surviving challenge, or testing positive for the presence of *S. pneumoniae*, compared to the total number of mice in each group.

Demonstration of the anti-HSP72 specificity of the antibody elicited by immunization with recombinant HSP72 or C-169 proteins came from Western Blot analyses using *S. pneumoniae* cell lysates as antigens. A single band corresponding to HSP72 was detected by all rabbit and mouse antisera tested. These serologic results suggested that the protection following the immunization with recombinant proteins was due to the production of antibodies reactive with *S. pneumoniae* HSP72.

EXAMPLE 6 - Heat-Inducible Expression System for High Level Production of the C-151 Terminal Portion of the HSP72 Protein

A. Construction of Plasmid pURV3 Containing the C-151 terminal coding region of the HSP72 of *S. pneumoniae*

The DNA region coding for 151 amino acids at the carboxyl end of the HSP72 of *S. pneumoniae* was inserted downstream of the promoter λ *PL* into the translation vector p629 [H. J. George et al., Bio/Technology 5, pp. 600-603 (1987)]. This vector contains a cassette of the bacteriophage λ *c*I857 temperature sensitive repressor gene from which the functional P_R promoter has been deleted. The inactivation of the *c*I857 repressor by a temperature increase from the ranges of 30-37°C to 37-42°C results in the induction of the gene under the control of λ *PL*. The induction of gene expression in *E. coli* cells by a temperature shift is advantageous for large scale fermentation since it can easily be achieved with modern fermenters. However, it should be understood that while *E. coli* was the microorganism of choice in the experiments herein described, other host organisms, such as yeast, are intended to be included within the scope of this invention.

A fragment of 477 nucleotides, including the region of 457 bases between 2050 to 2506 in HSP72 gene of *S. pneumoniae* (see SEQ ID NO 4), was amplified by the polymerase chain reaction (PCR) from the *S. pneumoniae* type 6 strain 64 genomic DNA using the oligonucleotide primers OCRR26 (5'-GGCAGATCTATGAAGGCCAAAGACCTTGGAAC) and OCRR27 (5'-CGCGGATCCTTACTTTTCCGTAAACTCTCCGT). Chromosomal DNA was prepared from a 90 ml culture of exponentionally growing cells of *S. pneumoniae* in heart infusion broth using the method of Jayarao et al. [J. Clin. Microbiol., 29, pp. 2774-2778 (1991)]. DNA amplification reactions were made using a DNA Thermal Cycler, Perkin Elmer, San Jose, CA. In OCRR26, an ATG start codon is present in frame just upstream of the

coding region for the amino-terminus region of the C-151. The primers OCRR26 and OCRR27 contain, respectively, a *Bgl*II (AGATCT) and a *Bam*HI (GGATCC) recognition site in order to facilitate the cloning of the PCR product into the dephosphorylated restriction sites *Bgl*II and *Bam*HI of p629. The PCR product was purified from agarose gels by the method of phenol freeze [S. A. Benson, Biotechniques 2, pp. 67-68 (1984)] and digested with the restriction enzymes *Bgl*II and *Bam*HI. The *Bgl*II-*Bam*HI fragment of 471 base pairs was then ligated into the *Bgl*II and *Bam*HI recognition sites dephosphorylated of p629. A partial map of the resulting plasmid pURV3 is shown in FIG. 18. This plasmid was transformed by the method of Simanis [Hanahan, D. *In* D. M. Glover (ed.), DNA Cloning, pp. 109-135, (1985)] into the *E. coli* strain XLI Blue MRF' (Δ(*mcrA*)*183* Δ(*mcrCB-hsdSMR-mrr*)*173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac* [F' *proAB lacI*^{q}*ZΔM15* Tn*10* (Tet^{r})]^{c}) which was obtained from Stratagene, La Jolla, CA. The transformants grown at 37°C were screened by colony immunoblot [J. Sambrook et al. (supra)] using the MAb F1-Pn3.1 reactive with C-169$_{rec}$. Plasmid DNA was purified from a selected transformant and the DNA insert was sequenced by PCR using the Taq Dye Deoxy Terminator Cycle Sequencing kit of Applied Biosystems Inc. (ABI) and DNA electrophoresis was performed on automated DNA sequencer 373A (ABI). The nucleotide sequence of the insert perfectly matched the nucleotide sequence of the C-151 coding region of the HSP72 gene. (See SEQ ID No: 25 and corresponding amino acid sequence at SEQ ID No: 26.) The plasmid was transformed into the prototrophic *E. coli* strain W3110 (ATCC 27325) for the production of C-151$_{rec}$.

B. Expression of C-151rec and Antigen Preparation

The recombinant C-151$_{rec}$ was synthesized with a methionine residue at its amino end in *E. coli* strain W3110 harboring the plasmid pURV3. *E. coli* cells were

grown at 30°C in LB broth containing 100 µg of ampicillin-per ml until the A_{600} reached a value of 0.6. The cells were then cultivated at 40°C for 18 hours to induce the production of C-151$_{rec}$ protein. A semi-purified C-151$_{rec}$ protein was prepared using the following procedures. The bacterial cells were harvested by centrifugation and the resulting pellet was washed and resuspended in phosphate-buffered saline. Lysozyme was added and the cells were incubated for 15 min on ice before disruption by pulse sonication. The cell lysates were cleared by centrifugation and the supernatants were collected and subjected to separation using an Amicon's ultrafiltration equipment (stirred cells series 8000, Amicon Canada Ltd. Oakville, Ontario). The ultrafiltrate not retained by a YM30 membrane was recovered, analysed by SDS-PAGE and stained with Coomassie blue R-250. Protein concentrations were estimated by comparing the staining intensity of the C-151$_{rec}$ protein with those obtained with defined concentrations of soybean trypsin inhibitor.

C. Reactivity of MAbs Against C-151rec

A panel of 10 monoclonal antibodies selected for their reactivity with the *S. pneumoniae* HSP72 protein were tested for their reactivity to C-151$_{rec}$ by Western blot analysis using YM30-ultrafiltrates prepared as described above. The MAbs included a series of six monoclonal antibodies raised to the HSP72$_{rec}$ protein (F3-Pn3.5 to F3-Pn3.10) and monoclonal antibodies F1-Pn3.1, F2-Pn3.2, F2-Pn3.3, F2-Pn3.4. The three MAbs F1-Pn3.1, F2-Pn3.3 and F2-Pn3.4 that were reactive with C-169$_{rec}$ also recognized the C-151$_{rec}$ fragment. All other MAbs were only reactive with HSP72$_{rec}$ thus indicating that they may be directed against epitopes present in the amino terminal region of the HSP72 protein.

EXAMPLE 7 - Antibody Response of Balb/c Mice and Macaca-Fascicularis (cynomolgus) Monkeys to Recombinant HSP72 Antigens

A. Procedures

1. Immunization of Animals

Groups of 10 female Balb/c mice were immunized subcutaneously with either HSP72 $_{rec}$ or C-169 $_{rec}$ as described in Example 5. In order to assess the antibody response to C-151$_{rec}$, a group of 6 mice were immunized three times at two-week intervals with 0.5 µg of C-151$_{rec}$ absorbed to Alhydrogel adjuvant by intraperitoneal injection. Sera from blood samples collected prior each immunization and four to seven days after the third immunization were tested for antibody reactive with *S. pneumoniae* by ELISA using plates coated with *S. pneumoniae* cell wall extracts.

Female cynomolgus monkeys were immunized intramuscularly at Day 1, 22 and 77 with 0.5 ml containing 150 µg of purified HSP72$_{rec}$ or C-169$_{rec}$ antigens absorbed to Alhydrogel adjuvant. Blood samples were collected regularly before and after each immunization and the sera were tested for antibody reactive with *S. pneumoniae* HSP72 antigen by Western blot analysis.

The specificity of the raised antibodies for *S. pneumoniae* HSP72 was confirmed by Western blot analyses to *S. pneumoniae* cell extracts and purified recombinant antigens.

B. Results

The results previously described in Example 5 clearly demonstrate the protective nature of the antibody response elicited following immunization with recombinant HSP72 antigens. Here we monitored the appearance of serum antibody response in mice (FIG. 19, 20 and 21) and in monkeys (FIG. 22) during the immunization schedule. Both species responded strongly to the full-length and truncated recombinant HSP72 proteins used as immunogens

with average titers of 1:64000 after the third injection. Detailed analysis of individual sera revealed that each animal responded to the immunization in developping antibodies reactive with *S. pneumoniae* HSP72.

In mice immunized with C-169$_{rec}$, the two doses tested, i.e. 1 and 5 µg, were similarly efficient with the induction of similar antibody titers (FIG. 20). A strong boost response was observed after the second injection with C-169$_{rec}$ with no enhancement in the antibody titers after a third injection. In contrast to this, we observed that the immune response to the HSP72$_{rec}$ was dose-dependent. Increases in the specific antibody titers were observed after a second and a third injection with either HSP72$_{rec}$ or C-151$_{rec}$ (FIG. 19 and 21).

Study of the immune response of monkeys clearly indicated that the immunogenicity of recombinant HSP72 antigens is not restricted to rodents such as rabbit and mouse. The humoral response following the second injection with either antigen is characterized by a strong increase in HSP72-specific antibody titers that can persist for several weeks without any detectable decrease in their antibody titers (FIG. 22). In addition, specific serum antibodies were detectable in the sera of each monkey after a single injection of recombinant antigens.

EXAMPLE 8 - B-Cell Epitope Mapping of HSP72 Stress Protein

In Example 3, it was shown that significant variability in the primary sequence of the HSP70 proteins was mainly localized to two regions corresponding to amino acid residues 244 to 330 and 510 to 607 of the *S. pneumoniae* HSP72 protein. These variable regions may contain B-cell epitopes responsable for the antigenic heterogeneity reported in Example 4. To investigate this possibility, the reactivity of polyclonal and monoclonal

antibodies to *S. pneumoniae* HSP72 were tested against fourteen peptides selected to cover most of these regions.

A. Procedures

Fourteen peptides of 14 to 30 amino acids residues were synthesized. The peptide sequences and their locations in the protein are summarized in Table 5. Peptides CS870, CS873, CS874, CS875, CS876, CS877, CS878, CS879, CS880 and CS882 were synthesized by Biochem Immunosystem Inc. (Montreal, Canada) using an automated peptide synthesizer. Peptides MAP1, MAP2, MAP3 and MAP4 were synthesized onto a branching lysine core as Multiple Antigenic Peptides (MAP) by the Service de Séquence de Peptides de l'Est du Québec, Centre de recherche du CHUL (Sainte-Foy, Canada). Peptides were purified by reverse-phase high-pressure liquid chromatography. Peptides were solubilized in distilled water except for peptides CS874 and CS876 which were solubilized in a small volume of either 6M guanidine-HCl or dimethyl sulfoxide and then adjusted to 1 mg/ml with distilled water.

Peptide ELISA were performed by coating synthetic peptides onto Immunolon 4 microtitration plates (Dynatech Laboratories, Inc., Chantilly, VA) at a concentration of 50 µg/ml according to the prodedures described in J. Hamel et al. [supra]. To confirm the reactivity of MAbs with peptides, the ability of fluid-phase peptides to inhibit MAb binding to solid HSP72 was determined. For the inhibition assay, microtitration plates were coated with *S. pneumoniae* cell wall extracts. Hybridoma culture supernatants containing the HSP72-specific MAbs were incubated overnight at 4°C with several concentrations of peptide. Peptide treated and control supernatants were then tested by ELISA as described above.

Immune sera were from animals immunized three times with recombinant HSP72 antigens. One rabbit was immunized with 37.5 µg of purified $HSP72_{rec}$ according to the immunization protocol described in Example 5. Pool murine sera were from three Balb/c mice immunized with

$HSP72_{rec}$ from Example 5 and monkey pool sera were from groups of two animals immunized with either $HSP72_{rec}$ or $C\text{-}169_{rec}$.

TABLE 5: SEQUENCES AND LOCATIONS OF SYNTHETIC PEPTIDES CORRESPONDING TO S. PNEUMONIAE HSP72 AMINO ACID RESIDUES

Peptide	Location	Sequence	Sequence ID No.
CS876	247-261	TSTQISLPFITAGEA	7
CS877	257-271	TAGEAGPLHLEMTLT	8
CS878	268-281	MTLTRAKFDDLTRD	9
CS879	276-290	DDLTRDLVERTKVPV	10
CS880	286-299	TKVPVRQALSDAGL	11
CS882	315-333	RIPAVVEAVKAETGKEPNK	23
CS873	457-471	KAKDLGTQKEQTIVI	12
CS874	467-481	QTIVIQSNSGLTDEE	24
CS875	477-491	LTDEIDRMMKDAEA	13
MAP 1	487-510	KDAEANAESDKKRKEEVDLRNEVD	14
CS870	507-521	NEVDQAIFATEKTIK	15
MAP 2	517-544	EKTIKETEGKGFDAERDAAQAALD DLKK	16
MAP 3	544-573	KAQEDNNLDDMKAKLEALNEKAQG LAVKLY	17
MAP 4	583-607	QEGAEGAQATGNAGDDVVDGEFTE K	18

B. Identification and Localization of Linear B-Cell Epitopes

The results presented in FIG. 23 revealed that most of the immunological reactivity was observed with the

peptides localized within amino acid residues 457 and 607 corresponding to the C-151 fragment of HSP72. Rabbit, mice and monkey sera antibody from animals immunized with either recombinant $HSP72_{rec}$ of $C\text{-}169_{rec}$ were reactive with both, peptide MAP2 and peptide MAP4. Interestingly, the sequence of peptides MAP2 and MAP4 spans the hypervariable carboxyl-terminal region containing the sequences GFDAERDAAQAALDD (residues 527 to 541) and AEGAQATGNAGDDVV (residues 586 to 600) defined as exclusive to *S. pneumoniae* HSP72 based on the comparison of HSP70 protein sequences available in the data banks. Our data thus revealed that both peptide sequences contain linear B-cell epitopes. In addition, the peptide MAP4 alone was also recognized by the MAb F1-Pn3.1. This reactivity was confirmed by fluid-phase inhibition assays in which 10 µg/ml of MAP4 caused complete inhibition of F1-Pn3.1 binding to HSP72. Polyclonal antisera from animals immunized with the complete HSP72 recombinant protein also recognized B-cell epitopes localized on peptides CS875, MAP1 and MAP3. All together these data indicate that the hypervariable C-151 terminal fragment of the HSP72 stimulates B-cell responses and possibly constitutes the immunodominant portion of the HSP72 protein. The lack of reactivity of MAbs F2-Pn3.3 and F2-Pn3.4 with the synthetic peptides suggest that they react with conformational determinants present on the C-terminal region of the HSP72. The existence of protective epitopes in the C-151 region was strongly suggested in Example 5 where mice immunized with purified $C\text{-}169_{rec}$ were protected from fatal infection with a virulent strain of *S. pneumoniae* thus suggesting that the carboxyl-terminal fragments C-169 or C-151 of *S. pneumoniae* HSP72 or even smaller fragments thereof may prove very useful for the development of a future vaccine.

The variable region comprised within the amino acid residues 244 to 330 also constitutes an antigenic domain. Linear epitopes located on overlapping peptides

CS877 (amino acids 257 to 271) and CS878 (amino acids 268 to 281), peptides CS880 (amino acis 286-299) and peptides CS882 (amino acids 315-333) were identified by hyperimmune sera.

EXAMPLE 9 - HSP70 (DnaK) from *Streptococcus pyogenes* and *Streptococcus agalactiae*: Molecular Cloning and DNA Sequencing of the *hsp70* Genes; Nucleotide and Protein Sequence Analyses; Antigenic Relatedness to *S. pneumoniae*; Increased *Streptococcus agalactiae* HSP70 synthesis in response to heat.

A. Procedures

1. Bacterial Strains and Plasmid Vector

The strains of *S. pyogenes* (Group A *Streptococcus*) and *S. agalactiae* (Group B *Streptococcus*) used in this study were provided by the Laboratoire de la Santé Publique du Québec (LSPQ), Sainte-Anne de Bellevue, Québec, Canada. *S. agalactiae* type II strain V8 corresponds to the ATCC strain 12973. *S. pyogenes* strain Bruno corresponds to the ATCC strain 19615. The *E. coli* strain XLI Blue MRF' was obtained from Stratagene.

Streptococcal strains were grown at 37°C in a 5 % CO_2 incubator. The streptococci were streaked on tryptic soy agar plates containing 5 % sheep blood (Les Laboratoires Quélab, Montréal, Canada), liquid cultures were made in heart infusion broth (Difco Laboratories, Detroit, MI) without agitation. The *E. coli* strain was grown at 37°C in L-broth with agitation at 250 rpm or on L-agar.

The general cloning phagemid pBluescript KS(-) was purchased from Stratagene.

2. Recombinant DNA Techniques

Restriction enzymes, T4 DNA ligase, and calf intestinal phosphatase were used as recommended by the suppliers (Pharmacia [Canada] Inc., Baie d'Urfe, Canada; and New England Biolabs Ltd., Mississauga, Canada).

Preparation of plasmids by equilibrium centrifugation in CsCl-ethidium bromide gradients, agarose gel electrophoresis of DNA fragments, Southern hybridization, and colony DNA hybridization were performed as described by J. Sambrook et al.[supra]. Chromosomal DNA of the streptococcal bacteria was prepared using the procedure of B. M. Jayarao et al. [J. Clin. Microbiol., 29, pp. 2774-2778 (1991)] adapted for bacterial cultures of 90 ml. Rapid plasmid preparations were made accordingly to D. Ish-Horowicz et al. [Nucl. Acids Res. 9, pp. 2989-2998 (1981)]. Plasmids used for DNA sequencing were purified using plasmid kits from Qiagen Inc. (Chatsworth, CA). DNA fragments were purified from agarose gels by the method of phenol freeze [S. A. Benson, Biotechniques 2, pp. 67-68 (1984)]. DNA probes were labeled with a^{32}P-dCTP or digoxigenin (DIG)-11-dUTP using the random primer labeling kits of Boehringer Mannheim (Laval, Canada). Plasmid transformations were carried out by the method of Simanis [Hanahan, D. *In* D. M. Glover (ed.), DNA Cloning, pp. 109-135, (1985)]. The sequencing of genomic DNA inserts in plasmids was done using synthetic oligonucleotides. The sequencing reactions were carried out by the polymerase chain reaction (PCR) using the Taq Dye Deoxy Terminator Cycle Sequencing kit (ABI) and DNA electrophoresis was performed on automated DNA sequencer 373A (ABI). The assembly of the DNA sequence was performed using the program Sequencher 3.0 from the Gene Codes Corporation (Ann Arbor, MI). Analysis of the DNA sequences and their predicted polypeptides were performed with the program Gene Works version 2.45 from Intelligenetics, Inc. (Mountain View, CA). DNA amplification reactions were made using a DNA Thermal Cycler 480, Perkin Elmer. Oligonucleotides were synthesized by oligonucleotide synthesizer model 394 (ABI).

3. Molecular Cloning of the Genes *hsp70/dnak* of *S. agalactiae* and *S. pyogenes*

Chromosomal DNA from *S. agalactiae* and *S. pyogenes* was digested to completion with various restriction enzymes with palindromic hexanucleotide recognition sequences. The digests were analysed by Southern hybridization using a labeled PCR-amplified DNA probe corresponding to a 782 base-pairs region starting at base 332 downstream from the ATG initiation codon of the HSP72 gene of *S. pneumoniae* (see SEQ ID NO 4). This DNA region was selected because it is relatively well conserved among the *hsp70* genes of Gram-positive bacteria that have been characterized. The PCR amplification was done on the genomic DNA of *S. pneumoniae* using the oligonucleotides OCRR2 (5'-AAGCTGTTATCACAGTTCCGG) and OCRR3 (5'-GATACCAAGTGACAATGGCG). Hybridizing genomic restriction fragments of sufficient size to code for a 70-kDa polypeptide (>1.8 kb) were partially purified by extraction of genomic fragments of corresponding size from agarose gel. Verification of the presence of the *hsp70* gene among the purified genomic restriction fragments was done by Southern hybridization using the labeled 782-bp *S. pneumoniae* DNA probe.

The purified genomic DNA restriction fragments were cloned into dephosphorylated compatible restriction sites of pBluescript KS(-) and transformed into the *E. coli* strain XLI Blue MRF'. The colonies were screened by DNA hybridization using the labeled 782-bp *S. pneumoniae* DNA probe. Extracted plasmids were digested with various restriction enzymes to evaluate the size of the inserts and to verify the presence of the *hsp70* gene by Southern hybridization using the labeled 782-bp *S. pneumoniae* DNA probe. Plasmid pURV5 contains a 4.2-kb *Hin*dIII insert of the genomic DNA of *S. agalactiae*. Plasmid pURV4 contains a 3.5-kb *Hin*dIII fragment of the genomic DNA of *S. pyogenes*.

4. Heat Shock and Protein Labeling

The stress response of *S. agalactiae* to an heat shock was assayed by pulse-labeling with [^{35}S]methionine as described before in Example 1. *S. agalactiae* bacteria grown overnight in SMAM (Methionine assay Medium supplemented with 1 mg/l methionine, 1% (v/v) Isovitalex and 1 mg/l choline chloride) were pelleted by centrifugation and then resuspended in the methionine-free SMAM medium. The bacteria were incubated at 37°C for 1 h and then divided into two fractions of equal volume. The samples were either incubated at 37 or 43°C for 10 minutes and then labeled with 100 µCi/ml [^{35}S]methionine for 30 minutes at 37°C. The bacteria were extensively washed with PBS and cell extracts were prepared by treatment with mutanolysine and lysozyme as described for the DNA isolation (M.Jayarao et al., supra) followed by sonication.

5. Immunological Characterization

A series of six monoclonal antibodies raised to the $HSP72_{rec}$ protein (F3-Pn3.5 to F3-Pn3.10) and the monoclonal antibodies F1-Pn3.1, F2-Pn3.2, F2-Pn3.3, F2-Pn3.4 were tested for their reactivity to HSP70 antigens from *S. pyogenes* and *S. agalactiae* by Western blot analysis. Cell lysates from *S. pyogenes* and *S. agalactiae* were obtained from treatment with mutanolysine and lysozyme (M.Jayarao et al., supra)., sonication and boiling in SDS-PAGE sample buffer. Cell lysates from *E. coli* transformed with either pURV4 or pURV6 producing truncated *S. pyogenes* HSP70 antigens were tested after boiling in SDS-PAGE sample buffer.

B. DNA Sequence Analysis of the *hsp70 /dnak* Genes of *Streptococcus pyogenes, Streptococcus agalactiae* and *Streptococcus pneumoniae*

A region of 2438 bases in the 4.2-kb *Hin*dIII insert of plasmid pURV5 was sequenced. This sequence

contains an open reading frame (ORF) of 1830 nucleotides coding for a polypeptide of 609 amino acids with a molecular weight of 64907 (see SEQ ID NO: 7). The ORF has an ATG start codon beginning at position 248 and TAA stop codon ending at position 2077. The ATG start codon is preceeded by the sequence GAGG, starting at position 237, which is complementary to 16S rRNA and serves as a ribosome binding site in *E. coli* [G. D. Stormo et al., Nucleic Acids Res. 10, pp. 2971-2996 (1982)]. The ORF and the polypeptide of the HSP70 of *S. agalactiae* are, respectively, identical at 85 and 95 % to the ORF and polypeptide of the HSP72 of *S. pneumoniae*.

Preliminary sequence comparisons with the HSP72 of *S. pneumoniae* showed that the 3.5-kb *Hin*dIII insert in plasmid pURV4 lacks the 3'-end coding region of the *hsp70* of *S. pyogenes*. An attempt to clone a 3-kb *Sal*I genomic fragment containing the entire coding region of *hsp70* of *S. pyogenes* yielded plasmid pURV6 containing a 3.1-kb insert lacking the 5'-end coding region of the gene. The assembly of the *hsp70* gene regions present in plasmids pURV4 and pURV6 gave a 2183 nucleotide region containing an ORF of 1824 bases coding for a polypeptide of 608 amino acids with a molecular weight of 64847 (see SEQ ID NO: 20). The ATG start codon begins at position 204 and the TAA stop codon extends to position 2030. Similarly to the *hsp70* of *S. agalactiae*, the ATG start codon is preceeded by a putative ribosome binding site sequence GAGG starting at position 193[G. D. Stormo, supra]. The ORF and the deduced polypeptide of the *hsp70* of *S. pyogenes* are, respectively, identical at 85 and 94 % to the ORF and polypeptide of the HSP72 of *S. pneumoniae*. The ORF of plasmid pURV4 lacks 125 base pairs coding for 41 amino acids at the carboxyl end of the HSP70 of *S. pyogenes* ; the ORF thus codes for the 567 amino acids of the amino end of that HSP70 ($N\text{-}567_{rec}$). The ORF of plasmid pURV6 lacks 114 base pairs coding for 38 amino acids at the amino end of the HSP70 of *S. pyogenes* ; the ORF thus codes

for the 570 amino acids of the carboxyl end of that HSP70 ($C\text{-}570_{rec}$).

The global comparison of the DNA open reading frames (FIG. 24) and amino acid sequences (FIG. 25) of the HSP70/DnaK of *S.pyogenes*, *S. agalactiae*, and *S. pneumoniae* gave percentages of identity of 82 and 93 %, respectively.

C. Increased Synthesis of HSP70 by *S. agalactiae* in Response to Heat

One dimensional SDS-polyacrylamide gel electrophoretic analysis of cell extracts of heat-shocked and control *S. agalactiae* pulse-labeled with [^{35}S]methionine revealed that the synthesis of a 70 kDa-protein was significantly increased after a thermal stress (FIG. 26, lanes 1 and 2). Radioimmunoprecipitation analysis revealed that the heat inducible 70kDa-protein was easily detected at 43°C using monoclonal antibody F2-Pn3.4 thus indicating that the protein belongs to the heat shock protein 70 (hsp70/DnaK) family (FIG. 26, lanes 3 and 4).

D. Antigenic Relatedness of HSP70 Proteins in *S. pneumoniae*, *S. pyogenes* and *S. agalactiae*

In this study, a panel of MAbs were used to investigate the antigenic relatedness of *S. pyogenes*, *S. agalactiae* and *S. pneumoniae* HSP70 proteins. Eight of ten MAbs reacted with all three *Streptoccocus* species thus indicating that some B-cell epitopes are widely distributed among *S. pneumoniae* , *S. pyogenes* and *S. agalactiae*. The MAb F1-Pn3.1 which is directed against an epitope located between amino acid residues 584 and 607 of HSP72 from *S. pneumoniae* did not react with HSP70 antigens from either *S.pyogenes* or *S. agalactiae*. Comparison of this region among the three *Streptococcus* species revealed differences in 5 to 8 amino acids located between amino acids 589 and 596. The MAb F2-Pn3.3 which

was also directed against epitopes present in the C-151 region was reactive with *S. agalactiae* but not wih *S. pyogenes*. These data clearly indicate that HSP70 proteins from *Streptococcus* species are structurally and immunologically related. There is however immunological distinction.

Analysis of the reactivity of MAbs F3-Pn3.5, F3-Pn3.6, F3-Pn3.7 and F3-Pn3.10 with truncated recombinant *S. pyogenes* HSP70 antigens allowed the identification of an antigenic region near the amino-terminal end on the *S. pneumoniae* HSP72. These MAbs reacted with constructs expressing the N-terminal 567 amino acid residues but failed to react with constructs expressing the C-570 fragment. These data localized the epitopes recognized by the MAbs F3-Pn3.5, F3-Pn3.6, F3-Pn3.7 and F3-Pn3.10 to between residues 1 and 38 of the HSP72 protein.

EXAMPLE 10 - Use of HSP70/HSP72 As A Human Vaccine

To formulate a vaccine for human use, appropriate HSP72 antigens may be selected from the polypeptides described herein. For example, one of skill in the art could design a vaccine around the HSP70/HSP72 polypeptide or fragments thereof containing an immunogenic epitope. The use of molecular biology techniques is particularly well-suited for the preparation of substantially pure recombinant antigens.

The vaccine composition may take a variety of forms. These include, for example solid, semi-solid and liquid dosage forms, such as powders, liquid solutions or suspensions, and liposomes. Based on our belief that the HSP70/HSP72 antigens of this invention may elicit a protective immune response when administered to a human, the compositions of this invention will be similar to those used for immunizing humans with other proteins and polypeptides, e.g. tetanus and diphtheria. Therefore, the

compositions of this invention will preferably comprise a pharmaceutcially acceptable adjuvant such as incomplete Freund's adjuvant, aluminum hydroxide, a muramyl peptide, a water-in oil emulsion, a liposome, an ISCOM or CTB, or a non-toxic B subunit from cholera toxin. Most preferably, the compositions will include a water-in-oil emulsion or aluminum hydroxide as adjuvant.

The composition would be administered to the patient in any of a number of pharmaceutically acceptable forms including intramuscular, intradermal, subcutaneous or topic. Preferrably, the vaccine will be administered intramuscularly.

Generally, the dosage will consist of an initial injection, most probably with adjuvant, of about 0.01 to 10 mg, and preferably 0.1 to 1.0 mg HSP72 antigen per patient, followed most probably by one or more booster injections. Preferably, boosters will be administered at about 1 and 6 months after the initial injection.

An important consideration relating to pneumococcal vaccine development is the question of mucosal immunity. The ideal mucosal vaccine will be safely taken orally or intranasally as one or a few doses and would elicit protective antibodies on the appropriate surfaces along with systemic immunity. The mucosal vaccine composition may include adjuvants, inert particulate carriers or recombinant live vectors.

The anti-HSP72 antibodies of this invention are useful for passive immunotherapy and immunoprophylaxis of humans infected with *S. pneumoniae, S. pyogenes, S. agalactiae* or related bacteria. The dosage forms and regimens for such passive immunization would be similar to those of other passive immunotherapies.

An antibody according to this invention is exemplified by a hybridoma producing MAb F1-Pn3.1 deposited in the American Type Culture Collection in Rockville, Maryland, USA on July 21, 1995, and identified

as Murine Hybridoma Cell Line, F1-Pn3.1. This deposit was assigned accession number HB 11960.

While we have described herein a number of embodiments of this invention, it is apparent that our basic embodiments may be altered to provide other embodiments that utilize the compositions and processes of this invention. Therefore, it will be appreciated that the scope of this invention includes all alternative embodiments and variations that are defined in the foregoing specification and by the claims appended hereto; and the invention is not to be limited by the specific embodiments which have been presented herein by way of example.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Hamel, Josee
Brodeur, Bernard R
Martin, Denis
Rioux, Clement

(ii) TITLE OF INVENTION: STREPTOCOCCAL HEAT SHOCK PROTEINS MEMBERS OF THE HSP70 FAMILY

(iii) NUMBER OF SEQUENCES: 26

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Goudreau Gage Dubuc & Martineau Walker
(B) STREET: 800 Place Victoria, Suite 3400, Stock Exchange Tower
(C) CITY: Montreal
(D) STATE: Quebec
(E) COUNTRY: CANADA
(F) ZIP: H4Z1E9

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/472,534
(B) FILING DATE: 07-JUN-1995

(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US (PROVIS)60/001,805
(B) FILING DATE: 04-AUG-1995

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Leclerc/Dubuc/Prince, Alain/Jean/Gaetan
(C) REFERENCE/DOCKET NUMBER: BIOVAC2-PCT

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (514) 397-7400
(B) TELEFAX: (514) 397-4382

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3167 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus pneumoniae

(ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCATION: 30..755

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 771..2912
(D) OTHER INFORMATION: /product= "FucI/HSP72 (C-169)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GAACTTCATT TTTAGAAAGG AGTGAGTTT ATG TCT CAA GAT GAA AAA TTA ATT        53
                                Met Ser Gln Asp Glu Lys Leu Ile
                                  1               5

CGT GAA CAG ATT TGT GAT GTT TGT CAT AAG ATG TGG CAA CTT GGT TGG       101
Arg Glu Gln Ile Cys Asp Val Cys His Lys Met Trp Gln Leu Gly Trp
     10                  15                  20

GTT GCT GCT AAC GAT GGG AAT GTA TCT GTT CGA TTA GAT GAG GAT ACC       149
Val Ala Ala Asn Asp Gly Asn Val Ser Val Arg Leu Asp Glu Asp Thr
 25                  30                  35                  40

ATT CTT GCA ACA CCT ACT GGT ATC AGC AAA AGT TTT ATT ACA CCA GAA       197
Ile Leu Ala Thr Pro Thr Gly Ile Ser Lys Ser Phe Ile Thr Pro Glu
                 45                  50                  55

AAG CTG GTG AAG TTA AAT CTT AAA GGA GAG ATT TTA GAA GCA GAA GGT       245
Lys Leu Val Lys Leu Asn Leu Lys Gly Glu Ile Leu Glu Ala Glu Gly
             60                  65                  70

GAT TAC TGT CCT TCT AGT GAA ATT AAA ATG CAC ATT CGG TGC TAC GAA       293
Asp Tyr Cys Pro Ser Ser Glu Ile Lys Met His Ile Arg Cys Tyr Glu
         75                  80                  85

GAA CGT GAG GAT GTT CGT TCA GTT GTT CAC GCG CAT CCA CCG ATT GCA       341
Glu Arg Glu Asp Val Arg Ser Val Val His Ala His Pro Pro Ile Ala
     90                  95                  100

ACA GGA TTT GCT CTT GCA CAC ATT CCT TTA GAT ACT TAT TCA CTA ATT       389
Thr Gly Phe Ala Leu Ala His Ile Pro Leu Asp Thr Tyr Ser Leu Ile
105                 110                 115                 120

GAG AGC GCG ATT GTG GTT GGG GCA ATT CCT ATT ACC CCA TTT GGA GTA       437
Glu Ser Ala Ile Val Val Gly Ala Ile Pro Ile Thr Pro Phe Gly Val
                125                 130                 135

CCG TCT ACA ATG GAA GTG CCA GAA GCA ATT ACA CCT TAT CTG CCC GAT       485
Pro Ser Thr Met Glu Val Pro Glu Ala Ile Thr Pro Tyr Leu Pro Asp
            140                 145                 150

CAT GAT GTC ATG CTA TTA GAA AAT CAT GGA GCT CTG ACT GTC GGA AGC       533
His Asp Val Met Leu Leu Glu Asn His Gly Ala Leu Thr Val Gly Ser
        155                 160                 165

GAT GTC ATT ACA GCA TAC TAC CGT ATG GAA ACT TTA GAA TTA GTC GCA       581
Asp Val Ile Thr Ala Tyr Tyr Arg Met Glu Thr Leu Glu Leu Val Ala
    170                 175                 180

AAG ACA ACC TTC CAC GGA AGA ATG TTA CTT TCT ACA AAG GGC ATT GAG       629
Lys Thr Thr Phe His Gly Arg Met Leu Leu Ser Thr Lys Gly Ile Glu
185                 190                 195                 200

GAG CAA GAA ATT GCT CGT CCG ACT TTA GAA CGT CTA TTC TCA ATG CGA       677
Glu Gln Glu Ile Ala Arg Pro Thr Leu Glu Arg Leu Phe Ser Met Arg
                205                 210                 215

GAA AAT TAT AAG GTT ACA GGT CGT CAC CCA GGC TAC CGT AAA TAT AAT       725
Glu Asn Tyr Lys Val Thr Gly Arg His Pro Gly Tyr Arg Lys Tyr Asn
            220                 225                 230
```

```
GGC GAT GGT AGT ATA AAA GAA ACA AAA AAA TAAGAGGAAA GTATT ATG ATC      776
Gly Asp Gly Ser Ile Lys Glu Thr Lys Lys                   Met Ile
        235                 240                             1

CAA CAT CCA CGT ATT GGG ATT CGT CCG ACT ATT GAT GGT CGT CGT CAA      824
Gln His Pro Arg Ile Gly Ile Arg Pro Thr Ile Asp Gly Arg Arg Gln
          5                  10                  15

GGT GTA CGC GAA TCA CTT GAA GTA CAA ACA ATG AAC ATG GCT AAA AGT      872
Gly Val Arg Glu Ser Leu Glu Val Gln Thr Met Asn Met Ala Lys Ser
     20                  25                  30

GTG GCA GAT TTG ATT TCA AGC ACA TTG AAA TAT CCA GAT GGG GAA CCT      920
Val Ala Asp Leu Ile Ser Ser Thr Leu Lys Tyr Pro Asp Gly Glu Pro
 35                  40                  45                  50

GTG GAA TGT GTG ATT TCT CCA TCT ACC ATT GGT CGT GTT CCA GAG GCT      968
Val Glu Cys Val Ile Ser Pro Ser Thr Ile Gly Arg Val Pro Glu Ala
                55                  60                  65

GCA GCT TCC CAT GAG TTG TTT AAA AAA TCA AAT GTT TGC GCA ACA ATT     1016
Ala Ala Ser His Glu Leu Phe Lys Lys Ser Asn Val Cys Ala Thr Ile
            70                  75                  80

ACA GTT ACA CCA TGC TGG TGT TAT GGT AGT GAA ACT ATG GAT ATG TCT     1064
Thr Val Thr Pro Cys Trp Cys Tyr Gly Ser Glu Thr Met Asp Met Ser
          85                  90                  95

CCA GAT ATT CCT CAT GCT ATT TGG GGA TTT AAT GGG ACA GAA CGC CCA     1112
Pro Asp Ile Pro His Ala Ile Trp Gly Phe Asn Gly Thr Glu Arg Pro
     100                 105                 110

GGA GCT GTC TAT CTT GCA GCT GTA CTA GCT TCA CAT ACT CAA AAA GGG     1160
Gly Ala Val Tyr Leu Ala Ala Val Leu Ala Ser His Thr Gln Lys Gly
115                 120                 125                 130

ATT CCA GCC TTT GGG ATT TAT GGT AGA GAT GTT CAG GAA GCT AAT GAT     1208
Ile Pro Ala Phe Gly Ile Tyr Gly Arg Asp Val Gln Glu Ala Asn Asp
                135                 140                 145

ACA GCT ATT CCA GAA GAT GTC AAA GAA AAA CTT TTA CGT TAT GCG CGG     1256
Thr Ala Ile Pro Glu Asp Val Lys Glu Lys Leu Leu Arg Tyr Ala Arg
            150                 155                 160

GCA GTT CTT GCA ACT GGC TTG ATG AGA GAC ACT GCT TAC CTA TCA ATG     1304
Ala Val Leu Ala Thr Gly Leu Met Arg Asp Thr Ala Tyr Leu Ser Met
          165                 170                 175

GGT AGT GTT TCG ATG GGG ATT GGT GGT TCT ATT GTA AAT CCA GAT TTC     1352
Gly Ser Val Ser Met Gly Ile Gly Gly Ser Ile Val Asn Pro Asp Phe
     180                 185                 190

TTC CAA GAA TAC TTA GGA ATG CGA AAT GAA TCG GTA GAT ATG ACG GAG     1400
Phe Gln Glu Tyr Leu Gly Met Arg Asn Glu Ser Val Asp Met Thr Glu
195                 200                 205                 210

TTC ACG CGC CGT ATG GAC CGT GGT ATT TAC GAC CCT GAA GAG TTC GAA     1448
Phe Thr Arg Arg Met Asp Arg Gly Ile Tyr Asp Pro Glu Glu Phe Glu
                215                 220                 225

CGT GCG CTC AAA TGG GTG AAA GAA AAC GTA AAA GAA GGA TTC GAC CAT     1496
Arg Ala Leu Lys Trp Val Lys Glu Asn Val Lys Glu Gly Phe Asp His
            230                 235                 240

AAC CGT GAA GAC CTT GTT TTA AGC CGT GAA GAA AAA GAT AGA CAA TGG     1544
Asn Arg Glu Asp Leu Val Leu Ser Arg Glu Glu Lys Asp Arg Gln Trp
          245                 250                 255
```

```
GAA TTT GTT ATT AAG ATG TTC ATG ATT GGA CGT GAC TTA ATG GTT GGT      1592
Glu Phe Val Ile Lys Met Phe Met Ile Gly Arg Asp Leu Met Val Gly
    260                 265                 270

AAC CCA AGA CTT GCT GAA CTT GGT TTT GAG GAA GAA GCA GTT GGT CAC      1640
Asn Pro Arg Leu Ala Glu Leu Gly Phe Glu Glu Glu Ala Val Gly His
275                 280                 285                 290

CAT GCT TTA GTA GCT GGT TTC CAA GGT CAA CGT CAG TGG ACA GAC CAT      1688
His Ala Leu Val Ala Gly Phe Gln Gly Gln Arg Gln Trp Thr Asp His
                295                 300                 305

TTT CCA AAT GGG GAC TTT ATG GAA ACT TTC CTC AAT ACT CAG TTT GAC      1736
Phe Pro Asn Gly Asp Phe Met Glu Thr Phe Leu Asn Thr Gln Phe Asp
            310                 315                 320

TGG AAT GGT ATT CGA AAA CCA TTT GTA TTT GCG ACA GAG AAT GAT TCA      1784
Trp Asn Gly Ile Arg Lys Pro Phe Val Phe Ala Thr Glu Asn Asp Ser
        325                 330                 335

CTA AAT GGT GTG TCT ATG CTC TTT AAT TAT CTA TTA ACA AAT ACT CCA      1832
Leu Asn Gly Val Ser Met Leu Phe Asn Tyr Leu Leu Thr Asn Thr Pro
    340                 345                 350

CAA ATC TTT GCT GAT GTG CGT ACT TAT TGG AGT CCA GAG GCT GTT GAA      1880
Gln Ile Phe Ala Asp Val Arg Thr Tyr Trp Ser Pro Glu Ala Val Glu
355                 360                 365                 370

CGT GTA ACA GGA TAT ACT TTA GAG GGT CGT GCT GCA GCT GGA TTC TTA      1928
Arg Val Thr Gly Tyr Thr Leu Glu Gly Arg Ala Ala Ala Gly Phe Leu
                375                 380                 385

CAT CTA ATC AAC TCT GGA TCT TGT ACA TTG GAT GGT ACA GGT CAA GCT      1976
His Leu Ile Asn Ser Gly Ser Cys Thr Leu Asp Gly Thr Gly Gln Ala
            390                 395                 400

ACT CGA GAT GGC AAA CCT GTT ATG AAA CCA TTC TGG GAG TTG GAT GAA      2024
Thr Arg Asp Gly Lys Pro Val Met Lys Pro Phe Trp Glu Leu Asp Glu
        405                 410                 415

AGT GAA GTA CAG GCT ATG CTT GAA AAT ACA GAC TTC CCA CCA GCA AAC      2072
Ser Glu Val Gln Ala Met Leu Glu Asn Thr Asp Phe Pro Pro Ala Asn
    420                 425                 430

CGC GAA TAC TTC CGT GGA GGA GGA TTC TCA ACT CGT TTC TTG ACG AAG      2120
Arg Glu Tyr Phe Arg Gly Gly Gly Phe Ser Thr Arg Phe Leu Thr Lys
435                 440                 445                 450

GGG GAT ATG CCA GTA ACA ATG GTA CGT CTC AAT CTT TTA AAA GGG GTT      2168
Gly Asp Met Pro Val Thr Met Val Arg Leu Asn Leu Leu Lys Gly Val
                455                 460                 465

GGT CCA GTG CTA CAA ATT GCA GAA GGT TAC ACA CTT GAA CTT CCT GAA      2216
Gly Pro Val Leu Gln Ile Ala Glu Gly Tyr Thr Leu Glu Leu Pro Glu
            470                 475                 480

GAT GTT CAC CAT ACT TTA GAT AAT CGT ACA GAT CCA GGA TGG CCA ACT      2264
Asp Val His His Thr Leu Asp Asn Arg Thr Asp Pro Gly Trp Pro Thr
        485                 490                 495

ACT TGG TTT GCT CCA CGT TTG ACA GGA AAA GGT GCT TTC AAG TCT GTC      2312
Thr Trp Phe Ala Pro Arg Leu Thr Gly Lys Gly Ala Phe Lys Ser Val
    500                 505                 510

TAT GAC GTC ATG AAT AAT TGG GGA GCT AAT CAC GGA GCC ATA ACA TAT      2360
Tyr Asp Val Met Asn Asn Trp Gly Ala Asn His Gly Ala Ile Thr Tyr
515                 520                 525                 530
```

```
GGA CAC ATT GGA GCA GAC TTG ATT ACC TTG GCT TCT ATG TTG AGA ATT      2408
Gly His Ile Gly Ala Asp Leu Ile Thr Leu Ala Ser Met Leu Arg Ile
                535                 540                 545

CCT CAA ATC GAA GTA ACA TTT GAC ATC GAC AAG AAC GGT ATC GTG TCT      2456
Pro Gln Ile Glu Val Thr Phe Asp Ile Asp Lys Asn Gly Ile Val Ser
            550                 555                 560

GTT AAG GCC AAA GAC CTT GGA ACT CAA AAA GAA CAA ACT ATT GTC ATC      2504
Val Lys Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile Val Ile
        565                 570                 575

CAA TCG AAC TCA GGT TTG ACT GAC GAA GAA ATC GAC CGC ATG ATG AAA      2552
Gln Ser Asn Ser Gly Leu Thr Asp Glu Glu Ile Asp Arg Met Met Lys
    580                 585                 590

GAT GCA GAA GCA AAC GCT GAA TCC GAT AAG AAA CGT AAA GAA GAA GTA      2600
Asp Ala Glu Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu Glu Val
595                 600                 605                 610

GAC CTT CGT AAT GAA GTG GAC CAA GCA ATC TTT GCG ACT GAA AAG ACA      2648
Asp Leu Arg Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr
                615                 620                 625

ATC AAG GAA ACT GAA GGT AAA GGC TTC GAC GCA GAA CGT GAC GCT GCC      2696
Ile Lys Glu Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg Asp Ala Ala
            630                 635                 640

CAA GCT GCC CTT GAT GAC CTT AAG AAA GCT CAA GAA GAC AAC AAC TTG      2744
Gln Ala Ala Leu Asp Asp Leu Lys Lys Ala Gln Glu Asp Asn Asn Leu
        645                 650                 655

GAC GAC ATG AAA GCA AAA CTT GAA GCA TTG AAC GAA AAA GCT CAA GGA      2792
Asp Asp Met Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala Gln Gly
    660                 665                 670

CTT GCT GTT AAA CTC TAC GAA CAA GCC GCA GCA GCG CAA CAA GCT CAA      2840
Leu Ala Val Lys Leu Tyr Glu Gln Ala Ala Ala Ala Gln Gln Ala Gln
675                 680                 685                 690

GAA GGA GCA GAA GGC GCA CAA GCA ACA GGA AAC GCA GGC GAT GAC GTC      2888
Glu Gly Ala Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp Asp Val
                695                 700                 705

GTA GAC GGA GAG TTT ACG GAA AAG TAAGATGAGT GTATTGGATG AAGAGTATCT     2942
Val Asp Gly Glu Phe Thr Glu Lys
            710

AAAAAATACA CGAAAAGTTT ATAATGATTT TTGTAATCAA GCTGATAACT ATAGAACATC    3002

AAAAGATTTT ATTGATAATA TTCCAATAGA ATATTTAGCT AGATATAGAG AAATTATATT    3062

AGCTGAGCAT GATAGTTGTG TCAAAAATGA TGAAGCGGTA AGGAATTTTG TTACCTCAGT    3122

ATTGTTGTCT GCATTTGTAT CGGCGATGGT ATCAGCTATG ATATC                     3167
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 242 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ser Gln Asp Glu Lys Leu Ile Arg Glu Gln Ile Cys Asp Val Cys
 1               5                  10                  15
```

```
His Lys Met Trp Gln Leu Gly Trp Val Ala Ala Asn Asp Gly Asn Val
            20                  25                  30

Ser Val Arg Leu Asp Glu Asp Thr Ile Leu Ala Thr Pro Thr Gly Ile
        35                  40                  45

Ser Lys Ser Phe Ile Thr Pro Glu Lys Leu Val Lys Leu Asn Leu Lys
    50                  55                  60

Gly Glu Ile Leu Glu Ala Glu Gly Asp Tyr Cys Pro Ser Ser Glu Ile
65                  70                  75                  80

Lys Met His Ile Arg Cys Tyr Glu Glu Arg Glu Asp Val Arg Ser Val
                85                  90                  95

Val His Ala His Pro Pro Ile Ala Thr Gly Phe Ala Leu Ala His Ile
            100                 105                 110

Pro Leu Asp Thr Tyr Ser Leu Ile Glu Ser Ala Ile Val Val Gly Ala
        115                 120                 125

Ile Pro Ile Thr Pro Phe Gly Val Pro Ser Thr Met Glu Val Pro Glu
    130                 135                 140

Ala Ile Thr Pro Tyr Leu Pro Asp His Asp Val Met Leu Leu Glu Asn
145                 150                 155                 160

His Gly Ala Leu Thr Val Gly Ser Asp Val Ile Thr Ala Tyr Tyr Arg
                165                 170                 175

Met Glu Thr Leu Glu Leu Val Ala Lys Thr Thr Phe His Gly Arg Met
            180                 185                 190

Leu Leu Ser Thr Lys Gly Ile Glu Glu Gln Glu Ile Ala Arg Pro Thr
        195                 200                 205

Leu Glu Arg Leu Phe Ser Met Arg Glu Asn Tyr Lys Val Thr Gly Arg
    210                 215                 220

His Pro Gly Tyr Arg Lys Tyr Asn Gly Asp Gly Ser Ile Lys Glu Thr
225                 230                 235                 240

Lys Lys
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 714 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Met Ile Gln His Pro Arg Ile Gly Ile Arg Pro Thr Ile Asp Gly Arg
 1               5                  10                  15

Arg Gln Gly Val Arg Glu Ser Leu Glu Val Gln Thr Met Asn Met Ala
            20                  25                  30

Lys Ser Val Ala Asp Leu Ile Ser Ser Thr Leu Lys Tyr Pro Asp Gly
        35                  40                  45

Glu Pro Val Glu Cys Val Ile Ser Pro Ser Thr Ile Gly Arg Val Pro
    50                  55                  60
```

```
Glu Ala Ala Ala Ser His Glu Leu Phe Lys Lys Ser Asn Val Cys Ala
 65                  70                  75                  80

Thr Ile Thr Val Thr Pro Cys Trp Cys Tyr Gly Ser Glu Thr Met Asp
                 85                  90                  95

Met Ser Pro Asp Ile Pro His Ala Ile Trp Gly Phe Asn Gly Thr Glu
            100                 105                 110

Arg Pro Gly Ala Val Tyr Leu Ala Ala Val Leu Ala Ser His Thr Gln
        115                 120                 125

Lys Gly Ile Pro Ala Phe Gly Ile Tyr Gly Arg Asp Val Gln Glu Ala
    130                 135                 140

Asn Asp Thr Ala Ile Pro Glu Asp Val Lys Glu Lys Leu Leu Arg Tyr
145                 150                 155                 160

Ala Arg Ala Val Leu Ala Thr Gly Leu Met Arg Asp Thr Ala Tyr Leu
                165                 170                 175

Ser Met Gly Ser Val Ser Met Gly Ile Gly Gly Ser Ile Val Asn Pro
            180                 185                 190

Asp Phe Phe Gln Glu Tyr Leu Gly Met Arg Asn Glu Ser Val Asp Met
        195                 200                 205

Thr Glu Phe Thr Arg Arg Met Asp Arg Gly Ile Tyr Asp Pro Glu Glu
    210                 215                 220

Phe Glu Arg Ala Leu Lys Trp Val Lys Glu Asn Val Lys Glu Gly Phe
225                 230                 235                 240

Asp His Asn Arg Glu Asp Leu Val Leu Ser Arg Glu Glu Lys Asp Arg
                245                 250                 255

Gln Trp Glu Phe Val Ile Lys Met Phe Met Ile Gly Arg Asp Leu Met
            260                 265                 270

Val Gly Asn Pro Arg Leu Ala Glu Leu Gly Phe Glu Glu Glu Ala Val
        275                 280                 285

Gly His His Ala Leu Val Ala Gly Phe Gln Gly Gln Arg Gln Trp Thr
    290                 295                 300

Asp His Phe Pro Asn Gly Asp Phe Met Glu Thr Phe Leu Asn Thr Gln
305                 310                 315                 320

Phe Asp Trp Asn Gly Ile Arg Lys Pro Phe Val Phe Ala Thr Glu Asn
                325                 330                 335

Asp Ser Leu Asn Gly Val Ser Met Leu Phe Asn Tyr Leu Leu Thr Asn
            340                 345                 350

Thr Pro Gln Ile Phe Ala Asp Val Arg Thr Tyr Trp Ser Pro Glu Ala
        355                 360                 365

Val Glu Arg Val Thr Gly Tyr Thr Leu Glu Gly Arg Ala Ala Ala Gly
    370                 375                 380

Phe Leu His Leu Ile Asn Ser Gly Ser Cys Thr Leu Asp Gly Thr Gly
385                 390                 395                 400

Gln Ala Thr Arg Asp Gly Lys Pro Val Met Lys Pro Phe Trp Glu Leu
                405                 410                 415

Asp Glu Ser Glu Val Gln Ala Met Leu Glu Asn Thr Asp Phe Pro Pro
            420                 425                 430
```

```
Ala Asn Arg Glu Tyr Phe Arg Gly Gly Gly Phe Ser Thr Arg Phe Leu
        435                 440                 445

Thr Lys Gly Asp Met Pro Val Thr Met Val Arg Leu Asn Leu Leu Lys
    450                 455                 460

Gly Val Gly Pro Val Leu Gln Ile Ala Glu Gly Tyr Thr Leu Glu Leu
465                 470                 475                 480

Pro Glu Asp Val His His Thr Leu Asp Asn Arg Thr Asp Pro Gly Trp
                485                 490                 495

Pro Thr Thr Trp Phe Ala Pro Arg Leu Thr Gly Lys Gly Ala Phe Lys
            500                 505                 510

Ser Val Tyr Asp Val Met Asn Asn Trp Gly Ala Asn His Gly Ala Ile
        515                 520                 525

Thr Tyr Gly His Ile Gly Ala Asp Leu Ile Thr Leu Ala Ser Met Leu
    530                 535                 540

Arg Ile Pro Gln Ile Glu Val Thr Phe Asp Ile Asp Lys Asn Gly Ile
545                 550                 555                 560

Val Ser Val Lys Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile
                565                 570                 575

Val Ile Gln Ser Asn Ser Gly Leu Thr Asp Glu Glu Ile Asp Arg Met
            580                 585                 590

Met Lys Asp Ala Glu Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu
        595                 600                 605

Glu Val Asp Leu Arg Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu
    610                 615                 620

Lys Thr Ile Lys Glu Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg Asp
625                 630                 635                 640

Ala Ala Gln Ala Ala Leu Asp Asp Leu Lys Lys Ala Gln Glu Asp Asn
                645                 650                 655

Asn Leu Asp Asp Met Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala
            660                 665                 670

Gln Gly Leu Ala Val Lys Leu Tyr Glu Gln Ala Ala Ala Ala Gln Gln
        675                 680                 685

Ala Gln Glu Gly Ala Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp
    690                 695                 700

Asp Val Val Asp Gly Glu Phe Thr Glu Lys
705                 710
```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4320 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus pneumoniae

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 682..2502
(D) OTHER INFORMATION: /product= ""Heat-shock protein 72""

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 3265..4320
(D) OTHER INFORMATION: /product= ""NH2-terminal portion of DNA J""

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 682..2502

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
AAGCTTGATT CACGCTTTGA AAGAAGAAGG AATTGAAGAA ATCGCAGCAG ATGGCGAATT      60

TGACCATAAC TACCATATGG CCATCCAAAC TCTCCCAGCA GACGATGAAC ACCCAGTAGA     120

TACCATCGCC CAAGTCTTTC AAAAAGGCTA CAAACTCCAT GACCGCATCC TACGCCCAGC     180

AATGGTAGTG GTGTATAACT AAGATACAAA GCCCGTAAAA AGCTCGCAGT AAAAATAGGA     240

GATTGACGAA GTGTTCGATG AACACAAGAA AATCTATCTT TTTTACTCAG AGCTTAGGGC     300

GTGTTCGATT CGGCAATTCT GACGGTAGCT AAAGCAACTC GTCAGAAAAC GGCAGTCGCT     360

ATGGCGTTTG TCTAGCTTCC TTACTAACTC GTCGTCGAAA TAAAATCGAT TTCGACTCTT     420

CGTGTCGCAA TTTACATAAT AGAAAACTTG TCCGAAACGA CAATAAACTA TGAAGAAAGA     480

TAAAATATGT TTGGCTTTGT AATAGTGAGC GAAGCGAACC AAAGACGATA CTCTTCGCTG     540

TGGCGCTATT TGCGCAAATT TTGAGACCTT AGGCTCAAAG TTTAGTCAAA GAGATTGACA     600

AAGTCAAGCT CTGACGGCGT CGCCACTTAA GAAGAGTATC AAAAAGAAAA ATAGAAAATT     660

AACTAACAAG GAGAAAAACA C ATG TCT AAA ATT ATC GGT ATT GAC TTA GGT        711
                       Met Ser Lys Ile Ile Gly Ile Asp Leu Gly
                         1               5                  10

ACA ACA AAC TCA GCA GTT GCA GTT CTT GAA GGA ACT GAA AGC AAA ATC        759
Thr Thr Asn Ser Ala Val Ala Val Leu Glu Gly Thr Glu Ser Lys Ile
                15                  20                  25

ATC GCA AAC CCA GAA GGA AAC CGC ACA ACT CCA TCT GTA GTC TCA TTC        807
Ile Ala Asn Pro Glu Gly Asn Arg Thr Thr Pro Ser Val Val Ser Phe
            30                  35                  40

AAA AAC GGA GAA ATC ATC GTT GGT GAT GCT GCA AAA CGT CAA GCA GTT        855
Lys Asn Gly Glu Ile Ile Val Gly Asp Ala Ala Lys Arg Gln Ala Val
        45                  50                  55

ACA AAC CCA GAT ACA GTT ATC TCT ATC AAA TCT AAG ATG GGA ACT TCT        903
Thr Asn Pro Asp Thr Val Ile Ser Ile Lys Ser Lys Met Gly Thr Ser
    60                  65                  70

GAA AAA GTT TCT GCA AAT GGA AAA GAA TAC ACT CCA CAA GAA ATC TCA        951
Glu Lys Val Ser Ala Asn Gly Lys Glu Tyr Thr Pro Gln Glu Ile Ser
 75                  80                  85                  90

GCT ATG ATC CTT CAA TAC TTG AAA GGC TAC GCT GAA GAC TAC CTT GGT        999
Ala Met Ile Leu Gln Tyr Leu Lys Gly Tyr Ala Glu Asp Tyr Leu Gly
                95                  100                 105
```

```
GAG AAA GTA ACC AAA GCT GTT ATC ACA GTT CCG GCT TAC TTC AAC GAC      1047
Glu Lys Val Thr Lys Ala Val Ile Thr Val Pro Ala Tyr Phe Asn Asp
            110                 115                 120

GCT CAA CGT CAA GCA ACA AAA GAC GCT GGT AAA ATT GCT GGT CTT GAA      1095
Ala Gln Arg Gln Ala Thr Lys Asp Ala Gly Lys Ile Ala Gly Leu Glu
        125                 130                 135

GTA GAA CGT ATT GTT AAC GAA CCA ACT GCA GCA GCT CTT GCT TAT GGT      1143
Val Glu Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly
    140                 145                 150

TTG GAC AAG ACT GAC AAA GAA GAA AAA ATC TTG GTA TTT GAC CTT GGT      1191
Leu Asp Lys Thr Asp Lys Glu Glu Lys Ile Leu Val Phe Asp Leu Gly
155                 160                 165                 170

GGT GGT ACA TTC GAC GTC TCT ATC CTT GAA TTG GGT GAC GGT GTC TTC      1239
Gly Gly Thr Phe Asp Val Ser Ile Leu Glu Leu Gly Asp Gly Val Phe
                175                 180                 185

GAC GTA TTG TCA ACT GCA GGG GAC AAC AAA CTT GGT GGT GAC GAC TTT      1287
Asp Val Leu Ser Thr Ala Gly Asp Asn Lys Leu Gly Gly Asp Asp Phe
            190                 195                 200

GAC CAA AAA ATC ATT GAC CAC TTG GTA GCA GAA TTC AAG AAA GAA AAC      1335
Asp Gln Lys Ile Ile Asp His Leu Val Ala Glu Phe Lys Lys Glu Asn
        205                 210                 215

GGT ATC GAC TTG TCT ACT GAC AAG ATG GCA ATG CAA CGT TTG AAA GAT      1383
Gly Ile Asp Leu Ser Thr Asp Lys Met Ala Met Gln Arg Leu Lys Asp
    220                 225                 230

GCG GCT GAA AAA GCG AAG AAA GAC CTT TCT GGT GTA ACT TCA ACA CAA      1431
Ala Ala Glu Lys Ala Lys Lys Asp Leu Ser Gly Val Thr Ser Thr Gln
235                 240                 245                 250

ATC AGC TTG CCA TTT ATC ACT GCA GGT GAG GCT GGA CCT CTT CAC TTG      1479
Ile Ser Leu Pro Phe Ile Thr Ala Gly Glu Ala Gly Pro Leu His Leu
                255                 260                 265

GAA ATG ACT TTA ACT CGT GCG AAA TTT GAT GAT TTG ACT CGT GAC CTT      1527
Glu Met Thr Leu Thr Arg Ala Lys Phe Asp Asp Leu Thr Arg Asp Leu
            270                 275                 280

GTT GAA CGT ACA AAA GTT CCA GTT CGT CAA GCC CTT TCA GAT GCA GGT      1575
Val Glu Arg Thr Lys Val Pro Val Arg Gln Ala Leu Ser Asp Ala Gly
        285                 290                 295

TTG AGC TTG TCA GAA ATC GAC GAA GTT ATC CTT GTT GGT GGT TCA ACT      1623
Leu Ser Leu Ser Glu Ile Asp Glu Val Ile Leu Val Gly Gly Ser Thr
    300                 305                 310

CGT ATC CCT GCC GTT GTT GAA GCT GTT AAA GCT GAA ACT GGT AAA GAA      1671
Arg Ile Pro Ala Val Val Glu Ala Val Lys Ala Glu Thr Gly Lys Glu
315                 320                 325                 330

CCA AAC AAA TCA GTA AAC CCT GAT GAA GTA GTT GCT ATG GGT GCG GCT      1719
Pro Asn Lys Ser Val Asn Pro Asp Glu Val Val Ala Met Gly Ala Ala
                335                 340                 345

ATC CAA GGT GGT GTG ATT ACT GGT GAT GTC AAG GAT GTT GTC CTT CTT      1767
Ile Gln Gly Gly Val Ile Thr Gly Asp Val Lys Asp Val Val Leu Leu
            350                 355                 360

GAT GTA ACG CCA TTG TCA CTT GGT ATC GAA ACA ATG GGT GGA GTA TTT      1815
Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Met Gly Gly Val Phe
        365                 370                 375
```

```
ACA AAA CTT ATC GAT CGC AAC ACT ACA ATC CCA ACA TCT AAA TCA CAA      1863
Thr Lys Leu Ile Asp Arg Asn Thr Thr Ile Pro Thr Ser Lys Ser Gln
    380                 385                 390

GTC TTC TCA ACA GCA GCA GAC AAC CAA CCA GCC GTT GAT ATC CAC GTT      1911
Val Phe Ser Thr Ala Ala Asp Asn Gln Pro Ala Val Asp Ile His Val
395                 400                 405                 410

CTT CAA GGT GAA CGC CCA ATG GCA GCA GAT AAC AAG ACT CTT GGA CGC      1959
Leu Gln Gly Glu Arg Pro Met Ala Ala Asp Asn Lys Thr Leu Gly Arg
                415                 420                 425

TTC CAA TTG ACT GAT ATC CCA GCT GCA CCT CGT GGA ATT CCT CAA ATC      2007
Phe Gln Leu Thr Asp Ile Pro Ala Ala Pro Arg Gly Ile Pro Gln Ile
            430                 435                 440

GAA GTA ACA TTT GAC ATC GAC AAG AAC GGT ATC GTG TCT GTT AAG GCC      2055
Glu Val Thr Phe Asp Ile Asp Lys Asn Gly Ile Val Ser Val Lys Ala
        445                 450                 455

AAA GAC CTT GGA ACT CAA AAA GAA CAA ACT ATT GTC ATC CAA TCG AAC      2103
Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile Val Ile Gln Ser Asn
    460                 465                 470

TCA GGT TTG ACT GAC GAA GAA ATC GAC CGC ATG ATG AAA GAT GCA GAA      2151
Ser Gly Leu Thr Asp Glu Glu Ile Asp Arg Met Met Lys Asp Ala Glu
475                 480                 485                 490

GCA AAC GCT GAA TCC GAT AAG AAA CGT AAA GAA GAA GTA GAC CTT CGT      2199
Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu Glu Val Asp Leu Arg
                495                 500                 505

AAT GAA GTG GAC CAA GCA ATC TTT GCG ACT GAA AAG ACA ATC AAG GAA      2247
Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr Ile Lys Glu
            510                 515                 520

ACT GAA GGT AAA GGC TTC GAC GCA GAA CGT GAC GCT GCC CAA GCT GCC      2295
Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg Asp Ala Ala Gln Ala Ala
        525                 530                 535

CTT GAT GAC CTT AAG AAA GCT CAA GAA GAC AAC AAC TTG GAC GAC ATG      2343
Leu Asp Asp Leu Lys Lys Ala Gln Glu Asp Asn Asn Leu Asp Asp Met
    540                 545                 550

AAA GCA AAA CTT GAA GCA TTG AAC GAA AAA GCT CAA GGA CTT GCT GTT      2391
Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala Gln Gly Leu Ala Val
555                 560                 565                 570

AAA CTC TAC GAA CAA GCC GCA GCA GCG CAA CAA GCT CAA GAA GGA GCA      2439
Lys Leu Tyr Glu Gln Ala Ala Ala Ala Gln Gln Ala Gln Glu Gly Ala
                575                 580                 585

GAA GGC GCA CAA GCA ACA GGA AAC GCA GGC GAT GAC GTC GTA GAC GGA      2487
Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp Asp Val Val Asp Gly
            590                 595                 600

GAG TTT ACG GAA AAG TAAGATGAGT GTATTGGATG AAGAGTATCT AAAAAATACA      2542
Glu Phe Thr Glu Lys
        605

CGAAAAGTTT ATAATGATTT TTGTAATCAA GCTGATAACT ATAGAACATC AAAAGATTTT    2602

ATTGATAATA TTCCAATAGA ATATTTAGCT AGATATAGAG AAATTATATT AGCTGAGCAT    2662

GATAGTTGTG TCAAAAATGA TGAAGCGGTA AGGAATTTTG TTACCTCAGT ATTGTTGTCT    2722

GCATTTGTAT CGGCGATGGT ATCAGCTATG ATATCATTAG AAATACAAAC ATATAAATTT    2782

GTAATACCGT TCATAATTGG TATGATTTGG ACAGTAGTTG TATTTCTTAT GATCAATTGG    2842
```

```
AATTATATAG GCAAATACTA AGAAGAGACA AAAATATATA AATATTTCTG TACTTATAGG    2902

ATATTTAAAA TCCAAATAAA GTTAATTTAC TTATTTGCAG AGGTTGCAAC CCAGCCTCTG    2962

TTTTTCGATA AAAAGGGACG GAATCTCATT TGTTTGGGTT TTGTCTCATC AATAGAAAGG    3022

AACAAAGAGT GTTCGTAACT GAACACGGGT TTCAGAATTT CTTACTAAAT ATAAAAGAAA    3082

GGAATTGAAC CCGACCTAAA TGGTGGTTCG ATTCAGAACA TCAATAGAAA GGAATAAGGG    3142

TGTTCGTAAC TGAACACGGG CTACGGACTG TGCCAAAAAG ATAGTTTTTT CTAGGACGTA    3202

AGCGTCCGTC GTCAAAACTC CTAGATGGCT GTGTCCGTTT GACGCCCTTT GTATCTTGAA    3262

TT ATG AAC AAT ACT GAA TTT TAT GAT CGT CTG GGG GTA TCC AAA AAC        3309
   Met Asn Asn Thr Glu Phe Tyr Asp Arg Leu Gly Val Ser Lys Asn
     1               5                  10                  15

GCT TCG GCA GAC GAA ATC AAA AAG GCT TAT CGT AAG CTT TCC AAA AAA      3357
Ala Ser Ala Asp Glu Ile Lys Lys Ala Tyr Arg Lys Leu Ser Lys Lys
                 20                  25                  30

TAT CAC CCA GAT ATC AAC AAG GAG CCT GGT GCT GAG GAC AAG TAC AAG      3405
Tyr His Pro Asp Ile Asn Lys Glu Pro Gly Ala Glu Asp Lys Tyr Lys
            35                  40                  45

GAA GTT CAA GAA GCC TAT GAG ACT TTG AGT GAC GAC CAA AAA CGT GCT      3453
Glu Val Gln Glu Ala Tyr Glu Thr Leu Ser Asp Asp Gln Lys Arg Ala
        50                  55                  60

GCC TAT GAC CAG TAT GGT GCT GCA GGC GCC AAT GGT GGT TTT GGT GGA      3501
Ala Tyr Asp Gln Tyr Gly Ala Ala Gly Ala Asn Gly Gly Phe Gly Gly
    65                  70                  75

GCT GGT GGT TTC GGC GGT TTC AAT GGG GCA GGT GGC TTC GGT GGT TTT      3549
Ala Gly Gly Phe Gly Gly Phe Asn Gly Ala Gly Gly Phe Gly Gly Phe
80                  85                  90                  95

GAG GAT ATT TTC TCA AGT TTC TTC GGC GGA GGC GGT TCT TCG CGC AAT      3597
Glu Asp Ile Phe Ser Ser Phe Phe Gly Gly Gly Gly Ser Ser Arg Asn
                100                 105                 110

CCA AAC GCT CCT CGC CAA GGA GAT GAT CTC CAG TAT CGT GTC AAT TTG      3645
Pro Asn Ala Pro Arg Gln Gly Asp Asp Leu Gln Tyr Arg Val Asn Leu
            115                 120                 125

ACC TTT GAA GAA GCT ATC TTC GGA ACT GAG AAG GAA GTT AAG TAT CAT      3693
Thr Phe Glu Glu Ala Ile Phe Gly Thr Glu Lys Glu Val Lys Tyr His
        130                 135                 140

CGT GAA GCT GGC TGT CGT ACA TGT AAT GGA TCT GGT GCT AAG CCA GGG      3741
Arg Glu Ala Gly Cys Arg Thr Cys Asn Gly Ser Gly Ala Lys Pro Gly
    145                 150                 155

ACA AGT CCA GTC ACT TGT GGA CGC TGT CAT GGC GCT GGT GTC ATT AAC      3789
Thr Ser Pro Val Thr Cys Gly Arg Cys His Gly Ala Gly Val Ile Asn
160                 165                 170                 175

GTC GAT ACG CAG ACT CCT CTT GGT ATG ATG CGT CGC CAA GTA ACC TGT      3837
Val Asp Thr Gln Thr Pro Leu Gly Met Met Arg Arg Gln Val Thr Cys
                180                 185                 190

GAT GTC TGT CAC GGT CGA GGA AAA GAA ATC AAA TAT CCA TGT ACA ACC      3885
Asp Val Cys His Gly Arg Gly Lys Glu Ile Lys Tyr Pro Cys Thr Thr
            195                 200                 205

TGT CAT GGA ACA GGT CAT GAG AAA CAA GCT CAT AGC GTA CAT GTG AAA      3933
Cys His Gly Thr Gly His Glu Lys Gln Ala His Ser Val His Val Lys
        210                 215                 220
```

```
ATC CCT GCT GGT GTG GAA ACA GGT CAA CAA ATT CGC CTC GCT GGT CAA      3981
Ile Pro Ala Gly Val Glu Thr Gly Gln Gln Ile Arg Leu Ala Gly Gln
    225                 230                 235

GGT GAA GCA GGC TTT AAC GGT GGA CCT TAT GGT GAC TTG TAT GTA GTA      4029
Gly Glu Ala Gly Phe Asn Gly Gly Pro Tyr Gly Asp Leu Tyr Val Val
240                 245                 250                 255

GTT TCT GTG GAA GCT AGT GAC AAG TTT GAA CGT GAA GGA ACG ACT ATC      4077
Val Ser Val Glu Ala Ser Asp Lys Phe Glu Arg Glu Gly Thr Thr Ile
                260                 265                 270

TTC TAC AAT CTC AAC CTC AAC TTT GTC CAA GCG GCT CTT GGT GAT ACA      4125
Phe Tyr Asn Leu Asn Leu Asn Phe Val Gln Ala Ala Leu Gly Asp Thr
            275                 280                 285

GTA GAT ATT CCA ACT GTT CAC GGT GAT GTT GAA TTG GTT ATT CCA GAG      4173
Val Asp Ile Pro Thr Val His Gly Asp Val Glu Leu Val Ile Pro Glu
        290                 295                 300

GGA ACT CAG ACT GGT AAG AAA TTC CGC CTA CGT AGT AAG GGG GCA CCG      4221
Gly Thr Gln Thr Gly Lys Lys Phe Arg Leu Arg Ser Lys Gly Ala Pro
    305                 310                 315

AGC CTT CGT GGC GGT GCA GTT GGT GAC CAA TAC GTT ACT GTT AAT GTC      4269
Ser Leu Arg Gly Gly Ala Val Gly Asp Gln Tyr Val Thr Val Asn Val
320                 325                 330                 335

GTA ACA CCG ACA GGC TTG AAC GAC CGC CAA AAA GTA GCC TTG AAA GAA      4317
Val Thr Pro Thr Gly Leu Asn Asp Arg Gln Lys Val Ala Leu Lys Glu
                340                 345                 350

TTC                                                                 4320
Phe
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 607 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
Met Ser Lys Ile Ile Gly Ile Asp Leu Gly Thr Thr Asn Ser Ala Val
 1               5                  10                  15

Ala Val Leu Glu Gly Thr Glu Ser Lys Ile Ile Ala Asn Pro Glu Gly
            20                  25                  30

Asn Arg Thr Thr Pro Ser Val Val Ser Phe Lys Asn Gly Glu Ile Ile
        35                  40                  45

Val Gly Asp Ala Ala Lys Arg Gln Ala Val Thr Asn Pro Asp Thr Val
    50                  55                  60

Ile Ser Ile Lys Ser Lys Met Gly Thr Ser Glu Lys Val Ser Ala Asn
65                  70                  75                  80

Gly Lys Glu Tyr Thr Pro Gln Glu Ile Ser Ala Met Ile Leu Gln Tyr
                85                  90                  95

Leu Lys Gly Tyr Ala Glu Asp Tyr Leu Gly Glu Lys Val Thr Lys Ala
            100                 105                 110
```

```
Val Ile Thr Val Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln Ala Thr
        115                 120                 125

Lys Asp Ala Gly Lys Ile Ala Gly Leu Glu Val Glu Arg Ile Val Asn
    130                 135                 140

Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp Lys Thr Asp Lys
145                 150                 155                 160

Glu Glu Lys Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe Asp Val
                165                 170                 175

Ser Ile Leu Glu Leu Gly Asp Gly Val Phe Asp Val Leu Ser Thr Ala
            180                 185                 190

Gly Asp Asn Lys Leu Gly Gly Asp Asp Phe Asp Gln Lys Ile Ile Asp
        195                 200                 205

His Leu Val Ala Glu Phe Lys Lys Glu Asn Gly Ile Asp Leu Ser Thr
    210                 215                 220

Asp Lys Met Ala Met Gln Arg Leu Lys Asp Ala Ala Glu Lys Ala Lys
225                 230                 235                 240

Lys Asp Leu Ser Gly Val Thr Ser Thr Gln Ile Ser Leu Pro Phe Ile
                245                 250                 255

Thr Ala Gly Glu Ala Gly Pro Leu His Leu Glu Met Thr Leu Thr Arg
            260                 265                 270

Ala Lys Phe Asp Asp Leu Thr Arg Asp Leu Val Glu Arg Thr Lys Val
        275                 280                 285

Pro Val Arg Gln Ala Leu Ser Asp Ala Gly Leu Ser Leu Ser Glu Ile
    290                 295                 300

Asp Glu Val Ile Leu Val Gly Gly Ser Thr Arg Ile Pro Ala Val Val
305                 310                 315                 320

Glu Ala Val Lys Ala Glu Thr Gly Lys Glu Pro Asn Lys Ser Val Asn
                325                 330                 335

Pro Asp Glu Val Val Ala Met Gly Ala Ala Ile Gln Gly Gly Val Ile
            340                 345                 350

Thr Gly Asp Val Lys Asp Val Val Leu Leu Asp Val Thr Pro Leu Ser
        355                 360                 365

Leu Gly Ile Glu Thr Met Gly Gly Val Phe Thr Lys Leu Ile Asp Arg
    370                 375                 380

Asn Thr Thr Ile Pro Thr Ser Lys Ser Gln Val Phe Ser Thr Ala Ala
385                 390                 395                 400

Asp Asn Gln Pro Ala Val Asp Ile His Val Leu Gln Gly Glu Arg Pro
                405                 410                 415

Met Ala Ala Asp Asn Lys Thr Leu Gly Arg Phe Gln Leu Thr Asp Ile
            420                 425                 430

Pro Ala Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe Asp Ile
        435                 440                 445

Asp Lys Asn Gly Ile Val Ser Val Lys Ala Lys Asp Leu Gly Thr Gln
    450                 455                 460

Lys Glu Gln Thr Ile Val Ile Gln Ser Asn Ser Gly Leu Thr Asp Glu
465                 470                 475                 480
```

```
Glu Ile Asp Arg Met Met Lys Asp Ala Glu Ala Asn Ala Glu Ser Asp
                485                 490                 495

Lys Lys Arg Lys Glu Glu Val Asp Leu Arg Asn Glu Val Asp Gln Ala
            500                 505                 510

Ile Phe Ala Thr Glu Lys Thr Ile Lys Glu Thr Glu Gly Lys Gly Phe
        515                 520                 525

Asp Ala Glu Arg Asp Ala Ala Gln Ala Ala Leu Asp Asp Leu Lys Lys
    530                 535                 540

Ala Gln Glu Asp Asn Asn Leu Asp Asp Met Lys Ala Lys Leu Glu Ala
545                 550                 555                 560

Leu Asn Glu Lys Ala Gln Gly Leu Ala Val Lys Leu Tyr Glu Gln Ala
                565                 570                 575

Ala Ala Ala Gln Gln Ala Gln Glu Gly Ala Glu Gly Ala Gln Ala Thr
            580                 585                 590

Gly Asn Ala Gly Asp Asp Val Val Asp Gly Glu Phe Thr Glu Lys
        595                 600                 605
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 352 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Asn Asn Thr Glu Phe Tyr Asp Arg Leu Gly Val Ser Lys Asn Ala
  1               5                  10                  15

Ser Ala Asp Glu Ile Lys Lys Ala Tyr Arg Lys Leu Ser Lys Lys Tyr
            20                  25                  30

His Pro Asp Ile Asn Lys Glu Pro Gly Ala Glu Asp Lys Tyr Lys Glu
        35                  40                  45

Val Gln Glu Ala Tyr Glu Thr Leu Ser Asp Asp Gln Lys Arg Ala Ala
    50                  55                  60

Tyr Asp Gln Tyr Gly Ala Ala Gly Ala Asn Gly Gly Phe Gly Gly Ala
65                  70                  75                  80

Gly Gly Phe Gly Gly Phe Asn Gly Ala Gly Gly Phe Gly Gly Phe Glu
                85                  90                  95

Asp Ile Phe Ser Ser Phe Phe Gly Gly Gly Gly Ser Ser Arg Asn Pro
            100                 105                 110

Asn Ala Pro Arg Gln Gly Asp Asp Leu Gln Tyr Arg Val Asn Leu Thr
        115                 120                 125

Phe Glu Glu Ala Ile Phe Gly Thr Glu Lys Glu Val Lys Tyr His Arg
    130                 135                 140

Glu Ala Gly Cys Arg Thr Cys Asn Gly Ser Gly Ala Lys Pro Gly Thr
145                 150                 155                 160

Ser Pro Val Thr Cys Gly Arg Cys His Gly Ala Gly Val Ile Asn Val
                165                 170                 175
```

```
Asp Thr Gln Thr Pro Leu Gly Met Met Arg Arg Gln Val Thr Cys Asp
            180                 185                 190

Val Cys His Gly Arg Gly Lys Glu Ile Lys Tyr Pro Cys Thr Thr Cys
        195                 200                 205

His Gly Thr Gly His Glu Lys Gln Ala His Ser Val His Val Lys Ile
    210                 215                 220

Pro Ala Gly Val Glu Thr Gly Gln Gln Ile Arg Leu Ala Gly Gln Gly
225                 230                 235                 240

Glu Ala Gly Phe Asn Gly Gly Pro Tyr Gly Asp Leu Tyr Val Val Val
                245                 250                 255

Ser Val Glu Ala Ser Asp Lys Phe Glu Arg Glu Gly Thr Thr Ile Phe
            260                 265                 270

Tyr Asn Leu Asn Leu Asn Phe Val Gln Ala Ala Leu Gly Asp Thr Val
        275                 280                 285

Asp Ile Pro Thr Val His Gly Asp Val Glu Leu Val Ile Pro Glu Gly
    290                 295                 300

Thr Gln Thr Gly Lys Lys Phe Arg Leu Arg Ser Lys Gly Ala Pro Ser
305                 310                 315                 320

Leu Arg Gly Gly Ala Val Gly Asp Gln Tyr Val Thr Val Asn Val Val
                325                 330                 335

Thr Pro Thr Gly Leu Asn Asp Arg Gln Lys Val Ala Leu Lys Glu Phe
            340                 345                 350
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
Thr Ser Thr Gln Ile Ser Leu Pro Phe Ile Thr Ala Gly Glu Ala
1               5                   10                  15
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Thr Ala Gly Glu Ala Gly Pro Leu His Leu Glu Met Thr Leu Thr
1               5                   10                  15
```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids

(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Thr Leu Thr Arg Ala Lys Phe Asp Asp Leu Thr Arg Asp
1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp Asp Leu Thr Arg Asp Leu Val Glu Arg Thr Lys Val Pro Val
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Thr Lys Val Pro Val Arg Gln Ala Leu Ser Asp Ala Gly Leu
1 5 10

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Lys Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile Val Ile
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Thr Asp Glu Ile Asp Arg Met Met Lys Asp Ala Glu Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Lys Asp Ala Glu Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu Glu
1 5 10 15

Val Asp Leu Arg Asn Glu Val Asp
20

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr Ile Lys
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Glu Lys Thr Ile Lys Glu Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg
1 5 10 15

Asp Ala Ala Gln Ala Ala Leu Asp Asp Leu Lys Lys
20 25

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```
Lys Ala Gln Glu Asp Asn Asn Leu Asp Asp Met Lys Ala Lys Leu Glu
1               5                  10                  15

Ala Leu Asn Glu Lys Ala Gln Gly Leu Ala Val Lys Leu Tyr
            20                  25                  30
```

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```
Gln Glu Gly Ala Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp Asp
1               5                  10                  15

Val Val Asp Gly Glu Phe Thr Glu Lys
            20                  25
```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2183 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus pyogenes

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 204..2030

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```
CAGCGATGGT AGTTGTTTAT AACTAAGGTA AATGAGTTTT CGTTTTTGTC CGTAATGACA      60

GTAAACTAGA TAGCAAGTTA GAAGCTATTT CGCTTGCTGA TTAAACTATA GTGATTGCTT     120

AGAATTGGAA GTAAAATAAT TCGAGTGCTT ACTAAGATAA ATTGAAATAA AAAGTAATAA     180

AGTATAAAAT AAGAGGTATT AAC ATG TCT AAA ATT ATT GGT ATT GAC TTA           230
                           Met Ser Lys Ile Ile Gly Ile Asp Leu
                             1               5

GGT ACA ACA AAC TCA GCA GTA GCA GTT CTT GAA GGG ACT GAA TCA AAA         278
Gly Thr Thr Asn Ser Ala Val Ala Val Leu Glu Gly Thr Glu Ser Lys
 10                  15                  20                  25

ATC ATT GCT AAC CCA GAA GGC AAT CGT ACA ACT CCT TCA GTA GTA TCA         326
Ile Ile Ala Asn Pro Glu Gly Asn Arg Thr Thr Pro Ser Val Val Ser
                 30                  35                  40

TTC AAA AAT GGT GAA ATT ATC GTG GGT GAT GCT GCA AAA CGC CAA GCA         374
Phe Lys Asn Gly Glu Ile Ile Val Gly Asp Ala Ala Lys Arg Gln Ala
            45                  50                  55
```

```
GTG ACA AAC CCA GAA ACA GTA ATC TCT ATT AAA TCT AAA ATG GGA ACT      422
Val Thr Asn Pro Glu Thr Val Ile Ser Ile Lys Ser Lys Met Gly Thr
          60                  65                  70

TCT GAA AAA GTT TCT GCA AAT GGT AAA GAA TAT ACT CCT CAA GAA ATT      470
Ser Glu Lys Val Ser Ala Asn Gly Lys Glu Tyr Thr Pro Gln Glu Ile
     75                  80                  85

TCA GCA ATG ATT CTT CAA TAC CTT AAA GGT TAT GCT GAA GAC TAT CTT      518
Ser Ala Met Ile Leu Gln Tyr Leu Lys Gly Tyr Ala Glu Asp Tyr Leu
 90                  95                 100                 105

GGA GAA AAA GTA GAA AAA GCA GTT ATT ACT GTT CCA GCT TAT TTC AAC      566
Gly Glu Lys Val Glu Lys Ala Val Ile Thr Val Pro Ala Tyr Phe Asn
                110                 115                 120

GAT GCA CAA CGT CAA GCA ACT AAA GAC GCT GGT AAA ATT GCA GGT CTT      614
Asp Ala Gln Arg Gln Ala Thr Lys Asp Ala Gly Lys Ile Ala Gly Leu
            125                 130                 135

GAA GTA GAA CGT ATC GTT AAT GAA CCA ACA GCA GCT GCA CTT GCT TAT      662
Glu Val Glu Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr
        140                 145                 150

GGT ATG GAC AAG ACT GAC AAG GAT GAA AAA ATC TTA GTT TTT GAC CTT      710
Gly Met Asp Lys Thr Asp Lys Asp Glu Lys Ile Leu Val Phe Asp Leu
    155                 160                 165

GGT GGT GGT ACA TTT GAC GTA TCA ATC CTT GAA TTA GGT GAT GGT GTC      758
Gly Gly Gly Thr Phe Asp Val Ser Ile Leu Glu Leu Gly Asp Gly Val
170                 175                 180                 185

TTC GAC GTT CTT GCA ACA GCA GGT GAT AAC AAA CTT GGT GGT GAC GAC      806
Phe Asp Val Leu Ala Thr Ala Gly Asp Asn Lys Leu Gly Gly Asp Asp
                190                 195                 200

TTT GAC CAA AAA ATT ATT GAT TTC TTA GTG GCT GAA TTT AAG AAA GAA      854
Phe Asp Gln Lys Ile Ile Asp Phe Leu Val Ala Glu Phe Lys Lys Glu
            205                 210                 215

AAT GGT ATT GAC TTA TCA CAA GAT AAG ATG GCA CTT CAA CGC TTG AAA      902
Asn Gly Ile Asp Leu Ser Gln Asp Lys Met Ala Leu Gln Arg Leu Lys
        220                 225                 230

GAT GCT GCT GAA AAA GCT AAA AAA GAT CTT TCA GGT GTG ACA CAA ACA      950
Asp Ala Ala Glu Lys Ala Lys Lys Asp Leu Ser Gly Val Thr Gln Thr
    235                 240                 245

CAA ATT TCA TTA CCG TTC ATC ACT GCT GGT TCT GCT GGT CCT CTT CAC      998
Gln Ile Ser Leu Pro Phe Ile Thr Ala Gly Ser Ala Gly Pro Leu His
250                 255                 260                 265

TTA GAG ATG AGC TTA TCT CGT GCT AAA TTT GAC GAT CTC ACT CGT GAC     1046
Leu Glu Met Ser Leu Ser Arg Ala Lys Phe Asp Asp Leu Thr Arg Asp
                270                 275                 280

CTT GTT GAA CGT ACG AAA ACT CCA GTT CGT CAA GCT CTT TCA GAT GCA     1094
Leu Val Glu Arg Thr Lys Thr Pro Val Arg Gln Ala Leu Ser Asp Ala
            285                 290                 295

GGA TTG TCA TTG TCA GAA ATT GAT GAA GTT ATC CTT GTT GGT GGA TCA     1142
Gly Leu Ser Leu Ser Glu Ile Asp Glu Val Ile Leu Val Gly Gly Ser
        300                 305                 310

ACT CGT ATC CCA GCA GTT GTC GAA GCT GTA AAA GCT GAA ACT GGT AAA     1190
Thr Arg Ile Pro Ala Val Val Glu Ala Val Lys Ala Glu Thr Gly Lys
    315                 320                 325
```

```
GAA CCA AAT AAA TCT GTA AAC CCT GAT GAA GTG GTT GCT ATG GGT GCT      1238
Glu Pro Asn Lys Ser Val Asn Pro Asp Glu Val Val Ala Met Gly Ala
330                 335                 340                 345

GCT ATC CAA GGT GGG GTT ATC ACT GGG GAT GTG AAA GAC GTT GTC CTT      1286
Ala Ile Gln Gly Gly Val Ile Thr Gly Asp Val Lys Asp Val Val Leu
                350                 355                 360

CTT GAC GTA ACA CCA TTG TCA CTT GGT ATT GAA ACA ATG GGT GGT GTC      1334
Leu Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Met Gly Gly Val
            365                 370                 375

TTC ACT AAA TTG ATC GAC CGC AAT ACA ACT ATC CCA ACA TCT AAA TCA      1382
Phe Thr Lys Leu Ile Asp Arg Asn Thr Thr Ile Pro Thr Ser Lys Ser
        380                 385                 390

CAA GTC TTC TCA ACA GCA GCA GAC AAC CAA CCA GCC GTT GAT ATC CAT      1430
Gln Val Phe Ser Thr Ala Ala Asp Asn Gln Pro Ala Val Asp Ile His
    395                 400                 405

GTT CTT CAA GGT GAA CGC CCA ATG GCA GCA GAT AAC AAG ACT CTT GGT      1478
Val Leu Gln Gly Glu Arg Pro Met Ala Ala Asp Asn Lys Thr Leu Gly
410                 415                 420                 425

CGC TTC CAA TTG ACT GAT ATC CCA GCT GCA CCT CGT GGA ATC CCA CAA      1526
Arg Phe Gln Leu Thr Asp Ile Pro Ala Ala Pro Arg Gly Ile Pro Gln
                430                 435                 440

ATT GAA GTA ACA TTT GAT ATC GAT AAA AAC GGT ATT GTT TCT GTA AAA      1574
Ile Glu Val Thr Phe Asp Ile Asp Lys Asn Gly Ile Val Ser Val Lys
            445                 450                 455

GCT AAA GAC CTT GGT ACG CAA AAG GAA CAA CAC ATC GTT ATC AAA TCA      1622
Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln His Ile Val Ile Lys Ser
        460                 465                 470

AAC GAC GGA CTT TCT GAA GAA GAA ATT GAT CGC ATG ATG AAA GAC GCT      1670
Asn Asp Gly Leu Ser Glu Glu Glu Ile Asp Arg Met Met Lys Asp Ala
    475                 480                 485

GAA GCT AAT GCC GAA GCC GAT GCG AAA CGT AAA GAA GAA GTT GAC CTT      1718
Glu Ala Asn Ala Glu Ala Asp Ala Lys Arg Lys Glu Glu Val Asp Leu
490                 495                 500                 505

AAA AAC GAA GTT GAC CAA GCT ATC TTT GCT ACT GAA AAA ACA ATC AAA      1766
Lys Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr Ile Lys
                510                 515                 520

GAA ACT GAA GGT AAA GGC TTT GAC ACA GAA CGC GAT GCA GCG CAA TCA      1814
Glu Thr Glu Gly Lys Gly Phe Asp Thr Glu Arg Asp Ala Ala Gln Ser
            525                 530                 535

GCT CTT GAC GAG TTA AAA GCT GCG CAA GAA TCT GGC AAC CTT GAC GAC      1862
Ala Leu Asp Glu Leu Lys Ala Ala Gln Glu Ser Gly Asn Leu Asp Asp
        540                 545                 550

ATG AAA GCT AAA CTT GAA GCA TTA AAT GAA AAA GCG CAA GCT TTG GCT      1910
Met Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala Gln Ala Leu Ala
    555                 560                 565

GTT AAA ATG TAC GAG CAA GCT GCA GCA GCT CAA CAA GCA GCA CAA GGT      1958
Val Lys Met Tyr Glu Gln Ala Ala Ala Ala Gln Gln Ala Ala Gln Gly
570                 575                 580                 585

GCA GAA GGT GCA CAA GCT AAT GAT TCA GCA AAT AAT GAT GAT GTT GTA      2006
Ala Glu Gly Ala Gln Ala Asn Asp Ser Ala Asn Asn Asp Asp Val Val
                590                 595                 600
```

GAT GGC GAA TTT ACA GAA AAG TAATGATTTA GTTATCTAGT AACATTAATA 2057
Asp Gly Glu Phe Thr Glu Lys
605

TCCGAATTCA GAGGTTGTAC CAAACCTCTG TTTTTGGCTA AATAAAATGT AAAAATGCTG 2117

ACGTCAAAAT ATTTTAAGAA AGGAATACAA GTTCGATTAT TCGAACACAG GCTAAAGCGT 2177

GTAAAG 2183

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 608 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met Ser Lys Ile Ile Gly Ile Asp Leu Gly Thr Thr Asn Ser Ala Val
1 5 10 15

Ala Val Leu Glu Gly Thr Glu Ser Lys Ile Ile Ala Asn Pro Glu Gly
20 25 30

Asn Arg Thr Thr Pro Ser Val Val Ser Phe Lys Asn Gly Glu Ile Ile
35 40 45

Val Gly Asp Ala Ala Lys Arg Gln Ala Val Thr Asn Pro Glu Thr Val
50 55 60

Ile Ser Ile Lys Ser Lys Met Gly Thr Ser Glu Lys Val Ser Ala Asn
65 70 75 80

Gly Lys Glu Tyr Thr Pro Gln Glu Ile Ser Ala Met Ile Leu Gln Tyr
85 90 95

Leu Lys Gly Tyr Ala Glu Asp Tyr Leu Gly Glu Lys Val Glu Lys Ala
100 105 110

Val Ile Thr Val Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln Ala Thr
115 120 125

Lys Asp Ala Gly Lys Ile Ala Gly Leu Glu Val Glu Arg Ile Val Asn
130 135 140

Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Met Asp Lys Thr Asp Lys
145 150 155 160

Asp Glu Lys Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe Asp Val
165 170 175

Ser Ile Leu Glu Leu Gly Asp Gly Val Phe Asp Val Leu Ala Thr Ala
180 185 190

Gly Asp Asn Lys Leu Gly Gly Asp Asp Phe Asp Gln Lys Ile Ile Asp
195 200 205

Phe Leu Val Ala Glu Phe Lys Lys Glu Asn Gly Ile Asp Leu Ser Gln
210 215 220

Asp Lys Met Ala Leu Gln Arg Leu Lys Asp Ala Ala Glu Lys Ala Lys
225 230 235 240

Lys Asp Leu Ser Gly Val Thr Gln Thr Gln Ile Ser Leu Pro Phe Ile
245 250 255

```
Thr Ala Gly Ser Ala Gly Pro Leu His Leu Glu Met Ser Leu Ser Arg
            260                 265                 270

Ala Lys Phe Asp Asp Leu Thr Arg Asp Leu Val Glu Arg Thr Lys Thr
        275                 280                 285

Pro Val Arg Gln Ala Leu Ser Asp Ala Gly Leu Ser Leu Ser Glu Ile
    290                 295                 300

Asp Glu Val Ile Leu Val Gly Gly Ser Thr Arg Ile Pro Ala Val Val
305                 310                 315                 320

Glu Ala Val Lys Ala Glu Thr Gly Lys Glu Pro Asn Lys Ser Val Asn
                325                 330                 335

Pro Asp Glu Val Val Ala Met Gly Ala Ala Ile Gln Gly Gly Val Ile
            340                 345                 350

Thr Gly Asp Val Lys Asp Val Val Leu Leu Asp Val Thr Pro Leu Ser
        355                 360                 365

Leu Gly Ile Glu Thr Met Gly Gly Val Phe Thr Lys Leu Ile Asp Arg
    370                 375                 380

Asn Thr Thr Ile Pro Thr Ser Lys Ser Gln Val Phe Ser Thr Ala Ala
385                 390                 395                 400

Asp Asn Gln Pro Ala Val Asp Ile His Val Leu Gln Gly Glu Arg Pro
                405                 410                 415

Met Ala Ala Asp Asn Lys Thr Leu Gly Arg Phe Gln Leu Thr Asp Ile
            420                 425                 430

Pro Ala Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe Asp Ile
        435                 440                 445

Asp Lys Asn Gly Ile Val Ser Val Lys Ala Lys Asp Leu Gly Thr Gln
    450                 455                 460

Lys Glu Gln His Ile Val Ile Lys Ser Asn Asp Gly Leu Ser Glu Glu
465                 470                 475                 480

Glu Ile Asp Arg Met Met Lys Asp Ala Glu Ala Asn Ala Glu Ala Asp
                485                 490                 495

Ala Lys Arg Lys Glu Glu Val Asp Leu Lys Asn Glu Val Asp Gln Ala
            500                 505                 510

Ile Phe Ala Thr Glu Lys Thr Ile Lys Glu Thr Glu Gly Lys Gly Phe
        515                 520                 525

Asp Thr Glu Arg Asp Ala Ala Gln Ser Ala Leu Asp Glu Leu Lys Ala
    530                 535                 540

Ala Gln Glu Ser Gly Asn Leu Asp Asp Met Lys Ala Lys Leu Glu Ala
545                 550                 555                 560

Leu Asn Glu Lys Ala Gln Ala Leu Ala Val Lys Met Tyr Glu Gln Ala
                565                 570                 575

Ala Ala Ala Gln Gln Ala Ala Gln Gly Ala Glu Gly Ala Gln Ala Asn
            580                 585                 590

Asp Ser Ala Asn Asn Asp Asp Val Val Asp Gly Glu Phe Thr Glu Lys
        595                 600                 605
```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2438 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus agalactiae

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 248..2077

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```
CTTTCAAAAG GGATATAAAT TGCACGAGCG TCTGCTAAGA CCAGCGATGG TAGTTGTCTA      60

TAACTAAGGT AAATGAGTTT TCGTTTTTGT CCGTAATGAC AGTAAACTAG ATAGCAAGTT     120

AGAAGCTATT CAGCTTGCTG ATTAAACTAT AGTGATTGCT TAGAATTGGA AGTAAAATAA     180

TTCGAGTGCT TACTAAGATA AATTGAAATA AAAAGTAATA AAGTATTATA AAATAAGAGG     240

TATTAAC ATG TCT AAA ATT ATT GGT ATT GAC TTA GGT ACA ACA AAC TCA       289
        Met Ser Lys Ile Ile Gly Ile Asp Leu Gly Thr Thr Asn Ser
          1               5                  10

GCA GTA GCA GTT CTT GAA GGG ACT GAA TCA AAA ATC ATT GCT AAC CCA       337
Ala Val Ala Val Leu Glu Gly Thr Glu Ser Lys Ile Ile Ala Asn Pro
 15                  20                  25                  30

GAA GGC AAT CGT ACA ACT CCT TCA GTA GTA TCA TTC AAA AAT GGT GAA       385
Glu Gly Asn Arg Thr Thr Pro Ser Val Val Ser Phe Lys Asn Gly Glu
                 35                  40                  45

ATT ATC GTG GGT GAT GCT GCA AAA CGT CAA GCG GTA ACA AAT CCA GAT       433
Ile Ile Val Gly Asp Ala Ala Lys Arg Gln Ala Val Thr Asn Pro Asp
             50                  55                  60

ACT GTT ATC TCT ATC AAA TCA AAG ATG GGA ACT TCT GAA AAA GTT TCT       481
Thr Val Ile Ser Ile Lys Ser Lys Met Gly Thr Ser Glu Lys Val Ser
         65                  70                  75

GCA AAT GGT AAA GAA TAT ACT CCT CAA GAA ATT TCA GCA ATG ATT CTT       529
Ala Asn Gly Lys Glu Tyr Thr Pro Gln Glu Ile Ser Ala Met Ile Leu
     80                  85                  90

CAA TAC CTT AAA GGT TAT GCT GAA GAC TAT CTT GGA GAA AAA GTA GAA       577
Gln Tyr Leu Lys Gly Tyr Ala Glu Asp Tyr Leu Gly Glu Lys Val Glu
 95                  100                 105                 110

AAA GCA GTT ATT ACT GTT CCA GCT TAC TTC AAC GAT GCA CAA CGT CAG       625
Lys Ala Val Ile Thr Val Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln
                115                 120                 125

GCA ACT AAA GAC GCT GGT AAA ATT GCA GGT CTT GAA GTA GAA CGT ATC       673
Ala Thr Lys Asp Ala Gly Lys Ile Ala Gly Leu Glu Val Glu Arg Ile
            130                 135                 140
```

```
GTT AAC GAA CCA ACA GCA GCC GCA CTT GCT TAT GGT ATG GAC AAG ACT      721
Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Met Asp Lys Thr
        145                 150                 155

GAC AAG GAT GAA AAA ATC TTA GTT TTT GAC CTT GGT GGT GGT ACA TTT      769
Asp Lys Asp Glu Lys Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe
    160                 165                 170

GAC GTA TCA ATC CTT GAA TTA GGT GAT GGT GTC TTC GAC GTT CTT GCA      817
Asp Val Ser Ile Leu Glu Leu Gly Asp Gly Val Phe Asp Val Leu Ala
175                 180                 185                 190

ACA GCA GGT GAT AAC AAA CTT GGT GGT GAC GAC TTT GAC CAG AAA ATT      865
Thr Ala Gly Asp Asn Lys Leu Gly Gly Asp Asp Phe Asp Gln Lys Ile
                195                 200                 205

ATT GAT TTC TTG GTA GAA GAA TTC AAG AAA GAA AAT GGT ATT GAT CTT      913
Ile Asp Phe Leu Val Glu Glu Phe Lys Lys Glu Asn Gly Ile Asp Leu
            210                 215                 220

TCT CAA GAC AAA ATG GCT CTT CAA CGC TTG AAA GAT GCT GCT GAA AAA      961
Ser Gln Asp Lys Met Ala Leu Gln Arg Leu Lys Asp Ala Ala Glu Lys
        225                 230                 235

GCT AAA AAA GAC CTT TCA GGT GTA ACT CAA ACT CAA ATT TCA TTA CCG      1009
Ala Lys Lys Asp Leu Ser Gly Val Thr Gln Thr Gln Ile Ser Leu Pro
    240                 245                 250

TTC ATC ACT GCT GGT TCT GCT GGT CCT CTT CAC TTG GAG ATG AGC TTA      1057
Phe Ile Thr Ala Gly Ser Ala Gly Pro Leu His Leu Glu Met Ser Leu
255                 260                 265                 270

TCA CGT GCT AAA TTT GAC GAT CTC ACT CGT GAC CTT GTT GAA CGT ACG      1105
Ser Arg Ala Lys Phe Asp Asp Leu Thr Arg Asp Leu Val Glu Arg Thr
                275                 280                 285

AAA ACT CCA GTT CGT CAA GCT CTT TCA GAT GCA GGC TTG TCA TTG TCA      1153
Lys Thr Pro Val Arg Gln Ala Leu Ser Asp Ala Gly Leu Ser Leu Ser
            290                 295                 300

GAA ATT GAT GAA GTT ATC CTC GTT GGT GGA TCA ACA CGT ATC CCA GCA      1201
Glu Ile Asp Glu Val Ile Leu Val Gly Gly Ser Thr Arg Ile Pro Ala
        305                 310                 315

GTT GTT GAA GCT GTA AAA GCT GAA ACT GGT AAA GAA CCA AAT AAA TCT      1249
Val Val Glu Ala Val Lys Ala Glu Thr Gly Lys Glu Pro Asn Lys Ser
    320                 325                 330

GTT AAC CCT GAT GAA GTG GTT GCC ATG GGT GCT GCT ATC CAA GGT GGT      1297
Val Asn Pro Asp Glu Val Val Ala Met Gly Ala Ala Ile Gln Gly Gly
335                 340                 345                 350

GTT ATC ACT GGG GAT GTG AAA GAC GTT GTA CTT CTT GAC GTA ACA CCA      1345
Val Ile Thr Gly Asp Val Lys Asp Val Val Leu Leu Asp Val Thr Pro
                355                 360                 365

TTG TCA CTT GGT ATT GAA ACA ATG GGT GGT GTC TTC ACT AAA TTG ATC      1393
Leu Ser Leu Gly Ile Glu Thr Met Gly Gly Val Phe Thr Lys Leu Ile
            370                 375                 380

GAC CGC AAC ACA ACT ATC CCA ACA TCT AAA TCA CAA GTC TTC TCA ACA      1441
Asp Arg Asn Thr Thr Ile Pro Thr Ser Lys Ser Gln Val Phe Ser Thr
        385                 390                 395

GCA GCA GAC AAC CAA CCA GCC GTT GAT ATC CAT GTT CTT CAA GGT GAA      1489
Ala Ala Asp Asn Gln Pro Ala Val Asp Ile His Val Leu Gln Gly Glu
    400                 405                 410
```

```
CGC CCA ATG GCA GCA GAT AAC AAA ACA CTC GGT CGC TTC CAA TTG ACT      1537
Arg Pro Met Ala Ala Asp Asn Lys Thr Leu Gly Arg Phe Gln Leu Thr
415                 420                 425                 430

GAT ATC CCA GCT GCA CCT CGT GGA ATC CCA CAA ATT GAA GTA ACA TTT      1585
Asp Ile Pro Ala Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe
                435                 440                 445

GAT ATC GAT AAA AAT GGT ATT GTA TCT GTT AAA GCT AAA GAT CTC GGT      1633
Asp Ile Asp Lys Asn Gly Ile Val Ser Val Lys Ala Lys Asp Leu Gly
            450                 455                 460

ACT CAA AAA GAA CAA CAC ATT GTT ATC CAA TCT AAT TCA GGA TTA ACT      1681
Thr Gln Lys Glu Gln His Ile Val Ile Gln Ser Asn Ser Gly Leu Thr
        465                 470                 475

GAT GAA GAA ATT GAT AAA ATG ATG AAA GAT GCT GAA GCA AAT GCT GAA      1729
Asp Glu Glu Ile Asp Lys Met Met Lys Asp Ala Glu Ala Asn Ala Glu
    480                 485                 490

GCA GAT GCA AAA CGT AAA GAA GAA GTT GAT CTT AAA AAT GAA GTT GAC      1777
Ala Asp Ala Lys Arg Lys Glu Glu Val Asp Leu Lys Asn Glu Val Asp
495                 500                 505                 510

CAA GCC ATC TTT GCA ACA GAA AAA ACT ATT AAA GAA ACT GAA GGC AAA      1825
Gln Ala Ile Phe Ala Thr Glu Lys Thr Ile Lys Glu Thr Glu Gly Lys
                515                 520                 525

GGT TTT GAT ACA GAA CGC GAT GCA GCG CAA TCA GCA CTT GAT GAG TTG      1873
Gly Phe Asp Thr Glu Arg Asp Ala Ala Gln Ser Ala Leu Asp Glu Leu
            530                 535                 540

AAA AAA GCT CAA GAA TCA GGT AAC CTT GAC GAC ATG AAA GCT AAA CTT      1921
Lys Lys Ala Gln Glu Ser Gly Asn Leu Asp Asp Met Lys Ala Lys Leu
        545                 550                 555

GAA GCT CTT AAC GAA AAA GCA CAA GCT CTT GCA GTT AAA CTT TAC GAA      1969
Glu Ala Leu Asn Glu Lys Ala Gln Ala Leu Ala Val Lys Leu Tyr Glu
    560                 565                 570

CAA GCG GCT GCA GCA CAA CAA GCA GCT CAA GGG GCT GAA GGT GCA CAA      2017
Gln Ala Ala Ala Ala Gln Gln Ala Ala Gln Gly Ala Glu Gly Ala Gln
575                 580                 585                 590

TCA GCT GAT TCA TCA AGC AAG GGT GAT GAT GTT GTA GAT GGC GAA TTC      2065
Ser Ala Asp Ser Ser Ser Lys Gly Asp Asp Val Val Asp Gly Glu Phe
                595                 600                 605

ACT GAG AAA TAATTATTAA TATTGTTCAG ATTCATTTGA ATATAAGCAT              2114
Thr Glu Lys
            610

GAAAACTATA CTAGCATAGT AAAGTTCTTC GTGATAGGGA TTGCTCAATA ATCTAGATAA    2174

GTTTCAGATT ACATAAGCTA ATTTCGCTAT CACTAAATAA AAACATATTA ATAATAAATA    2234

GGCGGGGCGC CTCGCTCCGT CTGTTTTATT AAGTGTCATA TATATGTTAA CTATTTAGAG    2294

CTGTAACTGG GCAAGAATAA TTGTTAATCT CTTCAAGTGT AGTATATGAA CAAAATATAA    2354

AGGATTAGAT AATGAACAAT ACAGAATTTT ATGATCGTCT TGGCGTTTCA AAAGATGCTT    2414

CTCAGGACGA AATAAAAAAA GCTT                                           2438
```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 609 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
Met Ser Lys Ile Ile Gly Ile Asp Leu Gly Thr Thr Asn Ser Ala Val
 1               5                  10                  15

Ala Val Leu Glu Gly Thr Glu Ser Lys Ile Ile Ala Asn Pro Glu Gly
            20                  25                  30

Asn Arg Thr Thr Pro Ser Val Val Ser Phe Lys Asn Gly Glu Ile Ile
        35                  40                  45

Val Gly Asp Ala Ala Lys Arg Gln Ala Val Thr Asn Pro Asp Thr Val
    50                  55                  60

Ile Ser Ile Lys Ser Lys Met Gly Thr Ser Glu Lys Val Ser Ala Asn
65                  70                  75                  80

Gly Lys Glu Tyr Thr Pro Gln Glu Ile Ser Ala Met Ile Leu Gln Tyr
                85                  90                  95

Leu Lys Gly Tyr Ala Glu Asp Tyr Leu Gly Glu Lys Val Glu Lys Ala
            100                 105                 110

Val Ile Thr Val Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln Ala Thr
        115                 120                 125

Lys Asp Ala Gly Lys Ile Ala Gly Leu Glu Val Glu Arg Ile Val Asn
    130                 135                 140

Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Met Asp Lys Thr Asp Lys
145                 150                 155                 160

Asp Glu Lys Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe Asp Val
                165                 170                 175

Ser Ile Leu Glu Leu Gly Asp Gly Val Phe Asp Val Leu Ala Thr Ala
            180                 185                 190

Gly Asp Asn Lys Leu Gly Gly Asp Asp Phe Asp Gln Lys Ile Ile Asp
        195                 200                 205

Phe Leu Val Glu Glu Phe Lys Lys Glu Asn Gly Ile Asp Leu Ser Gln
    210                 215                 220

Asp Lys Met Ala Leu Gln Arg Leu Lys Asp Ala Ala Glu Lys Ala Lys
225                 230                 235                 240

Lys Asp Leu Ser Gly Val Thr Gln Thr Gln Ile Ser Leu Pro Phe Ile
                245                 250                 255

Thr Ala Gly Ser Ala Gly Pro Leu His Leu Glu Met Ser Leu Ser Arg
            260                 265                 270

Ala Lys Phe Asp Asp Leu Thr Arg Asp Leu Val Glu Arg Thr Lys Thr
        275                 280                 285

Pro Val Arg Gln Ala Leu Ser Asp Ala Gly Leu Ser Leu Ser Glu Ile
    290                 295                 300

Asp Glu Val Ile Leu Val Gly Gly Ser Thr Arg Ile Pro Ala Val Val
305                 310                 315                 320

Glu Ala Val Lys Ala Glu Thr Gly Lys Glu Pro Asn Lys Ser Val Asn
                325                 330                 335

Pro Asp Glu Val Val Ala Met Gly Ala Ala Ile Gln Gly Gly Val Ile
            340                 345                 350
```

```
Thr Gly Asp Val Lys Asp Val Val Leu Leu Asp Val Thr Pro Leu Ser
        355                 360                 365

Leu Gly Ile Glu Thr Met Gly Gly Val Phe Thr Lys Leu Ile Asp Arg
    370                 375                 380

Asn Thr Thr Ile Pro Thr Ser Lys Ser Gln Val Phe Ser Thr Ala Ala
385                 390                 395                 400

Asp Asn Gln Pro Ala Val Asp Ile His Val Leu Gln Gly Glu Arg Pro
                405                 410                 415

Met Ala Ala Asp Asn Lys Thr Leu Gly Arg Phe Gln Leu Thr Asp Ile
            420                 425                 430

Pro Ala Ala Pro Arg Gly Ile Pro Gln Ile Glu Val Thr Phe Asp Ile
        435                 440                 445

Asp Lys Asn Gly Ile Val Ser Val Lys Ala Lys Asp Leu Gly Thr Gln
    450                 455                 460

Lys Glu Gln His Ile Val Ile Gln Ser Asn Ser Gly Leu Thr Asp Glu
465                 470                 475                 480

Glu Ile Asp Lys Met Met Lys Asp Ala Glu Ala Asn Ala Glu Ala Asp
                485                 490                 495

Ala Lys Arg Lys Glu Glu Val Asp Leu Lys Asn Glu Val Asp Gln Ala
            500                 505                 510

Ile Phe Ala Thr Glu Lys Thr Ile Lys Glu Thr Glu Gly Lys Gly Phe
        515                 520                 525

Asp Thr Glu Arg Asp Ala Ala Gln Ser Ala Leu Asp Glu Leu Lys Lys
    530                 535                 540

Ala Gln Glu Ser Gly Asn Leu Asp Asp Met Lys Ala Lys Leu Glu Ala
545                 550                 555                 560

Leu Asn Glu Lys Ala Gln Ala Leu Ala Val Lys Leu Tyr Glu Gln Ala
                565                 570                 575

Ala Ala Ala Gln Gln Ala Ala Gln Gly Ala Glu Gly Ala Gln Ser Ala
            580                 585                 590

Asp Ser Ser Ser Lys Gly Asp Asp Val Val Asp Gly Glu Phe Thr Glu
        595                 600                 605

Lys
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
Arg Ile Pro Ala Val Val Glu Ala Val Lys Ala Glu Thr Gly Lys Glu
1               5                   10                  15

Pro Asn Lys
```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
Gln Thr Ile Val Ile Gln Ser Asn Ser Gly Leu Thr Asp Glu Glu
 1               5                  10                  15
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 460 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Streptococcus pneumoniae

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..456
(D) OTHER INFORMATION: /product= "C-terminal 151-residue fragment (C-151) of HSP72"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
ATG AAG GCC AAA GAC CTT GGA ACT CAA AAA GAA CAA ACT ATT GTC ATC        48
Met Lys Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile Val Ile
  1               5                  10                  15

CAA TCG AAC TCA GGT TTG ACT GAC GAA GAA ATC GAC CGC ATG ATG AAA        96
Gln Ser Asn Ser Gly Leu Thr Asp Glu Glu Ile Asp Arg Met Met Lys
            20                  25                  30

GAT GCA GAA GCA AAC GCT GAA TCC GAT AAG AAA CGT AAA GAA GAA GTA       144
Asp Ala Glu Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu Glu Val
        35                  40                  45

GAC CTT CGT AAT GAA GTG GAC CAA GCA ATC TTT GCG ACT GAA AAG ACA       192
Asp Leu Arg Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr
    50                  55                  60

ATC AAG GAA ACT GAA GGT AAA GGC TTC GAC GCA GAA CGT GAC GCT GCC       240
Ile Lys Glu Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg Asp Ala Ala
65                  70                  75                  80

CAA GCT GCC CTT GAT GAC CTT AAG AAA GCT CAA GAA GAC AAC AAC TTG       288
Gln Ala Ala Leu Asp Asp Leu Lys Lys Ala Gln Glu Asp Asn Asn Leu
                85                  90                  95

GAC GAC ATG AAA GCA AAA CTT GAA GCA TTG AAC GAA AAA GCT CAA GGA       336
Asp Asp Met Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala Gln Gly
            100                 105                 110
```

```
CTT GCT GTT AAA CTC TAC GAA CAA GCC GCA GCA GCG CAA CAA GCT CAA      384
Leu Ala Val Lys Leu Tyr Glu Gln Ala Ala Ala Ala Gln Gln Ala Gln
        115                 120                 125

GAA GGA GCA GAA GGC GCA CAA GCA ACA GGA AAC GCA GGC GAT GAC GTC      432
Glu Gly Ala Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp Asp Val
    130                 135                 140

GTA GAC GGA GAG TTT ACG GAA AAG TAAG                                 460
Val Asp Gly Glu Phe Thr Glu Lys
145                 150
```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 152 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```
Met Lys Ala Lys Asp Leu Gly Thr Gln Lys Glu Gln Thr Ile Val Ile
  1               5                  10                  15

Gln Ser Asn Ser Gly Leu Thr Asp Glu Glu Ile Asp Arg Met Met Lys
            20                  25                  30

Asp Ala Glu Ala Asn Ala Glu Ser Asp Lys Lys Arg Lys Glu Glu Val
        35                  40                  45

Asp Leu Arg Asn Glu Val Asp Gln Ala Ile Phe Ala Thr Glu Lys Thr
    50                  55                  60

Ile Lys Glu Thr Glu Gly Lys Gly Phe Asp Ala Glu Arg Asp Ala Ala
65                  70                  75                  80

Gln Ala Ala Leu Asp Asp Leu Lys Lys Ala Gln Glu Asp Asn Asn Leu
                85                  90                  95

Asp Asp Met Lys Ala Lys Leu Glu Ala Leu Asn Glu Lys Ala Gln Gly
            100                 105                 110

Leu Ala Val Lys Leu Tyr Glu Gln Ala Ala Ala Ala Gln Gln Ala Gln
        115                 120                 125

Glu Gly Ala Glu Gly Ala Gln Ala Thr Gly Asn Ala Gly Asp Asp Val
    130                 135                 140

Val Asp Gly Glu Phe Thr Glu Lys
145                 150
```

We claim:

1. A polypeptide selected from the group consisting of:

(a) the HSP72 polypeptide having the amino acid sequence of SEQ ID NO:5;

(b) the HSP70(DnaK) polypeptide having the amino acid sequence of SEQ ID NO:20;

(c) the HSP70 (DnaK) polypeptide having the amino acid sequence of SEQ ID NO:22;

(d) polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with the polypeptide of paragraph (a), (b), or (c);

(e) polypeptides that are capable of eliciting antibodies that are immunologically reactive with the polypeptide of paragraph (a), (b), or (c);

(f) polypeptides that are immunologically reactive with antibodies elicited by immunization with the polypeptide of paragraph (a), (b), or (c); and

(g) fragments of any of the foregoing polypeptides, either alone or in combination with other polypeptides to form a fusion protein.

2. The polypeptide of claim 1, wherein the polypeptides of paragraph (d) are selected from the group consisting of polypeptides of the genera *Streptococcus* and *Enterococcus*.

3. The polypeptide of claim 1, wherein the polypeptides of paragraph (d) are selected from the group consisting of polypeptides of the species *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Streptococcus*

pyogenes, *Streptococcus mutans*, *Streptococcus sanguis*, and *Enterococcus faecalis*.

4. The polypeptide of claim 1, wherein the polypeptides of paragraph (d) are selected from the group consisting of polypeptides of the species *Streptococcus pneumoniae*, *Streptococcus agalactiae*, and *Streptococcus pyogenes*.

5. The polypeptide of claim 1, wherein the fragments of paragraph (g) are selected from the group consisting of amino acids 439-607 of SEQ ID NO:5 (C-169), amino acids 457-607 of SEQ ID NO:5 (C-151), amino acids 527-541 of SEQ ID NO:5, and amino acids 586-600 of SEQ ID NO:5.

6. A polypeptide having the amino acid sequence of SEQ ID NO:5 analogues, homologues and derivatives thereof.

7. A polypeptide having the amino acid sequence of SEQ ID NO:20, analogues, homologues and derivatives thereof.

8. A polypeptide having the amino acid sequence of SEQ ID NO:22, analogues, homologues and derivatives thereof.

9. A polypeptide having the amino acid sequence of SEQ ID NO:26, analogues, homologues and derivatives thereof.

10. A polypeptide having the amino acid sequence of SEQ ID NO:7, analogues, homologues and derivatives thereof.

11. A polypeptide having the amino acid sequence of SEQ ID NO:8, analogues, homologues and derivatives thereof.

12. A polypeptide having the amino acid sequence of SEQ ID NO:9, analogues, homologues and derivatives thereof.

13. A polypeptide having the amino acid sequence of SEQ ID NO:10, analogues, homologues and derivatives thereof.

14. A polypeptide having the amino acid sequence of SEQ ID NO:11, analogues, homologues and derivatives thereof.

15. A polypeptide having the amino acid sequence of SEQ ID NO:12, analogues, homologues and derivatives thereof.

16. A polypeptide having the amino acid sequence of SEQ ID NO:13, analogues, homologues and derivatives thereof.

17. A polypeptide having the amino acid sequence of SEQ ID NO:14, analogues, homologues and derivatives thereof.

18. A polypeptide having the amino acid sequence of SEQ ID NO:15, analogues, homologues and derivatives thereof.

19. A polypeptide having the amino acid sequence of SEQ ID NO:16 analogues, homologues and derivatives thereof.

20. A polypeptide having the amino acid sequence of SEQ ID NO:17, analogues, homologues and derivatives thereof.

21. A polypeptide having the amino acid sequence of SEQ ID NO:18, analogues, homologues and derivatives thereof.

22. The polypeptide of any one of claims 1 to 21 and 100-101, wherein said polypeptide elicits an immune reaction that is specific to Streptococcal strains.

23. A polypeptide selected from the group consisting of:

(a) the HSP72 polypeptide having the amino acid sequence of SEQ ID NO:5;

(b) polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with the HSP72 polypeptide of paragraph (a);

(c) polypeptides that are capable of eliciting antibodies that are immunologically reactive with the HSP72 polypeptide of paragraph (a);

(d) polypeptides that are immunologically reactive with antibodies elicited by immunization with the HSP72 polypeptide of paragraph (a); and

(e) fragments of any of the foregoing polypeptides, either alone or in combination with other polypeptides to form a fusion protein.

24. The polypeptide of claim 23, wherein the polypeptides of paragraph (b) are selected from the group consisting of polypeptides of the genera *Streptococcus* and *Enterococcus*.

25. The polypeptide of claim 23, wherein the polypeptides of paragraph (b) are selected from the group consisting of polypeptides of the species *Streptococcus pyogenes*, *Streptococcus mutans*, *Streptococcus sanguis*, and *Enterococcus faecalis*.

26. The polypeptide of claim 23, wherein the fragments of paragraph (e) are selected from the group consisting of amino acids 439-607 of SEQ ID NO:5 (C-169); amino acids 527-541 of SEQ ID NO:5, and amino acids 586-600 of SEQ ID NO:5.

27. The polypeptide of claim 23, wherein the fusion protein of paragraph (e) is the Fucose Isomerase-HSP72 (C-169) protein having the amino acid sequence of SEQ ID NO:3.

28. A DNA sequence selected from the group consisting of:

(a) the HSP72 DNA sequence of SEQ ID NO:4;

(b) the HSP70 (DnaK) DNA sequence of SEQ ID NO:19;

(c) the HSP70 (DnaK) DNA sequence of SEQ ID NO:21;

(d) DNA sequences encoding polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with the HSP72 polypeptide (SEQ ID NO:5);

(e) DNA sequences encoding polypeptides that are capable of eliciting antibodies that are immunologically reactive with the HSP72 polypeptide (SEQ ID NO:5);

(f) DNA sequences encoding polypeptides that are immunologically reactive with antibodies elicited by immunization with the HSP72 polypeptide (SEQ ID NO:5);

(g) DNA sequences that are degenerate to any of the foregoing DNA sequences; and

(h) fragments of any of the foregoing DNA sequences, either alone or in combination with other DNA sequences to form a fusion DNA sequence.

29. The DNA sequence of claim 28, wherein the DNA sequences of paragraph (d) are selected from the group consisting of DNA sequences of the genera *Streptococcus* and *Enterococcus*.

30. The DNA sequence of claim 28, wherein the DNA sequences of paragraph (d) are selected from the group consisting of DNA sequences of the species *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Streptococcus pyogenes*, *Streptococcus mutans*, *Streptococcus sanguis*, and *Enterococcus faecalis*.

31. The DNA sequence of claim 28, wherein the DNA sequences of paragraph (d) are selected from the group

consisting of DNA sequences of the species *Streptococcus pneumoniae*, *Streptococcus agalactiae*, and *Streptococcus pyogenes*.

32. A DNA sequence of the formula of SEQ ID NO:4 from nucleotide 682 to nucleotide 2502, or derivatives thereof, coding for HSP72.

33. A DNA sequence of the formula of SEQ ID NO:4 from nucleotide 1996 to nucleotide 2502, or derivatives thereof, coding for the C-169 fragment of HSP72.

34. A DNA sequence of the formula of SEQ ID NO:4 from nucleotide 2050 to nucleotide 2502, or derivatives thereof, coding for the C-151 fragment of HSP72.

35. A DNA sequence of the formula of SEQ ID NO:4 from nucleotide 2260 to nucleotide 2304, or derivatives thereof.

36. A DNA sequence of the formula of SEQ ID NO:4 from nucleotide 2437 to nucleotide 2481, or derivatives thereof.

37. A DNA sequence of the formula of SEQ ID NO:19 from nucleotide 204 to nucleotide 2027, or derivatives thereof, coding for HSP70 of *Streptococcus agalactiae*.

38. A DNA sequence of the formula of SEQ ID NO:21 from nucleotide 248 to nucleotide 2074, or

derivatives thereof, coding for HSP70 of *Streptococcus pyogenes*.

39. A DNA sequence of the formula of SEQ ID NO:25 from nucleotide 4 to nucleotide 456, or derivatives thereof, coding for the C-terminal 151-residue fragment (C-151) of HSP72.

40. A DNA sequence coding for a polypeptide according to any one of claims 1-21 and 100-101.

41. A DNA sequence selected from the group consisting of:

(a) the HSP72 DNA sequence of SEQ ID NO:4;

(b) DNA sequences encoding polypeptides that are immunologically reactive with antibodies generated by infection of a mammalian host with *Streptococcus pneumoniae* cells, which antibodies are immunologically reactive with the HSP72 polypeptide (SEQ ID NO:5);

(c) DNA sequences encoding polypeptides that are capable of eliciting antibodies that are immunologically reactive with the HSP72 polypeptide (SEQ ID NO:5);

(d) DNA sequences encoding polypeptides that are immunologically reactive with antibodies elicited by immunization with the HSP72 polypeptide (SEQ ID NO:5);

(e) DNA sequences that are degenerate to any of the foregoing DNA sequences; and

(f) fragments of any of the foregoing DNA sequences, either alone or in combination with other DNA sequences to form a fusion DNA sequence.

42. The DNA sequence of claim 41, wherein the DNA sequences of paragraph (b) are selected from the group

consisting of DNA sequences of the genera *Streptococcus* and *Enterococcus*.

43. The DNA sequence of claim 41, wherein the DNA sequences of paragraph (b) are selected from the group consisting of DNA sequences of the species *Streptococcus pyogenes*, *Streptococcus mutans*, *Streptococcus sanguis*, and *Enterococcus faecalis*.

44. The DNA sequence of claim 41, wherein the fragments of paragraph (f) are selected from the group consisting of nucleotide 1996-2502 (amino acids 439-607) of SEQ ID NO:4 (C-169); nucleotide 2260-2304 (amino acids 527-541) of SEQ ID NO:4; and nucleotide 2437-2481 (amino acids 586-600) of SEQ ID NO:4.

45. The DNA sequence of claim 41, wherein the fusion DNA sequence of paragraph (f) is the Fucose Isomerase-HSP72 (C-169) DNA sequence of SEQ ID NO:1 (nucleotides 771-2912).

46. An expression vector including at least one DNA sequence according to claim 41 operably linked to a promoter.

47. A recombinant DNA molecule comprising a DNA sequence according to any one of claims 28 to 40, and one or more expression control sequence operably linked to the DNA sequence.

48. The recombinant DNA molecule of claim 47, wherein said expression control sequence is an inducible expression vector.

49. The recombinant molecule of claim 48, wherein said expression vector comprises the λ PL promoter.

50. A recombinant molecule according to claim 47 consisting of a plasmid selected from the group consisting of: pURV3, pURV4, pURV5, pURV6, pJBD291, pJBDΔ4, pJBDk51, pJBD177, pJBD171, pJBD177, pJBD179, pJBDΔ1, pJBDf51, and pJBDf62.

51. A unicellular host transformed with an expression vector of claim 46.

52. A unicellular host transformed with a recombinant DNA molecule of claim 47.

53. A unicellular host according to claim 52, wherein said host is selected from the group consisting of: *E.coli* strains XLI Blue MRF', W3110, JM109, Y1090 and BL21(DE3).

54. A method for producing a polypeptide or fragment thereof comprising the steps of culturing the unicellular host of claim 51 and isolating said polypeptide or fragment.

55. An antibody or fragment thereof that specifically binds to a polypeptide of claim 23.

56. An antibody or fragment thereof that specifically binds to the epitope recognized by monoclonal antibody F1-Pn3.1.

57. The antibody or fragment of claim 55, which is a monoclonal antibody.

58. The monoclonal antibody or fragment of claim 57, which is of murine origin.

59. The monoclonal antibody or fragment of claim 58, which is of IgG type.

60. The monoclonal antibody of claim 59, which is selected from the group consisting of F1-Pn3.1, F2-Pn3.2, F2-Pn3.3, and F2-Pn3.4.

61. The monoclonal antibody F1-Pn3.1.

62. A method for isolating the antibody of claim 55 comprising:

(a) introducing a preparation of the polypeptide of claim 23 into a mammal; and

(b) isolating serum from the mammal containing said antibody.

63. A method for isolating the monoclonal antibody of claim 57 comprising:

(a) introducing a preparation of the polypeptide of claim 23 to antibody producing cells of a mammal;

(b) fusing the antibody producing cells with myeloma cells to form hybridoma cells, and

(c) isolating said monoclonal antibody from the hybridoma cells.

64. A pharmaceutical composition comprising a polypeptide of claim 23.

65. The pharmaceutical composition of claim 64, which is a vaccine.

66. The pharmaceutical composition of claim 64, further comprising one or more pharmaceutically acceptable excipients.

67. A method for preventing infection of a patient by *Streptococcus pneumoniae* or related bacteria comprising the administration of a pharmaceutically effective amount of the vaccine of claim 65.

68. A pharmaceutical composition comprising one or more antibodies or fragments thereof according to claim 55.

69. The pharmaceutical composition of claim 68, which is a vaccine.

70. The pharmaceutical composition of claim 69, further comprising a pharmaceutically acceptable excipient.

71. The pharmaceutical composition of claim 69, wherein the antibody is selected from the group consisting of F1-Pn3.1, F2-Pn3.2, F2-Pn3.3, and F2-Pn3.4.

72. The pharmaceutical composition of claim 69, wherein the antibody is F1-Pn3.1.

73. A method for treating a patient infected with or suspected of being infected with *Streptococcus pneumoniae* or related bacteria comprising the

administration of a pharmaceutically effective amount of the vaccine of claim 69.

74. A method for the detection of *Streptococcus pneumoniae* or related bacteria in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating the antibody or fragment of claim 55 with the biological sample to form a mixture; and

(c) detecting specifically bound antibody or fragment in the mixture which indicates the presence of *Streptococcus pneumoniae or* related bacteria.

75. The method of claim 74, wherein the antibody is selected from the group consisting of F1-Pn3.1, F2-Pn3.2, F2-Pn3.3, and F2-Pn3.4.

76. The method of claim 74, wherein the antibody is F1-Pn3.1.

77. A method for the detection of antibodies specific to *Streptococcus pneumoniae* or related bacteria in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating a polypeptide of claim 23 with the biological sample to form a mixture; and

(c) detecting specifically bound polypeptide in the mixture, which indicates the presence of antibodies specific to *Streptococcus pneumoniae* or related bacteria.

78. A method for the detection of *Streptococcus pneumoniae* or related bacteria in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating a DNA probe having the DNA sequence of claim 41 with the biological sample to form a mixture; and

(c) detecting specifically bound DNA probe in the mixture which indicates the presence of *Streptococcus pneumoniae* and related bacteria.

79. The method of claim 78, wherein the DNA probe is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of a DNA sequence of claim 41.

80. The method of claim 79, which further comprises:

(a) providing a set of oligomers which are primers for a polymerase chain reaction method and which flank the target region; and

(b) amplifying the target region via the polymerase chain reaction method.

81. The use of a pharmaceutically effective amount of the polypeptide of claim 23 for the prevention of *Streptococcus pneumoniae* or related bacterial infections in humans.

82. The use of a pharmaceutically effective amount of an antibody specific to HSP72 for the prevention of *Streptococcus pneumoniae* or related bacterial infections in humans.

83. A method for producing a polypeptide or fragment thereof comprising the steps of culturing the unicellular host of claim 52 or 53 and isolating said polypeptide or fragment.

84. A polypeptide in substantially pure form as obtained by the method of claim 83.

85. An antibody or fragment thereof that specifically binds to a polypeptide of claim 1 or 22.

86. A method for isolating the antibody of claim 86 comprising:

(a) introducing a preparation of the polypeptide of claim 1 or 22 into a mammal; and

(b) isolating serum from the mammal containing said antibody.

87. A pharmaceutical composition comprising a polypeptide of claim 1 or 22.

88. The pharmaceutical composition of claim 87, which is a vaccine.

89. The pharmaceutical composition of claim 87, further comprising one or more pharmaceutically acceptable excipients.

90. A method for preventing infection of a patient by *Streptococcus pneumoniae, Streptococcus pyogenes or Streptococcus agalactiae* comprising the administration of a pharmaceutically effective amount of the vaccine of claim 88.

91. An antibody or fragment thereof that specifically binds to a polypeptide of claim 1 or 22.

92. A method for the detection of *Streptococcus pneumoniae*, *Streptococcus pyogenes* or *Streptococcus agalactiae* in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating the antibody or fragment of claim 91 with the biological sample to form a mixture; and

(c) detecting specifically bound antibody or fragment in the mixture which indicates the presence of *Streptococcus pneumoniae*, *Streptococcus pyogenes* or *Streptococcus agalactiae*.

93. A method for the detection of antibodies specific to *Streptococcus pneumoniae*, *Streptococcus pyogenes* or *Streptococcus agalactiae* in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating a polypeptide of claim 1 or 22 with the biological sample to form a mixture; and

(c) detecting specifically bound polypeptide in the mixture, which indicates the presence of antibodies specific to *Streptococcus pneumoniae*, *Streptococcus pyogenes* or *Streptococcus agalactiae*.

94. A method for the detection of *Streptococcus pneumoniae*, *Streptococcus pyogenes* or *Streptococcus agalactiae* in a biological sample comprising:

(a) isolating the biological sample from a patient;

(b) incubating a DNA probe having the DNA sequence of claim 28 with the biological sample to form a mixture; and

(c) detecting specifically bound DNA probe in the mixture which indicates the presence of *Streptococcus pneumoniae, Streptococcus pyogenes* or *Streptococcus agalactiae*.

95. The method of claim 94, wherein the DNA probe is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of a DNA sequence of claim 28.

96. The method of claim 95, which further comprises:

(a) providing a set of oligomers which are primers for a polymerase chain reaction method and which flank the target region; and

(b) amplifying the target region via the polymerase chain reaction method.

97. The use of a pharmaceutically effective amount of the polypeptide of claim 1 or 22 for the prevention of *Streptococcus pneumoniae, Streptococcus pyogenes* or *Streptococcus agalactiae* infection in humans.

98. The use of a pharmaceutically effective amount of an antibody specific to HSP72 for the prevention of *Streptococcus pneumoniae, Streptococcus pyogenes* or *Streptococcus agalactiae* infection in humans.

99. The use of a pharmaceutically effective amount of a polypeptide according to any one of claims 2

to 21 for the prevention of Streptococcal infections in humans.

100. A polypeptide having the amino acid sequence of SEQ ID NO:23, analogues, homologues, or derivatives thereof.

101. A polypeptide having the amino acid sequence of SEQ ID NO:24, analogues, homologues or derivatives thereof.



Fig. 1A



Fig. 1B



Fig. 3


HSP72
HSP80
HSP62
DISTANCE (mm X 10)
175
200
225
250
275
300
325
350
375
400
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

FIG. 2



FIG. 4



FIG. 5A



FIG. 5B



FIG. 6



FIG. 7A FIG. 7B

Fig. 8



Fig. 9



Fig. 10A

Fig. 10B

Fig. 10C



FIG. 11A



FIG. 11B



FIG. 12



FIG. 13A



FIG. 13B



FIG. 13C

```
Consensus       .L....Q.L. ...-YE---- -.A..AQ... .......... ...-------   650

DNAK_ECOLI      E.AQVS.K.M EIA.-Q.... .QQHAQ.QTA GADASANNAK DDD.......   624
DNAK_BORBU      E.QKASYKIA EMM..KDSSQ QN.NSQ.ENG PQSNISEEGK EADY......   627
DNAK_BRUOV      A.AEVSMK.G QAM...AAQA AEGAG.EGGE QASSSKDDVV DADY......   627
DNAK_CHLPN      D.SKHM.KIG ESMQSQSASA AASSA.NAKG GPNINIEDLK KHSFSIKPPS   638
DNAK_BACME      E.QEIV.A.T VKL.......  .Q.QQ..-Q- ---A----GE QGA......Q   588
DNA2_BACSU      E.QTIV.E.S MKL.......  .E.AK..-Q- ---AQGGANA EGK......A   592
DNAK_STAAU      E.EKVI.E.S AKV.......  .Q.AQQ.-QQ AQGANAGQNN DST.......   595
HSP72_SPNEU     A.NEKA.G.A VKL.......  .Q.AA..--- ----QAQEGA EGA.QAIGNA   595
DNAK_LACLA      A.SEIA.N.A VKL.......  .Q.NA..GEA SEATDAQEGP KDA.......   596
DNAK_MYCIU      YFGHQVGDGE AGPGVA....  .GSGASDLRS SSGCVIGHWR CPP.......   597

Consensus       --...D.E.. E...------ ..                                  672

DNAK_ECOLI      ..-VV.A.FE .VKD...... KK                                  637
DNAK_BORBU      ..----EVVD .---...DKK --                                  635
DNAK_BRUOV      ..----E.ID D---...NKK SS                                  637
DNAK_CHLPN      NNGSSEDHIE .ADVEIIDND DK                                  660
DNAK_BACME      NDDVV.A.FE .VNDD..... KK                                  605
DNA2_BACSU      DDNVV.A.YE .VNDDQN... KK                                  611
DNAK_STAAU      ..-VE.A.FN .VKDDDK... --                                  609
HSP72_SPNEU     GDDVV.G.FT .K--...... --                                  607
DNAK_LACLA      ..NIF.GDFE .SK-...... --                                  607
DNAK_MYCIU      ..RRRAGRCP PRLG...... --                                  609
```

Fig. 13D



FIG. 14



FIG. 15


1 μg HSP72rec
5 μg HSP72rec
naive
% Survival
Days
0
10
20
30
40
50
60
70
80
90
100
0
2
4
6
8
10
12
14

Fig. 16


1 μg C-169rec
5 μg C-169rec
naive
% Survival
Days
0
10
20
30
40
50
60
70
80
90
100
0
2
4
6
8
10
12
14

Fig. 17


c1857
λPL
Bgl II
C-151
Coding Region
BamHI
T1
ColE1 ori
Ampi^R
pURV 3

Fig_18


Reciprocal of
anti-pneumococcal antibody titer
10 5
10 4
10 3
10 2
post-1st
post-2nd
post-3rd

Fig_19


Reciprocal of
anti-pneumococcal antibody titer
10 5
10 4
10 3
10 2
post-1st
post-2nd
post-3rd

Fig. 20


Reciprocal of
anti-pneumococcal antibody titer
10 5
10 4
10 3
10 2
post-1st
post-2nd
post-3rd

Fig. 21


100000
10000
1000
100
10
S. pneumoniae HSP72-specific Ab titer
1
15
22
29
77
85
92
Days after primary immunization
HSP72rec
HSP72rec
C-169rec
C-169rec

Fig 22


RABBIT HSP72rec
MURINE HSP72rec
MONKEY HSP72rec
MONKEY C-169rec
OPTICAL DENSITY
3
2.5
2
1.5
1
0.5
0
CS876
CS877
CS878
CS879
CS880
CS882
CS873
CS874
CS875
MAP1
CS870
MAP2
MAP3
MAP4
PEPTIDES

Fig 23

```
spn-orf     .......... ....C..... .......... .......... .......T..   50
sga-orf     .......... ....T..... .......... .......... .......A..   50
sgb-orf     .......... ....T..... .......... .......... .......A..   50

Consensus   ATGTCTAAAA TTATYGGTAT TGACTTAGGT ACAACAAACT CAGCAGTWGC   50


spn-orf     .......... ..A......A GC........ C..A...... .....A..C.  100
sga-orf     .......... ..G......T CA........ T..T...... .....C..T.  100
sgb-orf     .......... ..G......T CA........ T..T...... .....C..T.  100

Consensus   AGTTCTTGAA GGRACTGAAW SMAAAATCAT YGCWAACCCA GAAGGMAAYC  100


spn-orf     .C........ A..T.....C .......... .C..A..... C.....T...  150
sga-orf     .T........ T..A.....A .......... .T..T..... T.....G...  150
sgb-orf     .T........ T..A.....A .......... .T..T..... T.....G...  150

Consensus   GYACAACTCC WTCWGTAGTM TCATTCAAAA AYGGWGAAAT YATCGTKGGT  150


spn-orf     .......... ....T..... A..T.....C .....T..A. .T........  200
sga-orf     .......... ....C..... A..G.....C .....A..A. .A........  200
sgb-orf     .......... ....T..... G..A.....T .....T..T. .T........  200

Consensus   GATGCTGCAA AACGYCAAGC RGTDACAAAY CCAGAWACWG TWATCTCTAT  200


spn-orf     C.....T..G .......... .......... .......... ..A.......  250
sga-orf     T.....T..A .......... .......... .......... ..T.......  250
sgb-orf     C.....A..G .......... .......... .......... ..T.......  250

Consensus   YAAATCWAAR ATGGGAACTT CTGAAAAAGT TTCTGCAAAT GGWAAAGAAT  250


spn-orf     .C.....A.. ......C... ..T.....C. ........T. G.....C..C  300
sga-orf     .T.....T.. ......T... ..A.....T. ........C. T.....T..T  300
sgb-orf     .T.....T.. ......T... ..A.....T. ........C. T.....T..T  300

Consensus   AYACTCCWCA AGAAATYTCA GCWATGATYC TTCAATACYT KAAAGGYTAY  300


spn-orf     .......... .C.....T.. G......ACC .....T.... .C..A.....  350
sga-orf     .......... .T.....A.. A......GAA .....A.... .T..T.....  350
sgb-orf     .......... .T.....A.. A......GAA .....A.... .T..T.....  350

Consensus   GCTGAAGACT AYCTTGGWGA RAAAGTARMM AAAGCWGTTA TYACWGTTCC  350


spn-orf     G.....C... .....C..T. .......A.. ...A...... ..........  400
sga-orf     A.....T... .....T..A. .......A.. ...T...... ..........  400
sgb-orf     A.....C... .....T..A. .......G.. ...T...... ..........  400

Consensus   RGCTTAYTTC AACGAYGCWC AACGTCARGC AACWAAAGAC GCTGGTAAAA  400


spn-orf     ....T..... .......... .....T.... .C........ T.....A..T  450
sga-orf     ....A..... .......... .....C.... .T........ A.....T..A  450
sgb-orf     ....A..... .......... .....C.... .C........ A.....C..A  450

Consensus   TTGCWGGTCT TGAAGTAGAA CGTATYGTTA AYGAACCAAC WGCAGCHGCW  450


spn-orf     .......... ..T....... .........A ..A....... ....G..A..  500
sga-orf     .......... ..A....... .........G ..T....... ....A..T..  500
sgb-orf     .......... ..A....... .........G ..T....... ....A..T..  500

Consensus   CTTGCTTATG GTWTGGACAA GACTGACAAR GAWGAAAAAA TCTTRGTWTT  500
```

Fig 24A

```
spn-orf     ..........  ..........  .C.....C..  T.........  ..G.....C.  550
sga-orf     ..........  ..........  .T.....A..  A.........  ..A.....T.  550
sgb-orf     ..........  ..........  .T.....A..  A.........  ..A.....T.  550

Consensus   TGACCTTGGT  GGTGGTACAT  TYGACGTMTC  WATCCTTGAA  TTRGGTGAYG  550


spn-orf     ..........  ...AT.GT..  ..T.....G.  .C........  ..........  600
sga-orf     ..........  ...TC.TG..  ..A.....T.  .T........  ..........  600
sgb-orf     ..........  ...TC.TG..  ..A.....T.  .T........  ..........  600

Consensus   GTGTCTTCGA  CGTWYTKKCA  ACWGCAGGKG  AYAACAAACT  TGGTGGTGAC  600


spn-orf     ..........  .A.....C..  ...CCA...G  ..A.CA....  .C........  650
sga-orf     ..........  .A.....T..  ...TTT...A  ..G.CT....  .T........  650
sgb-orf     ..........  .G.....T..  ...TTT...G  ..A.AA....  .C........  650

Consensus   GACTTTGACC  ARAAAATYAT  TGAYYWCTTR  GTRGMWGAAT  TYAAGAAAGA  650


spn-orf     ...C.....C  ..CT.G..TA  CT..C..G..  ...AA.G...  ..T.......  700
sga-orf     ...T.....T  ..CT.A..AC  AA..T..G..  ...AC.T...  ..C.......  700
sgb-orf     ...T.....T  ..TC.T..TC  AA..C..A..  ...TC.T...  ..C.......  700

Consensus   AAAYGGTATY  GAYYTDTCWM  MWGAYAARAT  GGCWMTKCAA  CGYTTGAAAG  700


spn-orf     ....G.....  ......G..G  .....C....  .T.....A..  TTC...A...  750
sga-orf     ....T.....  ......T..A  .....T....  .A.....G..  ACA...A...  750
sgb-orf     ....T.....  ......T..A  .....C....  .A.....A..  TCA...T...  750

Consensus   ATGCKGCTGA  AAAAGCKAAR  AAAGAYCTTT  CWGGTGTRAC  WYMAACWCAA  750


spn-orf     ..CAGC..G.  .A..T.....  ...A...GAG  .....A....  .......G..  800
sga-orf     ..TTCA..A.  .G..C.....  ...T...TCT  .....T....  .......A..  800
sgb-orf     ..TTCA..A.  .G..C.....  ...T...TCT  .....T....  .......G..  800

Consensus   ATYWSMTTRC  CRTTYATCAC  TGCWGGTKMK  GCTGGWCCTC  TTCACTTRGA  800


spn-orf     A....CT...  A.T.....G.  .......T..  .T.G......  ..........  850
sga-orf     G....GC...  T.T.....T.  .......C..  .C.C......  ..........  850
sgb-orf     G....GC...  T.A.....T.  .......C..  .C.C......  ..........  850

Consensus   RATGASYTTA  WCWCGTGCKA  AATTTGAYGA  TYTSACTCGT  GACCTTGTTG  850


spn-orf     .......A..  .GT.......  ........C.  ..........  ...T...AGC  900
sga-orf     .......G..  .AC.......  ........T.  ..........  ...A...TCA  900
sgb-orf     .......G..  .AC.......  ........T.  ..........  ...C...TCA  900

Consensus   AACGTACRAA  ARYTCCAGTT  CGTCAAGCYC  TTTCAGATGC  AGGHTTGWSM  900


spn-orf     ..........  .C..C.....  ......T...  .....T....  .T........  950
sga-orf     ..........  .T..T.....  ......T...  .....A....  .T........  950
sgb-orf     ..........  .T..T.....  ......C...  .....A....  .A........  950

Consensus   TTGTCAGAAA  TYGAYGAAGT  TATCCTYGTT  GGTGGWTCAA  CWCGTATCCC  950


spn-orf     T..C.....T  ........T.  ..........  ..........  .....C....  1000
sga-orf     A..A.....C  ........A.  ..........  ..........  .....T....  1000
sgb-orf     A..A.....T  ........A.  ..........  ..........  .....T....  1000

Consensus   WGCMGTTGTY  GAAGCTGTWA  AAGCTGAAAC  TGGTAAAGAA  CCAAAYAAAT  1000
```

Fig. 24B

```
spn-orf      .A..A..... .........A .....T.... ....G..... .........T  1050
sga-orf      .T..A..... .........G .....T.... ....T..... .........G  1050
sgb-orf      .T..T..... .........G .....C.... ....T..... .........T  1050

Consensus    CWGTWAACCC TGATGAAGTR GTTGCYATGG GTGCKGCTAT CCAAGGTGGK  1050

spn-orf      ..G..T.... .T.....C.. G..T.....C ........T. ....G.....  1100
sga-orf      ..T..C.... .G.....G.. A..C.....C ........C. ....A.....  1100
sgb-orf      ..T..C.... .G.....G.. A..C.....A ........C. ....A.....  1100

Consensus    GTKATYACTG GKGATGTSAA RGAYGTTGTM CTTCTTGAYG TAACRCCATT  1100

spn-orf      .......... ..C....... .......A.. A..T..A... C.T....:T.  1150
sga-orf      .......... ..T....... .......T.. C..C..T... T.G.....C.  1150
sgb-orf      .......... ..T....... .......T.. C..C..T... T.G.....C.  1150

Consensus    GTCACTTGGT ATYGAAACAA TGGGTGGWGT MTTYACWAAA YTKATCGAYC  1150

spn-orf      ....C..T.. A......... .......... .......... ..........  1200
sga-orf      ....T..A.. T......... .......... .......... ..........  1200
sgb-orf      ....C..A.. T......... .......... .......... ..........  1200

Consensus    GCAAYACWAC WATCCCAACA TCTAAATCAC AAGTCTTCTC AACAGCAGCA  1200

spn-orf      .......... .......... ......C... .......... ..........  1250
sga-orf      .......... .......... ......T... .......... ..........  1250
sgb-orf      .......... .......... ......T... .......... ..........  1250

Consensus    GACAACCAAC CAGCCGTTGA TATCCAYGTT CTTCAAGGTG AACGCCCAAT  1250

spn-orf      .......... .....G..T. .T..A..... .......... ..........  1300
sga-orf      .......... .....G..T. .T..T..... .......... ..........  1300
sgb-orf      .......... .....A..A. .C..T..... .......... ..........  1300

Consensus    GGCAGCAGAT AACAARACWC TYGGWCGCTT CCAATTGACT GATATCCCAG  1300

spn-orf      .......... ......T..T .....C.... .......... C.....C..G  1350
sga-orf      .......... ......C..A .....T.... .......... T.....T..A  1350
sgb-orf      .......... ......C..A .....T.... .......... T.....T..A  1350

Consensus    CTGCACCTCG TGGAATYCCW CAAATYGAAG TAACATTTGA YATCGAYAAR  1350

spn-orf      ..C.....C. .G.....T.. G..C.....C ..T..A..T. ....A.....  1400
sga-orf      ..C.....T. .T.....A.. A..T.....C ..T..T..G. ....G.....  1400
sgb-orf      ..T.....T. .A.....T.. A..T.....T ..C..T..T. ....A.....  1400

Consensus    AAYGGTATYG TDTCTGTWAA RGCYAAAGAY CTYGGWACKC AAAARGAACA  1400

spn-orf      .ACT..T..C ...C....G. .CTCA..TT. GA....C... .....C..CC  1450
sga-orf      .CAC..C..T ...A....A. .CGAC..AC. TT....A... .....T..TC  1450
sgb-orf      .CAC..T..T ...C....T. .TTCA..AT. AA....T... .....T..TA  1450

Consensus    AMMYATYGTY ATCMAATCDA AYKMMGGWYT DWCTGAHGAA GAAATYGAYM  1450

spn-orf      GC........ ...T..A... ..A..C..T. ..T.C...AA G.........  1500
sga-orf      GC........ ...C..T... ..T..T..C. ..G.C...GC G.........  1500
sgb-orf      AA........ ...T..T... ..A..T..T. ..G.A...GC A.........  1500

Consensus    RMATGATGAA AGAYGCWGAA GCWAAYGCYG AAKCMGATRM RAAACGTAAA  1500
```

Fig. 24C

```
sga-orf         ........T. .C...AAA.. C.....T... .....T.... ....T..T..  1550
sgb-orf         ........T. .T...AAA.. T.....T... .....C.... ....A..A..  1550
Consensus       GAAGAAGTWG AYCTTMRWAA YGAAGTKGAC CAAGCHATCT TTGCDACWGA  1550

spn-orf         ...G..A..C ..G.......  ....T.....  C..C..CG..  .....T..C.  1600
sga-orf         ...A..A..C ..A.......  ....T.....  C..T..CA..  .....C..T.  1600
sgb-orf         ...A..T..T ..A.......  ....C.....  T..T..TA..  .....C..T.  1600
Consensus       AAARACWATY AARGAAACTG AAGGYAAAGG YTTYGAYRCA GAACGYGAYG  1600

spn-orf         .T..C...G. T..C.....T ..CC.T..GA AA..T.....  .GACAAC...  1650
sga-orf         .A..G...T. A..T.....C ..GT.A..AG CT..G.....  .TCTGGC...  1650
sgb-orf         .A..G...T. A..A.....T ..GT.G..AA AA..T.....  .TCAGGT...  1650
Consensus       CWGCSCAAKC WGCHCTTGAY GASYTDAARR MWGCKCAAGA AKMHRRYAAC  1650

spn-orf         T.G.......  .......A..  .........A T.G..C....  ....T....G  1700
sga-orf         C.T.......  .......T..  .........A T.A..T....  ....G....C  1700
sgb-orf         C.T.......  .......T..  .........T C.T..C....  ....A....C  1700
Consensus       YTKGACGACA TGAAAGCWAA ACTTGAAGCW YTDAAYGAAA AAGCDCAAGS  1700

spn-orf         AC.T..T...  ...C.C....  .A.....C..  A.....G...  .....TCAAG  1750
sga-orf         TT.G..T...  ...A.G....  .G.....T..  A.....T...  .....AGCAC  1750
sgb-orf         TC.T..A...  ...C.T....  .A.....G..  T.....A...  .....AGCTC  1750
Consensus       WYTKGCWGTT AAAMTBTACG ARCAAGCBGC WGCAGCDCAA CAAGCWSMWS  1750

spn-orf         ....A..A..  ...C......  G.AA------  ..GG..ACGC  A..C.....C  1794
sga-orf         ....T..A..  ...T......  G.TAA.....  ..GC..ATAA  ---T.....T  1797
sgb-orf         ....G..T..  ...T......  T.AGC.....  ..TC..GCAA  G..T.....T  1800
Consensus       AAGGDGCWGA AGGYGCACAA KCWRMTGATT CAKSAARYRM RGGYGATGAY  1800

spn-orf         ..C.....C.  .A..G..T..  G..A..G...                       1824
sga-orf         ..T.....T.  .C..A..T..  A..A..G...                       1827
sgb-orf         ..T.....T.  .C..A..C..  T..G..A...                       1830
Consensus       GTYGTAGAYG GMGARTTYAC DGARAARTAA                          1830
```

Fig. 24D

```
spn-prot    .......... .......... .......... .......... ..........  50
sga-prot    .......... .......... .......... .......... ..........  50
sgb-prot    .......... .......... .......... .......... ..........  50
Consensus   MSKIIGIDLG TTNSAVAVLE GTESKIIANP EGNRTTPSVV SFKNGEIIVG  50

spn-prot    .......... .......... .......... .......... .......... 100
sga-prot    .......... .E........ .......... .......... .......... 100
sgb-prot    .......... .......... .......... .......... .......... 100
Consensus   DAAKRQAVTN PDTVISIKSK MGTSEKVSAN GKEYTPQEIS AMILQYLKGY 100

spn-prot    .........T .......... .......... .......... .......... 150
sga-prot    .......... .......... .......... .......... .......... 150
sgb-prot    .......... .......... .......... .......... .......... 150
Consensus   AEDYLGEKVE KAVITVPAYF NDAQRQATKD AGKIAGLEVE RIVNEPTAAA 150

spn-prot    ....L..... E......... .......... .........S .......... 200
sga-prot    .......... .......... .......... .......... .......... 200
sgb-prot    .......... .......... .......... .......... .......... 200
Consensus   LAYGMDKTDK DEKILVFDLG GGTFDVSILE LGDGVFDVLA TAGDNKLGGD 200

spn-prot    ........H. .......... ...T....M. .......... .......S.. 250
sga-prot    .......... .......... .......... .......... .......... 250
sgb-prot    .......... .E........ .......... .......... .......... 250
Consensus   DFDQKIIDFL VAEFKKENGI DLSQDKMALQ RLKDAAEKAK KDLSGVTQTQ 250

spn-prot    .........E .........T. T......... .......V.. .......... 300
sga-prot    .......... .......... .......... .......... .......... 300
sgb-prot    .......... .......... .......... .......... .......... 300
Consensus   ISLPFITAGS AGPLHLEMSL SRAKFDDLTR DLVERTKTPV RQALSDAGLS 300

spn-prot    .......... .......... .......... .......... .......... 350
sga-prot    .......... .......... .......... .......... .......... 350
sgb-prot    .......... .......... .......... .......... .......... 350
Consensus   LSEIDEVILV GGSTRIPAVV EAVKAETGKE PNKSVNPDEV VAMGAAIQGG 350

spn-prot    .......... .......... .......... .......... .......... 400
sga-prot    .......... .......... .......... .......... .......... 400
sgb-prot    .......... .......... .......... .......... .......... 400
Consensus   VITGDVKDVV LLDVTPLSLG IETMGGVFTK LIDRNTTIPT SKSQVFSTAA 400

spn-prot    .......... .......... .......... .......... .......... 450
sga-prot    .......... .......... .......... .......... .......... 450
sgb-prot    .......... .......... .......... .......... .......... 450
Consensus   DNQPAVDIHV LQGERPMAAD NKTLGRFQLT DIPAAPRGIP QIEVTFDIDK 450

spn-prot    .......... .......T.. .......... .......... ....S.K... 500
sga-prot    .......... .......... .K..D..SE. .......... .......... 500
sgb-prot    .......... .......... .......... ...K...... .......... 500
Consensus   NGIVSVKAKD LGTQKEQHIV IQSNSGLTDE EIDRMMKDAE ANAEADAKRK 500

spn-prot    .....R.... .......... .........A ......A... D......DN. 550
sga-prot    .......... .......... .......... .......... ...A...... 550
sgb-prot    .......... .......... .......... .......... .......... 550
Consensus   EEVDLKNEVD QAIFATEKTI KETEGKGFDT ERDAAQSALD ELKKAQESGN 550

spn-prot    .......... ......G... .......... ..QE...... .TGN.G-... 598
sga-prot    .......... .......... .M........ .......... .N...NN... 599
sgb-prot    .......... .......... .......... .......... SA..SSKG.. 600
Consensus   LDDMKAKLEA LNEKAQALAV KLYEQAAAAQ QAAQGAEGAQ A.DSA..-DD 600

spn-prot    .........                                              607
sga-prot    .........                                              608
sgb-prot    .........                                              609
Consensus   VVDGEFTEK                                             609
```

FIG 25



FIG. 26

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/CA 96/00322

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/31 C07K14/315 C12N1/21 C07K16/12 A61K39/09
A61K39/395 G01N33/569 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GENE, vol. 142, no. 1, 3 May 1994, AMSTERDAM NL, pages 91-96, XP002013303 M.J.S.BARRIL ET AL.: "Cloning and sequencing of the Lactococcus lactis subsp. lactis dnaK gene using a PCR-based approach" see figure 3 ---	1,2, 6-21,23, 28,41
A	WO,A,93 17712 (BIOCINE SCLAVO SPA) 16 September 1993 see page 50 ---	1-101
A	WO,A,92 14488 (UAB RESEARCH FOUNDATION) 3 September 1992 see the whole document -----	1-101

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 September 1996	27.09.96

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Cupido, M

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

rnational application No.
PCT/CA96/00322

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 67,73,81,82,90,97-99
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 67,73,81,82,90 and 97-99 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

2. [ ] Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

...formation on patent family members

Interr ...al Application No
PCT/CA 96/00322

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9317712	16-09-93	CA-A-	2131551	16-09-93
		EP-A-	0632727	11-01-95
		JP-T-	7504423	18-05-95
WO-A-9214488	03-09-92	AU-B-	667668	04-04-96
		AU-A-	1445392	15-09-92
		AU-A-	4798096	27-06-96
		EP-A-	0571538	01-12-93
		JP-T-	6504446	26-05-94
		US-A-	5476929	19-12-95